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Background: Kisspeptins, recently discovered hypothalamic neuropeptides encoded 
by the KISS1 gene, are essential for normal pubertal development and are modulated 
by diverse endocrine, metabolic and environmental signals. Exogenous kisspeptin 
administration potently stimulates LH secretion - by direct action on GnRH neurons 
while kisspeptin antagonists inhibit pulsatile LH secretion. Human studies of 
kisspeptin had hitherto used kisspeptin-54 that is cleaved further and the smallest 
bioactive form is a decapeptide (kisspeptin-10) with a shorter half-life. Kisspeptin-10 
is thus putatively more attractive in studies assessing LH pulsatility and is also the 
basis for the development of antagonists. 
Unmet clinical needs: Decreased LH pulse frequency is the central pathology in 
pubertal delay, late-onset male hypogonadism and hypothalamic amenorrhoea. 
Manipulation of LH pulse frequency also has therapeutic potential in contraception, 
PCOS and sex-steroid dependant diseases such as endometriosis and prostatic 
hyperplasia.  
Hypothesis: That exogenous kisspeptin-10 enhances pulsatile LH secretion in 
healthy men and in patients with reproductive disorders associated with decreased 
pulse frequency. 
Research strategy: A first-in-human dose escalation study of kisspeptin-10 was 
performed in men and subsequently replicated in women. An intravenous infusion 
regime was optimised in healthy men and subsequently applied to hypogonadal 
patients. Specific questions were addressed sequentially as summarised below with 
key results. 
Dose escalation study:   
Question: Does kisspeptin-10 stimulate LH secretion in men? 
Findings: Six iv bolus doses (0.01 to 3 µg/kg) of GMP kisspeptin-10 and vehicle 
were administered at least a week apart to six healthy men. Rapid increase in LH, 
with peak concentrations was seen by 45 min post injection in all volunteers. There 
was a clear dose-dependent increase in LH concentrations in response to kisspeptin-
10 (P <0.0001).  Area-Under-Curve analysis over 60 min following kisspeptin-10 
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administration showed 0.3 and 1µg/kg doses to be maximally stimulatory (P <0.01) 
with a reduced response at 3 µg/kg.   
Assessing the effect of steroid milieu:  
Question: Steroid feedback is central to the regulation of LH secretion: what effect 
does the steroid milieu have on LH responses to kisspeptin-10?  
Findings: The response to iv kisspeptin-10 (0.3µg/kg,) in the normal follicular phase 
(n=10) was compared with that in the presence of low endogenous sex steroids/high 
LH secretion (6 postmenopausal women) and in women taking combined 
contraceptive therapy (n=8) with suppressed LH secretion. Despite widely varying 
baseline secretion, LH increased significantly following kisspeptin-10 administration 
in the follicular phase (6.3±1.2 to 9.4±1.3 IU/L P=0.006), postmenopausal (35.3±2.8 
to 44.7±3.4 IU/L P=0.005), etonogestrel (4.6±0.2 to 7.5±0.9 IU/L, P=0.02), and 
COCP groups (2.2±0.9 to 3.7±1.4 IU/L P<0.001). 
Pulse frequency study:  
Question: GnRH and LH secretion are pulsatile: can kisspeptin-10 enhance LH 
pulsatility? 
Findings: Four healthy men attended our clinical research facility for two visits five 
days apart for 10-min blood sampling. At the first visit, baseline LH pulsatility was 
assessed over a 9-hour period. During the second visit, an infusion of kisspeptin-10 
was administered for 9 hours at 1.5µg/kg/hr after an hour of baseline sampling. LH 
pulse frequency increased in all subjects, with a mean increase from 0.7±0.1 to 
1.0±0.2 pulses/hr (P = 0.01), with resultant increase in mean LH from 5.2±0.8 IU/L 
at baseline to 14.1±1.7 IU/L (P <0.01). 
High dose, longer duration infusion study:  
Question: Can kisspeptin-10 enhance testosterone secretion? 
Findings: Four healthy men attended our clinical research facility for a 34-hour 
supervised stay. Blood samples were collected at 10 min intervals for two 12 hour 
periods on consecutive days and hourly overnight. After 10.5 hours of baseline 
sampling a continuous intravenous infusion of kisspeptin-10 (4µg/kg/hr) was 
 
v 
maintained for 22.5 hrs. Mean LH increased from 5.5±0.8 at baseline to 20.9±4.9 
IU/L (P <0.05) and serum testosterone increased from 16.6±2.4 to 24.0±2.5 nmol/L 
(P <0.001).  
Translational studies in hypogonadal men with type 2 diabetes  
Question: Can kisspeptin-10 normalise testosterone secretion in hypogonadal men? 
Findings: Five hypogonadal men with T2DM (age 33.6±3 yrs, BMI 40.6±6.3, 
testosterone 8.5±1.0 nmol/L, LH 4.7±0.7 IU/L, HbA1c <8 %, duration of diabetes <5 
yrs) and seven age matched healthy men were studied. Kisspeptin-10 was 
administered intravenous (0.3 µg/kg) with frequent (10-min) blood sampling. Mean 
LH increased in controls (5.5±0.8 to 13.9±1.7 IU/L P <0.001) and in T2DM (4.7±0.7 
to 10.7±1.2 IU/L P=0.02) with comparable ΔLH (P=0.18).  
Baseline serum sampling for LH at 10-min intervals and hourly testosterone 
measurements were performed subsequently in four T2DM men for 12 hours. An 
intravenous infusion of kisspeptin-10 (4 µg/kg/hr) was administered 5 days later for 
11 hours, with increases in serum LH (3.9±0.1 IU/L to 20.7±1.1 IU/L (P=0.03,) and 
testosterone (8.5±1.0 to 11.4±0.9 nmol/L, P=0.002). LH pulse frequency at baseline 
was lower in hypogonadal men with diabetes (0.6±0.1 vs. 0.8±0.1 pulses/hr, P=0.03) 
and increased to 0.9±0 pulses/hr (P=0.05). 
Translational studies in pubertal delay:  
Question: Defective Neurokinin B activity is associated with pubertal delay and the 
hierarchical interactions between kisspeptins and Neurokinin B remain to be 
elucidated: can kisspeptin-10 stimulate LH secretion with impaired Neurokinin B 
signalling? 
Findings: Four patients with TAC3 or TACR3 inactivating mutations presenting with 
delayed puberty were admitted for two 12 hr blocks of blood sampling every 10 min 
with vehicle (saline) or kisspeptin-10 (1.5 µg/kg/hour) infused intravenously. Mean 
LH and LH pulses frequency increased with kisspeptin-10 (P<0.05). However, four 
patients with Kallmann syndrome (with defective GnRH neuron migration), studied 
in parallel, did not respond, suggesting a potential diagnostic application for 




In first-in-man studies of kisspeptin-10, it was demonstrated that endogenous LH 
pulse frequency can be enhanced in healthy men. The therapeutic potential of this 
finding in common reproductive endocrine disorders associated with decreased LH 
pulse frequency, i.e., late-onset male hypogonadism and pubertal dysfunction, was 
suggested in subsequent studies. Furthermore, kisspeptin signalling occurs upstream 
of GnRH neurons and is independent of Neurokinin B signalling in the central 
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1 Introduction 
1.1 GnRH – the principal regulator of reproduction 
1.1.1 The discovery of GnRH and evolutionary aspects 
Gonadotropin Releasing Hormone (GnRH) was first isolated and structurally 
identified from porcine hypothalami four decades ago as a decapeptide (pGlu-His-
Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly·NH2) (Baba, Matsuo et al. 1971; Matsuo, 
Arimura et al. 1971; Schally, Arimura et al. 1971; Schally, Arimura et al. 1971). This 
decapeptide was shown to potently stimulate LH and FSH release from the pituitary 
in a number of mammalian species (Schally, Arimura et al. 1971).  Hypophysiotropic 
properties of the naturally occurring peptide was also demonstrated to be comparable 
with those observed with its synthetic analogues (Schally, Arimura et al. 1971). Early 
work referred to this peptide as Luteinising Hormone Releasing Hormone (LH-RH), 
but has since been widely referred to as GnRH to reflect the dual stimulatory role – 
although many authors still refer to it as LH-RH (Schally 2000). The pivotal 
discovery of GnRH was acknowledged with the Nobel Prize for Medicine in 1977 
(Nobelprize.org 2009). 
Diverse forms of GnRH and its receptor exist among vertebrates, with over twenty 
primary structures relatively well conserved across species. This suggests that the 
GnRH signalling system developed early in the evolutionary sequence (Millar 2005; 
Okubo and Nagahama 2008). As the mammalian decapeptide was the first primary 
GnRH structure to be identified, it is referred to by convention as GnRH I 
(Miyamoto, Hasegawa et al. 1984).  Another vertebrate GnRH sequence was first 
identified from chicken brain (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2) 
structurally distinct from GnRH I - now referred to as GnRH II (Miyamoto, 
Hasegawa et al. 1984; Millar 2005). Subsequently, a third form has also been 
described in fish and is now referred to as GnRH III (White, Bond et al. 1994; Millar 
2005). In mammals, hypophysiotropic functions are limited to GnRH I (Gault, 
Maudsley et al. 2003) and hence in the human context GnRH I continues to be 
referred to as GnRH – hence all references to GnRH in this thesis refer to GnRH I.  
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1.1.2 Neuroanatomy of GnRH neurons and clinical significance 
GnRH neurons originate in the medial olfactory placode during embryological 
development and migrate along the olfactory bulb and tract to their final positions 
within the hypothalamus (Balasubramanian, Dwyer et al. 2010; Mitchell, Dwyer et 
al. 2011). Defective GnRH migration leads to the clinical syndrome of Kallmann 
Syndrome – characterised by GnRH deficiency and anosmia (Kallmann, Schönfeld et 
al. 1943-1944; Mitchell, Dwyer et al. 2011). A number of factors contributing to this 
migratory process have been identified. Anosmin-1 (the product of KAL gene) 
(Cariboni, Pimpinelli et al. 2004), neuropilins (Cariboni, Hickok et al. 2007) and 
Leukaemia Inhibitory factor (Magni, Dozio et al. 2007) are some of the various 
chemotactic factors described, along with mutations in  FGFR (Dode, Levilliers et al. 
2003). Mutations in PROK1 and PROK2 lead to hypogonadotropic hypogonadism 
without anosmia, suggesting that factors other than suboptimal migration can also 
lead to functional deficiencies in human GnRH function (Pitteloud, Zhang et al. 
2007; Martin, Balasubramanian et al. 2011; Mitchell, Dwyer et al. 2011). 
GnRH cell bodies are located in the medial preoptic area and the arcuate nucleus of 
the hypothalamus (ARC) and form a neural network with projections to the median 
eminence (Clifton and Steiner 2009). GnRH is secreted from the median eminence 
into the fenestrated capillaries of portal circulation and therein carried to the anterior 
pituitary (Clifton and Steiner 2009). Studies in male and female rats have quantified 
the number of GnRH neurons in the forebrain to be around 1300 (Wray and Hoffman 
1986). This number has been extrapolated to the human setting with estimates 
ranging between 1000 neurons (Millar 2005) and 1500 neurons (Balasubramanian, 
Dwyer et al. 2010). 
The co-location of GnRH neurons in the ARC with central neuronal regulators of 
other key physiological functions allows the GnRH neuronal network to be regulated 
by a range of neuroendocrine and metabolic inputs. Moreover, GnRH neurons 
receive afferent signals from the suprachiasmatic nucleus (SCN) – an area of the 
hypothalamus that expresses clock genes with circadian rhythmicity as well as 
Estrogen Receptor Alpha (ERα) (Clifton and Steiner 2009).  
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1.1.3 GnRH Pulsatility and interspecies differences 
Two distinct modes of GnRH secretion have been described – the pulsatile mode and 
the surge mode (Maeda, Ohkura et al. 2010). Pulsatile mode refers to the episodic 
release of GnRH observed in males and in females during most of the menstrual 
cycle, where there are distinct pulses of GnRH secretion into the portal circulation 
with undetectable GnRH concentrations in portal serum during inter-pulse intervals. 
During the preovulatory surge in LH secretion, there appears to be persistent 
presence of GnRH in the portal circulation – this pattern of GnRH secretion is 
referred to as the ‘surge mode’ of GnRH secretion (Maeda, Ohkura et al. 2010). 
However, it is unclear whether this persistence of GnRH in portal serum in between 
pulses is representative of continuous GnRH secretion or whether it is merely an 
artefact induced due to insufficiently frequent sampling and altered 
dilution/elimination kinetics in the context of a markedly increased pulse frequency 
(Moenter, Anthony DeFazio et al. 2003).  
1.1.3.1 Pulsatile mode of LH secretion 
The episodic nature of LH secretion was first suspected when Knobil and co-workers 
at the University of Pittsburgh, attempting to validate a radioimmunoassay to 
measure serum LH in the Rhesus monkey, noticed marked variations in hormone 
concentrations measured (Dierschke, Bhattacharya et al. 1970; Knobil 1981). 
Experimental studies with frequent blood sampling regime were set up to investigate 
this phenomenon (Dierschke, Bhattacharya et al. 1970). In adult female Rhesus 
monkeys ovariectomised 0.5-7 months prior to experimentation, frequent (10-30 
min) intra-cardiac sampling demonstrated that circulating LH concentrations showed 
pulsatile rise, with individual pulses occurring around an hour apart (Dierschke, 
Bhattacharya et al. 1970). When individual monkeys were studied repetitively, their 
LH secretory patterns also were reproducible and castrate animals demonstrated an 
increased pulse frequency in comparison with intact animals (Dierschke, 
Bhattacharya et al. 1970).  These key findings, i.e. the pulsatile nature of LH 
secretion and the negative feedback of gonadal steroids, were subsequently 
reproduced in sheep (Bolt 1971).  Pulsatility of LH secretion in human volunteers 
was described soon thereafter (Naftolin, Yen et al. 1972). LH pulses in women were 
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observed to follow varying frequency and amplitude, depending on the phase of 
menstrual cycle, with pulses observed every 1-2 hr during the early follicular phase, 
early luteal phase and midcycle surge, with decreased frequency (every 4 hrs) during 
the luteal phase (Yen, Tsai et al. 1972). Pulsatile secretion of LH has been 
subsequently demonstrated in a number of other mammalian species (Lincoln and 
Fraser 1979). 
1.1.3.2 Pulsatile GnRH secretion 
Direct evidence for pulsatile GnRH secretion in the primate was initially 
demonstrated in ovariectomised Rhesus monkeys using serial collection of 
hypothalamic-pituitary stalk portal blood (Carmel, Araki et al. 1976). Although 
correlation with peripheral LH concentrations was not possible using this model, the 
frequency of GnRH pulses correlated with previously documented LH pulse 
frequency in these animals (Carmel, Araki et al. 1976). Not long after these findings 
were published, pulsatile pattern of GnRH secretion with associated changes in LH 
concentrations was demonstrated in serial blood samples collected during pituitary 
surgery in patients with pituitary disease (Antunes, Carmel et al. 1978). 
Meanwhile, administration of GnRH antisera was shown to abolish LH pulses 
(Lincoln and Fraser 1979; Caraty, Martin et al. 1984) while normal LH pulses were 
re-established by hourly administration of a GnRH analogue (which did not cross-
react with the antiserum) (Caraty, Martin et al. 1984) –suggesting that LH pulse 
frequency was determined by the underlying GnRH pulse frequency.  Moreover, 
simultaneous measurement of GnRH and LH in sheep demonstrated temporal 
synchrony between pulsatile secretion of the two hormones (Clarke and Cumins 
1982). Simultaneous sampling of peripheral and portal blood in eugonadal, short-
term castrated (1-15 days) and long-term castrated (1-6 months) rams subsequently 
demonstrated that GnRH was secreted in a pulsatile manner and that each GnRH 
pulse was associated with an LH pulse (Caraty and Locatelli 1988). Gonadal status 
also influenced the frequency of GnRH pulsatility with a pulse every 2-4 hours in 
intact rams, a pulse every 70 min in short-term castrated rams and a pulse every 36 
minutes in long-term castrated rams (Caraty and Locatelli 1988).  
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The half-life of disappearance of exogenous GnRH from peripheral blood was 
initially estimated at 3.6 minutes – with elimination of most of GnRH from 
circulation at the time of maximal gonadotrophic stimulation (Arimura, Kastin et al. 
1974).  More detailed studies have shown that the half-life of GnRH (after 
discontinuation of an infusion) is linear for the first 8-10 min, followed by a slower 
component (Pimstone, Epstein et al. 1977). The half-life of the first component 
ranged from 5.5 to 8 min in normal subjects, 6.5-8 min in patients with impaired 
liver function but prolonged (12-16.5 min) in patients with renal impairment, 
suggesting renal metabolic clearance (Pimstone, Epstein et al. 1977). 
In humans, estimation of GnRH pulse frequency therefore has to be inferred from 
gonadotropic output as ethical considerations preclude routine sampling of 
hypophyseal blood or cerebrospinal fluid. LH pulse frequency has therefore been 
widely used as a surrogate of GnRH pulsatility (Sauer, Frager et al. 1984; Reame, 
Sauder et al. 1985). Free α subunit has been proposed as a complementary marker 
(Whitcomb, O'Dea et al. 1990). LH, FSH, TSH and Human Chorionic Gonadotropin 
(HCG) are composed of two non-covalently linked subunits – alpha and beta 
subunits. The alpha subunit, structurally identical in all of these three gonadotropins 
is secreted uncombined and hence referred to as the free subunit (Corless, Bielinska 
et al. 1987). With a short half-life (12-15 min) and good correlation with LH, free α 
subunit could be used a surrogate of GnRH pulse frequency. Although there is 
desensitisation in free α subunit secretion at rapid GnRH frequencies, it has been 
shown to be a superior marker to LH at GnRH frequencies around 30 min (Hayes, 
McNicholl et al. 1999). However, as the alpha subunit secretion can also be 
modulated by perturbations in the hypothalamic – pituitary – thyroid axis, caution 
has to be exercised in using its pulsatility as a surrogate for GnRH pulsatility. This is 
particularly relevant, as factors known to modulate gonadotropin secretion can also 
modulate TSH secretion (Samuels and Kramer 1996). Moreover, the secretion of 
alpha subunit is not affected by long-term GnRH agonist therapy while LH beta 
subunit secretion is suppressed (Kwekkeboom, Lamberts et al. 1990), raising the 
possibility that alpha and beta subunit secretion may not be in tandem across 
physiological states. 
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The mechanisms by which GnRH neurons co-ordinate their activity remains to be 
fully elucidated (Moenter, Anthony DeFazio et al. 2003). Co-ordination between 
GnRH nerve fibres at the median eminence has been suggested as one possibility, as 
explanted rat medial basal hypothalami (MBH) demonstrate pulsatile GnRH 
secretion (Rasmussen 1993). Episodic multi-unit electrical activity at the MBH 
(adjacent to ARC) is correlated with LH release (Thiéry and Pelletier 1981; Wilson, 
Kesner et al. 1984), suggesting that the GnRH ‘pulse generator’ mechanism is 
anatomically located in the MBH. Not entirely inconsistent with this notion, GnRH 
neurons do appear to be able to create GnRH pulses on their own. GT-1 cells, a 
GnRH producing cell line established from the mouse hypothalamus, demonstrate 
regular pulsatility in vitro (Martínez de la Escalera, Choi et al. 1992). GnRH neurons 
dissected from foetal olfactory placode also demonstrated intrinsic pulsatility when 
cultured in vitro (Terasawa, Keen et al. 1999). Several other reports of similar 
findings in other GnRH neurons have since been reported (Maeda, Ohkura et al. 
2010). 
1.1.3.3 Differential Regulation of LH and FSH with varying 
GnRH pulsatility 
The importance of GnRH pulsatility on LH and FSH secretion was first 
demonstrated in elegant experiments in rhesus monkeys administered GnRH as 
pulsatile bolus doses or continuous administration (Belchetz, Plant et al. 1978). 
Gonadotropin secretion was reinstated in these animals (where endogenous GnRH 
secretion was abolished by radio-frequency hypothalamic ablation) with hourly 
pulsatile administration of GnRH. In contrast, continuous infusion of GnRH only 
elicited a transient response. Moreover, when the animals were switched from 
continuous to pulsatile administration, a robust recovery of gonadotropin secretion 
was observed (Belchetz, Plant et al. 1978). 
The stimulatory effects of GnRH on LH and FSH are not identical, with FSH 
demonstrating a more constitutive release (Millar, Lu et al. 2004).  In ovariectomised 
sheep administered GnRH antisera, pulsatile secretion of LH was completely 
inhibited with the levels of the hormone becoming undetectable within 24 h, while 
the concentration of FSH fell more slowly and remained detectable (Caraty, Martin 
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et al. 1984). The frequency of GnRH input has been demonstrated to selectively 
regulate gonadotropin subunit gene transcription. Rapid GnRH pulse rates increase α 
and LH-β and slow GnRH pulse frequency increases FSH-β gene transcription 
(Dalkin, Haisenlender et al. 1989; Haisenleder, Dalkin et al. 1991; Kaiser, 
Jakubowiak et al. 1997). This is in keeping with earlier studies of GnRH frequency 
modulation demonstrating that decreasing the frequency of GnRH pulses effected a 
decrease in plasma LH, but an increase in FSH (Wildt, Hausler et al. 1981). 
Moreover, with acute progressive increases in GnRH frequency (from one pulse 
every 120 to 60 min, from 60 to 30 min, and from 30 to 15 min) in GnRH deficient 
men, mean LH rose despite a decrease in LH pulse amplitude while FSH and 
testosterone remained unchanged (Spratt, Finkelstein et al. 1987).  
The long-half-life of FSH (274 ± 45 min in men) (Urban, Padmanabhan et al. 1991), 
along with cross-reactivity of some FSH assays with the α subunit makes detection 
of FSH pulses harder than the detection of LH pulses when serum samples are 
obtained from peripheral circulation. However, when samples were obtained from 
the hypophyseal circulation, 93% of the GnRH pulses were associated with FSH 
pulses (Padmanabhan, McFadden et al. 1997). Unlike LH, there is also constitutive 
secretion of FSH (Padmanabhan, McFadden et al. 1997).  
1.1.3.4 Clinical relevance of GnRH pulsatility  
1.1.3.4.1 Pubertal development 
Appropriate modulation of LH pulse frequency is essential for normal development 
and maintenance of reproductive function. In infancy, LH secretion is pulsatile 
(Waldhauser, Weissenbacher et al. 1981), but later becomes quiescent. In 
longitudinal and cross sectional studies carried out in children aged six months to 9 
years, basal and GnRH stimulated LH concentrations are higher in early childhood (< 
five years), subdued in mid-childhood (5-11 yrs.) and increase with pubertal 
development thereafter (Roth, Kelch et al. 1972; Conte, Grumbach et al. 1980).  At 
the onset of puberty, LH pulses are synchronised with sleep (Boyar, Finkelstein et al. 
1972). Reversal of sleep-wake cycle does increase day-time LH secretion during 
puberty, but does not eliminate nocturnal secretion (Kapen, Boar et al. 1974). 
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Abnormal reactivation of GnRH pulse frequency is the central pathology associated 
with precocious and delayed puberty (Balasubramanian, Dwyer et al. 2010).  
Pre-pubertal suppression of the hypothalamus-pituitary-gonadal axis has been shown 
to occur in agonadal humans (Conte, Grumbach et al. 1980) and primates (Pohl, 
deRidder et al. 1995), suggesting that hypothalamo-hypophyseal factors play at least 
a part in effecting this post-natal quiescence of the reproductive axis, until puberty 
sets in. 
1.1.3.4.2 Maintenance of reproductive function 
In women, LH pulse frequency is lowest in the luteal phase, but increases during 
follicular and pre-ovulatory phases of the menstrual cycle (Yen, Tsai et al. 1972). In 
hypothalamic amenorrhoea, a clinical condition associated with anovulatory 
amenorrhoea and hypoestrogenemia, LH pulse frequency (and by inference GnRH 
pulse frequency) is lower than expected for the prevailing steroid profile and is 
comparable to luteal phase pulsatility in healthy volunteers (Reame, Sauder et al. 
1985). LH pulse frequency in hyperprolactinemic women is also lower than that 
observed in healthy women in the follicular phase and increases with bromocriptine 
therapy (Sauer, Frager et al. 1984). Administration of opioid antagonist naloxone 
increases LH pulsatility in some women with hypothalamic amenorrhea and 
hyperprolactinemia (Khoury, Reame et al. 1987; Cook, Nippoldt et al. 1991). 
In women with polycystic ovarian syndrome serum LH concentration is higher in 
comparison to that observed in the follicular phase of menstrual cycle (Yen, Vela et 
al. 1970). Subsequently, it has been demonstrated that the LH pulse frequency and 
amplitude were both increased in women with polycystic ovarian syndrome 
(Waldstreicher, Santoro et al. 1988). Moreover this increase in LH pulse frequency 
has also been demonstrated in both lean and obese women with polycystic ovarian 
syndrome (Morales, Laughlin et al. 1996; Arroyo, Laughlin et al. 1997). 
1.1.3.5 Detection of LH pulsatility in peripheral blood samples 
While the presence of distinct LH pulses in the peripheral circulation has been 
incontrovertible since it’s early description by the Pittsburgh group (Dierschke, 
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Bhattacharya et al. 1970), a consensus is yet to be reached on the optimal approach to 
objectively define LH pulse frequency and amplitude in the peripheral circulation. In 
early reports of pulsatile LH secretion in the human setting, a rise in serum LH by 5 
mIU/ml followed by a 5 mIU/ml drop sustained over two sampling points was 
defined as an LH pulse (Yen, Tsai et al. 1972). As the baseline LH secretion is 
variable across subjects, using this approach is likely to be less specific, while 
attempts to get independent blinded observers to count pulses is also fraught with a 
lack of specificity and poor reproducibility (Merriam and Wachter 1982). Therefore, 
baseline LH concentration was factored into the identification of LH pulses, with 
excursions of LH over and above 20% of local nadir defined as a pulse (Santen and 
Bardin 1973). While this approach was an improvement over earlier approaches, it’s 
ability to detect pulses with a broad profile was limited and there was no 
physiological or functional significance attached to the 20% threshold (Merriam and 
Wachter 1982). This was particularly relevant as in the original study by Santen and 
Bardin, the apparent half-life of endogenously secreted LH in a pulse was influenced 
by the peak LH concentrations observed, with a significant inverse correlation 
between pulse peak and ensuing half-life (Santen and Bardin 1973). As with other 
hormones secreted in a pulsatile manner, there are two phases involved in the 
apparent half-life of LH. The first phase, referred to as the ‘fast half-life’ represents 
the rapid dilution of the small quantity of LH into the circulating plasma. Slow half-
life represents the subsequent metabolic breakdown and excretion – apparent half-
life in peripheral circulation is therefore influenced by these two factors (Santen and 
Bardin 1973). In conditions such as chronic renal impairment where the elimination 
of LH is impaired, its overall half-life is prolonged (Veldhuis, Wilkowski et al. 
1993). Therefore, pulse detection based on a single excursion may miss broader 
pulses and the use of a fixed proportional excursion from baseline fails to recognise 
assay variability. Baird proposed an improvisation of the Santen and Bardin 
algorithm, by defining a pulse as a rise of at least four times the SD of assay 
sustained over two consecutive time points and also proposed the use of the mean of 
two preceding LH values as baseline (Baird 1978).   A number of approaches were 
subsequently made to develop statistical tools to identify pulses but each of them had 
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their own relative strengths and weaknesses – the latter often outweighing the former 
(Merriam and Wachter 1982; Urban, Evans et al. 1988). 
Development of computerised algorithms made it possible to automatically identify 
pulses whilst simultaneously factoring in circadian undulations in baseline LH 
secretion. These algorithms also incorporated assay error into the equation, whilst 
also being capable of identification of clustered peaks as well as identification of 
pulses based on both amplitude and duration (Merriam and Wachter 1982; Urban, 
Evans et al. 1988). The PULSAR algorithm (and its subsequent adaptations) 
calculated a smoothened baseline and single-point excursions from this baseline were 
required to have a wider amplitude than multi-point excursions (Merriam and 
Wachter 1982). The Cycle Detector (Clifton and Steiner 1983), on the other hand, 
used pre-defined thresholds to identify cyclical hormone secretion – attempting to 
differentiate true signals and noise. The next few years saw several new approaches 
being developed. Regional Dual-Threshold method used replicate values from LH 
immunoassays to calculate individual coefficients of variation for all samples and 
used pre-defined specific thresholds for upstroke and downstroke to identify pulsatile 
excursions from a moving baseline. Dependant on these variables, local coefficients 
of variation (taking a region of data at a time) were calculated automatically 
(Velduis, Weiss et al. 1986). Regions with high CV were therefore assigned higher 
thresholds for pulse detection while regions with low CV had lower thresholds 
(Velduis, Weiss et al. 1986).  
Cluster analysis techniques, developed shortly thereafter by the same team, was 
designed to evaluate the behaviour or groups of data (clusters) unlike earlier 
approaches that considered individual data-points in isolation (Veldhuis and Johnson 
1986). This approach involves the initial identification of a nadir cluster and 
subsequent identification of peak clusters by pooled t testing and marking of all 
significant increases (Urban, Evans et al. 1988). Once all significant increases are 
marked, all significant decreases in local data are also identified – a pulse being 
defined as a significant increase followed by a significant decrease (Veldhuis and 
Johnson 1986; Urban, Evans et al. 1988). The DETECT program that stemmed from 
efforts to study electrophoretic data was designed to be able to identify multiple 
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overlapping peaks and used a discrete deconvolution approach to account for 
apparent instantaneous secretion observed with intermittent sampling (Oerter, 
Guardabasso et al. 1986). The concept of deconvolution analysis for LH pulse 
identification was explored further by Veldhuis and colleagues by selecting pulses on 
the basis of the Akaike (AIC) and Bayesian information criteria (BIC) (Liu, Keenan 
et al. 2009). In the initial studies to detect the sensitivity and specificity of this 
approach, a range of minimal absolute concentration increment (0.1-0.3 IU/L) and 
minimal percentage peak-nadir rise (4-9%) were tested. This approach was found to 
have over 90% sensitivity with human, animal and simulated LH data (Liu, Keenan 
et al. 2009). Pulse frequency analyses described in this thesis were performed using 
this deconvolution method on software platforms that have been subsequently 
refined. Blinded data was analysed by Prof. Veldhuis at his facility at the Endocrine 
Research Unit at the Mayo Clinic (Rochester, MN, USA). 
1.2 An introduction to kisspeptins 
1.2.1 Discovery of the Kiss1 gene 
KiSS1, the gene encoding kisspeptins, was first described as a suppressor of 
metastasis in human malignant melanoma (Lee, Miele et al. 1996).  Melanoma cells 
(C8161) transfected with KiSS-1 cDNA showed suppressed metastasis in comparison 
to control C8161 cells when injected into athymic nude mice (Lee, Miele et al. 
1996). This gene was discovered in Hershey (Pennsylvania, USA) - a town founded 
by Milton Hershey to accommodate workers at his chocolate factory (Birchall 2009) 
famous for its brand of chocolates called ‘Hershey’s Kisses’. A number of civic 
amenities in Hershey are provided through funds from trusts established by the 
company and its founder (Birchall 2009). It is therefore not surprising that the 
scientists working on the gene felt it appropriate to name it after the town’s famous 
chocolate ‘Kisses’. The inclusion of SS in KiSS1 also indicates that it is a ‘suppressor 
sequence’. 
1.2.2 Genetics of kisspeptins 
KiSS1 maps to chromosome 1q32 and includes four exons of which the first two are 
not translated (West, Vojta et al. 1998). Exon III has 38 noncoding bases and 103 
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translated bases while the fourth exon has 335 translated and 121 non-translated 
bases (West, Vojta et al. 1998). The precursor 145 amino acid peptide is cleaved to a 
54 amino acid peptide, which can be further truncated to 14, 13 and 10 amino acid C-
terminal sequences, all of which share the C-terminal decapeptide sequence 
characterised by the Arg–Phe–NH2 (RF Amide) C-terminal sequence (Kotani, 
Detheux et al. 2001). 
1.2.3 Nomenclature of Kiss1 peptide and its receptor 
Nomenclature of kisspeptins and their receptor has evolved rapidly and has led to 
multiplicity of terminology in the literature. In this thesis, the proposed nomenclature 
by Gottsch and colleagues (Gottsch, Clifton et al. 2009) has been adhered to, but 
historical nomenclature is summarized below. 
1.2.3.1 Nomenclature of the peptide 
As knowledge has accumulated over the years with a shift of focus for kisspeptin 
from cancer biology to reproductive endocrinology, nomenclature of the peptide and 
its receptor has evolved. To acknowledge its anti-metastatic properties, the 54 amino 
acid peptide product of KiSS1 gene was christened ‘metastin’ (Ohtaki, Shintani et al. 
2001). This 54 amino acid peptide and its shorter cleavage products with 14, 13 and 
10 amino acids have since been collectively termed kisspeptins, to reflect the KISS1 
gene that encodes them. To differentiate kisspeptins of varying amino acid length, 
the terms kisspeptin-54, kisspeptin-14, kisspeptin-13 and kisspeptin-10 are used. 
Gottsch and colleagues have suggested abbreviating these to kp-10, kp-13, kp-14 and 
kp-54 for non-human kisspeptins with Kp-10, Kp-13, Kp-14 and Kp-54 used in the 
human context (Gottsch, Clifton et al. 2009). 
1.2.3.2 Nomenclature of the KISS1 gene and mRNA 
Lee and colleagues christened their newly discovered gene KiSS-1 (Lee, Miele et al. 
1996). The Human Genome Organization Gene Nomenclature Committee (HGNC) 
has proposed the symbol KiSS1 for the gene (HGNC 2009). Incorporating these 
proposed names with the nomenclature guidelines and recommendations of the 
International Committee on Standardized Genetic Nomenclature for Mice, Gottsch 
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and colleagues have recommended the use of the symbol KiSS1 for the human gene 
and Kiss1 for its non-human orthologues (Gottsch, Clifton et al. 2009). KISS1 mRNA 
and Kiss1 mRNA has also been recommended as standard terms for messenger 
transcripts of the human and non-human genes respectively (Gottsch, Clifton et al. 
2009).  
1.2.3.3 Nomenclature of the kisspeptin receptor 
The G–Protein Coupled Receptor (GPCR) now known to be the cognate receptor for 
kisspeptins was called GPR54 when it was one of the many orphan GPCRs and the 
gene encoding the receptor protein was also called GPR54 (Lee, Nguyen et al. 1999). 
The human genetic orthologues were called AXOR12 (Muir, Chamberlain et al. 
2001) and hOT7T175 (Ohtaki, Shintani et al. 2001) by groups that first described 
them.  
To simplify the number of terms used and to comply with recommendations from 
international committees on nomenclature of genes, it has been suggested that the 
symbols KISS1R and Kiss1R are used in the human and non-human context 
respectively to represent the gene and the protein (Gottsch, Clifton et al. 2009). 
Similarly, KISS1R mRNA and Kiss1R mRNA have been recommended as 
appropriate nomenclature for messenger transcripts from the human and non-human 
gene orthologues respectively (Gottsch, Clifton et al. 2009). Although these are 
appropriate nomenclature in the current context, naming a receptor after its ligand is 
fraught with the risk of adding further complexity to the literature if other ligands 
with affinity to the same receptor are discovered in the future. A number of authors 
therefore continue to use the term GPR54 to describe the kisspeptin receptor. 
1.2.4 Discovery of a reproductive role for kisspeptin  
Kisspeptin receptor was first described in the rat (Lee, Nguyen et al. 1999) (then 
called GPR54) and the human homologue (then called AXOR12 or hOT7T175) was 
described soon after, mapping to human chromosome 19p13.3. It has five exons, 
encoding a 398-amino acid protein with seven hydrophobic trans-membrane domains 
(Muir, Chamberlain et al. 2001) and with closest homology to the galanin receptor 
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family. Using RT-PCR, the receptor transcripts were shown to be abundant in 
placenta, pituitary, spinal cord, and pancreas (Kotani, Detheux et al. 2001). 
A reproductive role for kisspeptin in humans became apparent when two groups 
described patients with pubertal disorders associated with mutations of its receptor 
(de Roux, Genin et al. 2003; Seminara, Messager et al. 2003). A number of 
inactivating mutations of KISS1R have since been reported with all phenotypes 
characterised by pubertal delay. Whilst there are variations in laboratory, and 
molecular characteristics of patients with such mutations their reproductive 
phenotypes are remarkably similar (Chan, Broder-Fingert et al. 2009). 
An activating mutation (Arg386Pro) has also been described in a girl with precocious 
puberty, although the inheritance could not be characterized as the biological family 
was not available for genetic testing (Teles, Bianco et al. 2008). When compared to 
cells with wild-type transfected GPR54, cells with this mutation showed prolonged 
inositol phosphate accumulation and phosphorylation of extracellular signal–
regulated kinase, suggesting extended activation of intracellular signaling by the 
mutant GPR54 (Teles, Bianco et al. 2008). 
Missense mutations have also been reported in the KISS1 gene in three unrelated 
children with central precocious puberty (Silveira, Noel et al. 2010). Functional 
characterization studies of these mutant peptides demonstrated higher resistance to in 
vitro degradation but normal affinity at the kisspeptin receptor  – thus suggestive of 
increased bioavailability as the mechanism by which these abnormal kisspeptin 
peptides effect precocious puberty (Silveira, Noel et al. 2010). 
1.2.5 Stimulatory effect of Kisspeptin on GnRH and 
gonadotropin secretion 
The stimulatory effects of kisspeptin on LH secretion have been documented in a 
number of species. In adult male mice, 1 nmol of both kp-10 and kp-54 delivered 
intracerebroventricularly (ICV) stimulated significant LH release as estimated by 
orbital blood sampling 30 min post kisspeptin (Gottsch, Cunningham et al. 2004). 
ICV administration of varying doses of kp-54 (1 fmol to 5 nmol) in mice showed a 
significant increase in 30 min serum LH in comparison to vehicle with doses as low 
as 1 fmol (Gottsch, Cunningham et al. 2004).  
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LH response to kisspeptin-54 is prevented in mice pre-treated with a potent GnRH 
antagonist, acyline (Gottsch, Cunningham et al. 2004), suggesting that the 
stimulatory effect of kisspeptin on LH secretion is mediated through GnRH.  
Comparison of venacaval serum LH responses to intraperitoneal injections of mouse 
kisspeptin 105-119 in wild-type and Kiss1R knockout mice have shown a significant 
rise in LH in the wild-type and no detectable response in the mutants (Messager, 
Chatzidaki et al. 2005), suggesting that the stimulation of gonadotropins by 
kisspeptin is mediated through Kiss1R.  
These findings have also been replicated in larger species. In prepubertal gilts, ICV 
and intravenous (IV) administration of 10 µg and 100 µg of kisspeptin (peptide 
length unclear from published manuscript) showed a dose dependent increase in 
serum LH, as estimated through multiple small volume sampling through indwelling 
jugular cannulae (Lents, Heidorn et al. 2008). Administration of 380 pM of kp-10 IV 
in ovariectomised sheep have shown a doubling of mean serum LH and LH pulse 
amplitudes with significant increase in area under the curve (AUC) of LH pulses 
(Arreguin-Arevalo, Lents et al. 2007). The AUC of LH following 14 pM GnRH was 
higher than the AUC following 380 pM of kp-10 (Arreguin-Arevalo, Lents et al. 
2007). Passive immunization with anti-GnRH antibody abolished these stimulatory 
effects of kisspeptin (Arreguin-Arevalo, Lents et al. 2007), further suggesting that 
kisspeptin stimulation is mediated through GnRH receptor activation. ICV 
administration of Kp-10 in sheep has also shown significant increase in serum LH, 
with tandem assays of GnRH from intracerebroventricular catheters and LH in 
peripheral circulation showing temporally correlated increases in GnRH and LH 
during kisspeptin infusion (Messager, Chatzidaki et al. 2005), suggesting stimulation 
of GnRH secretion by kisspeptin as its mode of gonadotropin stimulation. LH 
response (AUC, when compared to vehicle) to intravenous kp-10 also depends on the 
reproductive status of the ewe, with significantly higher response in the non-breeding 
season than in the breading season (Smith, Saleh et al. 2009). Within the breeding 
season, the highest LH response in ewes was observed in the late follicular phase 
(Smith, Saleh et al. 2009). In anestrous sheep, intravenous administration of doses as 
low as 6 nmol Kp-10 robustly elevate plasma LH and FSH with human Kp-10 and 
murine kp-10 showing equipotency (Caraty, Smith et al. 2007). By simultaneous 
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sampling of CSF GnRH and serum LH in experimental sheep during an infusion of 
Kp-10 (50 nmols over four hours), simultaneous increases in LH and FSH has also 
been documented, providing further evidence of kisspeptin-related increases in 
gonadotropin secretion being mediated by GnRH (Messager, Chatzidaki et al. 2005). 
In prepubertal Holstein heifers, injection of 1 mg of Kp-10 (mean dosage 5 µg/kg) 
effected a five-fold increase in LH from baseline with peak LH noted at a mean of 27 
minutes from baseline (Kadokawa, Matsui et al. 2008). This study also noted a 
significant rise in growth hormone (GH) from baseline with peak serum 
concentrations noted at a mean of 75 minutes post kisspeptin administration 
(Kadokawa, Matsui et al. 2008). However, this stimulatory effect of kisspeptin on 
pituitary somatotroph cells remains to be reproduced. 
In male rhesus monkeys primed with pulsatile GnRH, intracerebroventricular and 
intravenous administration of 100 µg of Kp-10 (approximately 30 µg/kg) increased 
plasma LH over 25-fold from baseline (Shahab, Mastronardi et al. 2005). Pre-
treatment with GnRH antagonist acyline abolished these responses to kisspeptin, 
further suggesting that the modulation of gonadotropins by kisspeptin is mediated 
through GnRH signaling (Shahab, Mastronardi et al. 2005).  
1.2.5.1 Comparison of stimulatory efficacy of various 
kisspeptin fragments 
Comparison of 60-min serum samples of LH and testosterone in male Wistar rats 
following acute subcutaneous injections of a wide range of doses (0.1, 0.3, 1.0, and 
50 nmol) of Kp-10, Kp-14 and Kp-54 showed a significant increase only in the Kp-
54 treated animals at doses of 1 and 50 nmol (Thompson, Murphy et al. 2006). 
Murine kp-52 and human Kp-10 have been shown to effect a rise in LH at 30 
minutes post-injection when administered ICV to adult male mice with the longer 
peptide effecting higher absolute LH, but statistically similar to serum LH post kp-52 
injection (Gottsch, Cunningham et al. 2004). When 3.0 nmol/kg each of kp-10 and 
kp-52 were administered intravenously to male rats, similar peak LH levels achieved 
(Tovar, Vazquez et al. 2006).  Four boluses of Kisspeptin-10 administered at 75-min 
intervals evoked robust LH secretory bursts with similar pulse size. Serum LH 
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responses to intravenous kp-52 were slightly greater in magnitude and duration 
(Tovar, Vazquez et al. 2006).  
Mikkelsen and colleagues have studied the acute effects of murine kp-10, murine kp-
52, human Kp-54 and human Kp-10 on serum testosterone in experimental mice 
(Mikkelsen, Bentsen et al. 2009). Adult male NMRI mice receiving 3nmol/kg or 
more of all four kisspeptin fragments resulted in similar elevation in serum free 
testosterone. Maximal effect was seen at 10 nmol/kg, with the higher dose of 30 
nmol/kg achieving similar elevations of serum testosterone. Dose response curves 
observed with all the four peptides were similar except for Kp-54 (human) showing 
non-significantly higher potency. The ED50 was estimated as 3nmol/kg. 
The time-course of acute stimulatory effects of various kisspeptin fragments has also 
been studied (Mikkelsen, Bentsen et al. 2009). Murine kp-10, murine kp-52, human 
Kp-54 and human kp-10 all maximally elevated serum testosterone at 30 minutes 
following intraperitoneal injection of 10 nmol/kg of each peptide in adult male 
NMRI mice. Shorter peptides show quicker onset of action within the first 10 
minutes while Kp-54 showed a sustained stimulatory effect on serum testosterone 
lasting beyond 60 minutes (Mikkelsen, Bentsen et al. 2009). 
1.2.5.2 Stimulatory effect of kisspeptin in healthy human 
subjects 
Kisspeptin-54, when administered intravenously or subcutaneously in healthy men 
and women results in robust and significant increase in serum LH and gonadal 
steroids (Dhillo, Chaudhri et al. 2005; Dhillo, Chaudhri et al. 2007). 
In a study designed to establish dose response curve for Kp-54, healthy male 
volunteers were infused intravenously at doses ranging from 0.125 to 40 
pmol/kg/min for 30 minutes with a further 60 minutes of intravenous infusion at half 
the initial rate (Dhillo, Chaudhri et al. 2005). Mean LH increased in a dose dose-
depended manner from 0.25pmol/kg/min to 12 pmol/kg/min. Mean LH for doses 
above 12 pmol/kg/min tended to be non-significantly lower than the value achieved 
with 12 pmol/kg/min.  
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The time course of LH and FSH responses to an intravenous infusion of 4 
pmol/kg/min of Kp-54 for 30 minutes (i.e., 240pmol/kg), followed by half this rate 
for a further 60 min has also been demonstrated in 6 male volunteers (Dhillo, 
Chaudhri et al. 2005). Following discontinuation of the infusion, plasma kisspeptin 
immuno-reactivity (Kp-IR) decreased with first order kinetics with a calculated half-
life of 27.6 +-1.1 min. Peak LH levels correlated with Kp-IR and returned to baseline 
3 hours following the discontinuation of kisspeptin infusion. However, after an initial 
drop mirroring LH, serum testosterone showed a sustained rise, with peak values 
achieved 24 hours after the start of the infusion. However, the significance of this 
pattern of change in serum testosterone is uncertain as the control arm also showed a 
similar profile. 
Kp-54 (0 to 6.4 nmol/kg doses) administered subcutaneously (in the abdomen) in 
healthy women has also been shown to result in dose-dependent increases in LH, and 
FSH but not free estrogen index (Dhillo, Chaudhri et al. 2007). When 0.4 nmol/kg of 
Kp-54 was administered subcutaneously as bolus doses in women during follicular, 
pre-ovulatory and luteal phases of their menstrual cycles (Dhillo, Chaudhri et al. 
2007), maximal stimulation of LH was seen in the pre-ovulatory phase (Dhillo, 
Chaudhri et al. 2007), suggesting variation in kisspeptin dependent LH release is 
likely to be effected at the level of the pituitary. In studies involving the 
administration of an identical dose of GnRH to women across the menstrual cycle, 
maximal sensitivity to GnRH has been demonstrated in the pre-ovulatory phase 
(Yen, VandenBerg et al. 1972). Therefore, it is plausible that kisspeptinergic 
stimulation of GnRH secretion could be constant irrespective of the prevailing 
steroid milieu but that the amplified LH response observed in the pre-ovulatory 
phase is mediated by increased pituitary sensitivity to GnRH. 
1.2.5.3 Effect of chronic or continuous Kisspeptin 
administration on gonadotropin secretion 
Continuous administration of exogenous GnRH desensitizes the HPG axis, 
suppressing gonadotropin release from the pituitary following an initial stimulatory 
effect (Belchetz, Plant et al. 1978). Therefore, efforts have been made to assess the 
impact of continuous infusions of kisspeptin in a number of experimental settings. 
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In adult male Wistar rats weighing 275–325g, continuous subcutaneous 
administration of 50 nmol/day of Kp-54 effected a three-fold increase in LH on day 
one, but this stimulatory effect on LH was lost after 2 days with vehicle and 
treatment arms showing similar LH profiles on day three (Thompson, Murphy et al. 
2006). In parallel with the LH excursion, testosterone also increased, with a four-fold 
increase was seen in plasma free testosterone on day one. This stimulatory effect on 
LH was also lost after 2 days (Thompson, Murphy et al. 2006). 
In experimental sheep infused with Kp-10 over four hours, LH levels were robustly 
elevated, but serum LH declined from its peak values before the end of the infusion 
while CSF GnRH remained elevated for 2 hours following the discontinuation of the 
infusion (Messager, Chatzidaki et al. 2005). This raises the possibility that 
desensitization to GnRH could be occurring at the level of the pituitary gonadotrope. 
In agonadal juvenile male monkeys primed with GnRH, continuous intravenous 
infusion of 100µg/hr of Kp-10 led to an initial stimulatory effect on serum LH 
concentrations (Seminara, DiPietro et al. 2006) followed by a decrease in serum LH, 
dropping to levels comparable to vehicle infusion by 12 hours. Whilst maintained on 
the infusion, these experimental animals continued to respond to GnRH and N-
methyl-DL-aspartic acid (NMDA) (10 mg/kg) but not to intravenous bolus kisspeptin 
(10 µg Kp-10) suggesting that the pituitary responsiveness to GnRH is preserved 
whilst kisspeptinergic stimulation has been desensitized. Less than a day after 
discontinuing the infusion, the ability of an intravenous bolus of 10 µg of Kp-10 to 
stimulate LH was re-established. 
In adult male rhesus monkeys infused continuously with 200 µg/hr and 400 µg/hr (15 
and 30 nmol/kg•h) of Kp-10, serum LH returned to pre-infusion baseline after 24 
hours of infusion following an initial robust surge (Ramaswamy, Seminara et al. 
2007). LH responses to NMDA and GnRH on the first day of the study were 
comparable with vehicle infused control animals on day four of the low dose 
infusion. However, animals on the higher dose infusion (400 µg/hr) showed a 
reduced response. LH responses to bolus doses of intravenous Kp-10 were 
diminished whilst the animals were being infused with Kp-10. These effects 
recovered fully in the low-dose group and partially in the higher dose group. 
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Reduction in LH pulse frequency (four pulses per 6 h to less than one pulse per 6 h) 
and LH pulse amplitude were noted in the high dose group but not in the low dose 
cohort. Despite a reduction in circulating LH in animals infused with high dose Kp-
10, serum testosterone was significantly higher than baseline and control animal, 
prompting the authors to suggest a direct effect of Kp-10 at the level of the testes. 
In women with hypothalamic amenorrhea receiving subcutaneous Kp-54 (37 µg/kg; 
6.4 nmol/kg) twice daily for two weeks, potent increases in serum LH and FSH seen 
on day one were significantly diminished at the end of the study (Jayasena, Nijher et 
al. 2009). No changes in LH pulsatility were observed in this study. 
1.2.6 Neuroanatomy of the kisspeptin neuronal network 
1.2.6.1 Human hypothalamus 
Initial studies on the neuroanatomical distribution of kisspeptin neurons in the human 
brain were carried out in autopsy samples from premenopausal women (n=8; age = 
32 ± 2.7 years; age range, 21–41 years) and postmenopausal women (n=9; age = 72 ± 
2.7 years; range, 59–86 years) were analysed with hybridisation histochemistry. 
Endometrial biopsies were obtained to confirm reproductive status. The only focus of 
KISS1 expression was limited to the infundibular nucleus (homologous to the ARC 
in lower species), with no KISS1 expression in the preoptic area homologous to 
rodent AVPV. KISS-1 mRNA expressing neurons in the infundibular nucleus were 
more than double in the postmenopausal sections, suggesting a negative feedback for 
sex steroids on kisspeptin neurons (Rometo, Krajewski et al. 2007). 
A more recent study, carried out using both male and female autopsy samples, have 
demonstrated the presence of kisspeptin cell bodies in the infundibular nucleus, in 
keeping with earlier human and non-human studies (Hrabovszky, Ciofi et al. 2010). 
The study also showed another kisspeptin cell population in the rostral 
periventricular zone in female hypothalami. Female hypothalami also demonstrated 
higher kisspeptin immunoreactivity in the infudibular nucleus, raising the hypothesis 
that kisspeptin neurons are sexually dimorphic in the human. Axo-somatic, axo-
dendritic and axo-axonal contacts between kisspeptin- and GnRH-immunoreactive 
axons were also demonstrated in the infundibular stalk (Hrabovszky, Ciofi et al. 
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2010) in keeping with data obtained from primates (Ramaswamy, Guerriero et al. 
2008). Three-quarters of kisspeptin-immunoreactive cells in the infundibular nucleus 
were also shown to co-express neurokinin B (Hrabovszky, Ciofi et al. 2010), in 
keeping with observations in sheep (Goodman, Lehman et al. 2007) and rodents 
(Navarro, Castellano et al. 2011). As the population (Crowley and Mcarthur 1980) of 
Arcuate/Infundibular kisspeptin neurons co-localise neurokinin B and dynorphin, 
these neurons are also referred to as KNDy (Kisspeptin - Neurokinin B – Dynorphin) 
neurons (Lehman, Coolen et al. 2010). 
1.2.6.2 Non-human primates  
Experimental studies on reproduction in non-human primates offer valuable insights 
into human physiology as these animals also undergo distinct pubertal maturation 
associated with a GnRH surge (Shahab, Mastronardi et al. 2005).  As this species is 
also similar to the human in terms of having a distinct reproductive cycle with 
menstruation in women, primates are considered to be a better model of reproductive 
function than rodents (Pimstone, Epstein et al. 1977). However, where juvenile 
primates are used, the direct translation to adult human function is difficult, as 
various developmental and endocrine factors might confound observations. In 
particular, as these animals do not yet have a GnRH pulse generator with pulse 
frequency, and pulse-amplitude similar to adult animals, GnRH is administered as 
discrete fixed pulses(Seminara, DiPietro et al. 2006). Whilst this model has inherent 
strengths in mechanistic studies of hierarchical reproductive function, extrapolation 
of their findings to diseases associated with altered GnRH/LH pulsatility has to be 
tempered with an understanding of such limitations. 
Shahab and colleagues localised Kiss1 expression to the medial ARC nucleus using 
coronal sections from ovariectomised adult rhesus monkeys treated with estradiol 
(Shahab, Mastronardi et al. 2005). In the same study, Kiss1R mRNA expression was 
localised to the medial and lateral aspects of the ARC nucleus (Shahab, Mastronardi 
et al. 2005). The presence of focal Kiss1 expression has also been documented in the 
medio-basal hypothalamus (MBH, an area of the hypothalamus including the ARC) 
in agonadal male rhesus monkeys (Shibata, Friedman et al. 2007). Testosterone 
replacement with an LH suppressive dose using testosterone-filled silastic capsules 
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led to a decrease in Kiss1 mRNA in the MBH of these animals (Shibata, Friedman et 
al. 2007). The localisation of Kiss1 mRNA in the ARC nucleus has also been 
documented in both ovariectomised and non-ovariectomised adult cynomolgus 
monkeys, with the former showing significantly higher Kiss1 expression (Rometo, 
Krajewski et al. 2007). None of these studies showed demonstrable Kiss1 mRNA in 
the preoptic area (POA) of the hypothalamus. 
1.2.6.3 Rodents 
In rodents, two distinct dense populations of kisspeptin neurons exist; one in the 
rostral continuum of cells abutting the third ventricle in the preoptic periventricular 
nuclei (including the anteroventral periventricular nucleus [AVPV], the 
periventricular nucleus [PeN]) and the arcuate (ARC) nucleus) (Clarkson and 
Herbison 2006). The continuum of periventricular area extending caudally from the 
level of the organum vasculosum of the lamina terminalis to the AVPV and PeN has 
been recently described as the rostral periventricular region of the third ventricle 
(RP3V) (Herbison 2008; Clarkson, Tassigny et al. 2009). These periventricular 
nuclei show marked sexual dimorphism with the adult female hypothalami 
characterized by 10-fold greater number of kisspeptin neurons (Clarkson and 
Herbison 2006). In addition to the two dense populations of cell bodies in the RP3V 
and ARC, kisspeptin immunoreactive cells or Kiss1 mRNA have been described in 
the brainstem, dorsomedial nucleus, amygdala, posterior hypothalamus and the striae 
terminalis in mice. However, immunocytochemical analysis with more specific 
antibodies to mouse kisspeptin has only confirmed the presence of low-density 
kisspeptin immunoreactive cells in the posterior hypothalamus and the dorsomedial 
nucleus. 
Kisspeptin fiber distribution matches the distribution of cell bodies, showing 
predominant concentration in the ARC with dorsal and lateral extensions to adjacent 
regions of the brain (Clarkson and Herbison 2006). Kisspeptin immunoreactive cell 
bodies are undetectable in the AVPV and PeN in the postnatal juvenile period (P10) 
in both male and female mice but increase many-fold through pre-pubertal (P25) and 
peripubertal (P35) stages of reproductive development. In the male, cell bodies in 
both AVPV and PeN reach their peak quantity by puberty while in the female, there 
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is a doubling of cell bodies in the AVPV post puberty (Clarkson and Herbison 2006). 
The post-natal development of cell bodies in the ARC is yet to be established, 
although the distribution of kisspeptin immunoreactive fibers has been observed at 
all ages (Clarkson and Herbison 2006).  
Normal female mice express significantly more Kiss mRNA in the AVPV than 
normal male mice under identical hormonal milieu, when analyzed by in situ 
hybridisation. This difference also appears to occur perinatally, as neonatally 
androgenised female mice show a Kiss mRNA distribution similar to male mice 
(Kauffman, Gottsch et al. 2007). There is no sexual dimorphism in Kiss mRNA 
expression in the ARC nucleus (Kauffman, Gottsch et al. 2007) in mice. The 
distribution of kisspeptin immunoreactive cell bodies and fibres in mice has also 
been mapped by Clarkson and colleagues (Clarkson, Tassigny et al. 2009).  
Using transgenic Kiss1R LacZ knock-in mouse model, abundant Kiss1R expression 
was noted in a number of brain regions. Within the hypothalamus, Kiss1R expressing 
cells were found primarily in the GnRH neurons and a cell population in the 
posterior periventricular hypothalamus. Moreover, less than 40% of GnRH neurons 
in these mice had Xgal Kiss1R staining at birth, compared with 60-70% of 
peripubertal and adult GnRH neurons (Herbison, d'Anglemont de Tassigny et al. 
2009). This suggests post-natal maturation of the Kiss1R system in the GnRH 
neuron. 
1.2.6.4 Sheep 
As with rodents, kisspeptin cell body immunoreactivity has been identified in the 
ARC nuclei of sheep brain using immunocytochemistry (Smith, Coolen et al. 2008). 
Immunocytochemical analysis of ovine hypothalamus with antiserum specific to 
ovine kp-10 has demonstrated the presence of dense kisspeptin immunoreactive 
neurons in the ARC nucleus (Franceschini, Lomet et al. 2006) confirming similar 
findings obtained using rabbit polyclonal antibody against kp-10 (Pompolo, Pereira 
et al. 2006). In situ hybridisation has confirmed the presence of the largest population 
of kiss1 mRNA expressing cells in the ovine hypothalamus to be located in the ARC 
(Smith, Clay et al. 2007). A significant elevation of kiss1 mRNA has also been 
 
Literature Review 30 
demonstrated in the ARC prior to the onset of ovine breeding season, suggesting a 
role of kisspeptin as a neuroendocrine reproductive trigger (Smith, Clay et al. 2007). 
Kiss1 mRNA expression in the ARC is also under negative feedback from E and P 
(Smith, Clay et al. 2007). Kisspeptin neurons in the ovine ARC also co-express 
dynorphin-A and neurokinin-B, with the former co-expressed in almost all kisspeptin 
immunoreactive neurons and the latter in over two-thirds (Goodman, Lehman et al. 
2007). The expression of kiss1 mRNA (Estrada, Clay et al. 2006; Smith, Li et al. 
2009) and the number of kisspeptin immunoreactive cells (Smith, Li et al. 2009) are 
up-regulated in the caudal ARC during the preovulatory period of the ewe oestrous 
cycle suggesting that the ARC plays a role in mediating pre-ovulatory GnRH surge. 
The population of kisspeptin immunoreactive neurons putatively corresponding to 
the R3PV periventricular nuclei is more laterally located within the pre-optic area in 
sheep (Franceschini, Lomet et al. 2006; Pompolo, Pereira et al. 2006; Smith, Coolen 
et al. 2008). This population of kisspeptin neurons is located in the medial preoptic 
area, a region which in the ovine hypothalamus known to have abundant GnRH 
neuronal population (Franceschini, Lomet et al. 2006). Studies using ovine kp-10 
antisera have shown a higher quantity of kisspeptin immunoreactive cells 
(Franceschini, Lomet et al. 2006) in the preoptic area in comparison to 
immunocytochemical analysis using human kp-10 antibodies (Pompolo, Pereira et al. 
2006), suggesting a differential sensitivity of kisspeptin neurons to various kisspeptin 
antisera. In situ hybridisation complements immunohistochemcal studies by 
confirming the presence of kiss1 mRNA expression in the pre-optic area (Smith, Clay 
et al. 2007). No changes in the number of kisspeptin immunoreactive cell bodies was 
observed between non-breeding and breeding seasons (Smith, Coolen et al. 2008). 
Kiss1 mRNA expression is higher in the late follicular stage (preceding GnRH/LH 
surge) when compared to late luteal phase (Smith, Li et al. 2009). Kisspeptin protein 
and kiss1 mRNA expression in the pre-optic area is increased with estradiol treatment 
in ovariectomised ewes (Smith, Li et al. 2009) although only 50% of the kisspeptin 
immunoreactive cells in this area co-express ER alpha (Franceschini, Lomet et al. 
2006). Dynorphin A and neurokinin B co-expression is also not seen in this ovine 
population of kisspeptin neurons (Goodman, Lehman et al. 2007). 
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1.2.7 Kisspeptin analogues. 
As the central role played by the kisspeptin-GPR54 system in the development and 
maintenance of normal adult reproductive function has become apparent, efforts have 
been made to make analogues to explore the physiological roles and potential 
pharmacological applications in modulating the HPG axis. Roseweir and co-workers 
have systematically shortened and substituted amino acids in the kisspeptin-10 
decapeptide sequence to develop potent antagonists (Roseweir, Kauffman et al. 
2009; Pineda, Garcia-Galiano et al. 2010). Results from these studies and their 
relevance in understanding the physiological regulation of reproductive function are 
reviewed elsewhere in detail (Millar, Roseweir et al. 2010). Using similar methodical 
substitution of amino acid sequence, analogues with higher in vitro binding affinity 
and increased in vivo potency and efficacy have also been reported (Curtis, Cooke et 
al. 2009). 
In brief, kisspeptin antagonists have been demonstrated to show  
• Inhibition of kisspeptin stimulation of GnRH firing in brain slices from 
genetically modified female mice with green fluorescent protein expression in 
the GnRH. 
• Inhibition of pulsatile GnRH release in pubertal female rhesus monkeys. 
• Inhibition of post-castration LH rises in rats and mice. 
• Inhibition of kisspeptin-stimulated LH secretion in intact and castrated rats. 
• Inhibition of LH pulsatility in ovariectomised sheep. 
• Inhibition of pubertal development in rodents with decrease in vaginal 
opening, decreased uterine and ovarian size. 
• Inhibition of pre-ovulatory LH surge in the female rat. 
Unpublished data have shown marked suppression of gonadotropins with continuous 
administration of such potent analogues (Ohkura, Tanaka et al. 2011). Early phase 
clinical trials are currently underway to explore the therapeutic value of this 
approach in prostate cancer (Takeda.com, accessed 13 Sept 2011).  
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1.3 Regulation of GnRH and gonadotropin secretion 
Development and maintenance of normal adult reproductive function requires a 
coordinated interplay between environmental, metabolic and environmental factors. 
The GnRH-gonadotrope system plays a central role in the regulation of reproduction 
by being the final integrator of such diverse signals.   
1.3.1  Sex steroid feedback 
A crucial role for sex steroids in the feedback regulation of GnRH neurons and/or 
gonadotropes in the human was initially proposed as serial blood sampling and 
gonadotropin assays in apparently healthy women through phases of menstrual cycle 
showed an uneven distribution. A clear mid-cycle surge evident in LH and FSH 
concentrations (Midgley and Jaffe 1971). Two distinct mechanisms were proposed as 
plausible to mediate this effect. First, that the GnRH secretory pattern is altered in 
response to the steroid milieu. Second, that the sensitivity of the gonadotropes to a 
given GnRH input is sex-steroid dependant (Midgley and Jaffe 1971). Despite 
focussed and intense effort by a number of groups, the relative contribution of these 
two modes of feedback remains controversial, partly due to inter-species differences 
(Midgley and Jaffe 1971).  
Hypothalamic secretion of GnRH increases during proesterus in rats (Levine, Bauer-
Dantoin et al. 1991) sheep (Clarke 1988) and non-human primates (Pau, Berria et al. 
1993). However, in Rhesus monkeys with hypothalamic lesions induced to eliminate 
GnRH secretion, normal ovulation was restored by exogenous GnRH administered as 
a pulse every hour throughout the cycle, prompting the investigators to conclude that 
it was the “ebb and flow” of estrogen feedback on the pituitary that effected the LH 
surge (Knobil, Plant et al. 1980). In the human setting, induction of ovulation in 
patients with Kallmann syndrome with pulsatile GnRH delivered as 25 ng/kg pulses 
every 2 hours over 27 days provide further support to this hypothesis (Crowley and 
Mcarthur 1980). Moreover, there is evidence to suggest that in the human context, 
endogenous GnRH secretion is potentially diminished during the pre-ovulatory LH 
surge (Hall, Taylor et al. 1994). In studies carried out in healthy women across 
various phases of the menstrual cycle, there was greater suppression of 
gonadotropins with lower doses of a competitive GnRH receptor antagonist during 
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the mid-cycle surge, in comparison to the other phases of the menstrual cycle (Hall, 
Taylor et al. 1994). Whilst these findings support the notion that pituitary sensitivity 
to GnRH is enhanced during the mid-cycle surge, it is also consistent with 
modulation of GnRH secretion across the menstrual cycle (albeit a decrease in GnRH 
secretion and not an increase in GnRH feedback as expected) (Plant 2008). When 
men with hypogonadotropic hypogonadism treated with pulsatile GnRH therapy 
were administered exogenous estradiol or testosterone, gonadotropin concentrations 
decreased, demonstrating inhibitory effects of these hormones at the pituitary 
(Bagatell, Dahl et al. 1994).  A direct effect of estrogen on gonadotropes is further 
demonstrated by the in vitro inhibition of LH secretion from rat pituitary 
gonadotropes in culture (Emons, Ortmann et al. 1986). Moreover, LH and FSH 
levels as well as LH pulse amplitude have been demonstrated to be decreased in 
healthy volunteers and GnRH-deficient men on long-term pulsatile GnRH therapy 
exposed to exogenous E2 (Finkelstein, O'DEA et al. 1991). However, a number of 
studies, as discussed above, have demonstrated an inhibitory role for sex steroids at 
the hypothalamus - thus suggesting that there is feedback regulation occurring at the 
level of both the pituitary and the hypothalamus. Recent experimental evidence also 
supports this notion of dual-site feedback (Pitteloud, Dwyer et al. 2008), as 
anastrazole-suppressed healthy male volunteers demonstrated increases in LH pulse 
frequency and amplitude despite GnRH secretion remaining unaffected (Hayes, 
Seminara et al. 2000). 
1.3.1.1 Estrogen feedback 
A biphasic effect of estradiol on gonadotropin secretion has long been established, 
with an initial negative feedback (with greater suppression of FSH) and a subsequent 
positive feedback that is more prominent for LH (Yen and Tsai 1971; Keye and Jaffe 
1975). Pulse frequency analyses have since demonstrated a decrease in pulse 
frequency within 24 hours of exposure to exogenous estradiol, followed by an 
increase (observed at days 5 and 10 in the study) and a decrease thereafter (Veldhuis, 
Evans et al. 1987). These observations in human volunteers are consistent with 
studies in non-human primates where estradiol administration was shown to inhibit 
GnRH pulse generator Multi-Unit Electrical Activity (Kesner, Wilson et al. 1987) as 
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well as studies in rodents demonstrating that insertion of estrogen micro-implants in 
the ARC nucleus results in diminished LH pulse frequency (Akema, Tadokoro et al. 
1984). When the anti-estrogen clomiphene citrate was administered to women in 
early follicular phase, LH and FSH increased with associated increase in LH pulse 
frequency, suggesting a suppressive role for estrogen at the supra-pituitary level 
(Kerin, Liu et al. 1985). Similar observations have also been in made in men – with 
decreased LH pulse frequency and amplitude observed during administration of 
estradiol and converse enhancement of these markers when tamoxifen was 
administered (Veldhuis and Dufau 1987). 
Molecular mechanisms underpinning estrogen feedback remain to be fully 
elucidated. Immunohistochemical studies have failed to demonstrate the presence of 
estrogen receptor α (ERα) on GnRH neurons (Herbison 1998). Although some 
GnRH neurons express ERβ, these receptors may not have a functional role in 
effecting steroid feedback as ERβ knockout mice demonstrate normal fertility 
(Lubahn, Moyer et al. 1993; Krege, Hodgin et al. 1998). Moreover, the rapid onset of 
inhibitory effects of estradiol on LH pulse frequency would suggest that non-
genomic mechanisms not involving classic nuclear receptor pathway might also be 
involved (McDevitt, Glidewell-Kenney et al. 2008). Membrane receptors of estrogen 
located on GnRH neurons (GPR30) have also recently been described, suggesting 
that estrogen feedback on GnRH neurons is multimodal (Noel, Keen et al. 2009; Sun, 
Chu et al. 2010).  
There is now a wealth of evidence to suggest that kisspeptin neurons in the ARC 
mediate estrogen feedback on GnRH neurons in the female mouse and rat (Oakley, 
Clifton et al. 2009). In postmenopausal women, the infundibular nucleus (the 
homologous location to ARC in the human hypothalamus) is characterised by an 
increase in the size and number of KISS1 expressing neurons (Rometo, Krajewski et 
al. 2007). Similar findings were also observed in ovariectomised cynomolgus 
monkeys (Rometo, Krajewski et al. 2007). Moreover, in these non-human primates, 
estrogen (or estrogen + progesterone) add-back has been demonstrated to be 
associated with a decrease in the number of kiss1 neurons (Rometo, Krajewski et al. 
2007). These findings are also consistent with increases in kiss1, GPR54 and GnRH-
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1 mRNA expression observed in the medial basal hypothalamus of postmenopausal 
macaques in comparison to eugonadal adults (Kim, Jessen et al. 2009). Prolonged 
estrogen deprivation in rhesus monkeys ovariectomised four years prior to 
experimentation was associated with increased KiSS1 and NKB expression, with 
estradiol administration reversing these findings (Eghlidi, Haley et al. 2010). Shorter 
duration since ovariectomy and fluctuations in circulating estradiol levels was, 
however, not associated with changes in KiSS-1, NKB or PDYN (prodynorphin) 
expression in rhesus monkeys (Eghlidi, Haley et al. 2010; Smith, Shahab et al. 2010). 
The presence of two distinct kisspeptin populations (in the ARC nucleus and rostral 
periventricular region of the third ventricle (RP3V) in laboratory rodents with 
different functional roles makes the interpretation of findings from rodent and sheep 
models more complex. Nevertheless, neurophysiological observations pertaining to 
estrogen feedback at the ARC in these species, are consistent with observations in 
the primate (Oakley, Clifton et al. 2009). Studies in ERα and ERβ knock-out mice 
have demonstrated that modulation of KiSS1-mRNA expression by estradiol is 
signalled through ERα and that almost all kisspeptin neurons co-express ERα (Smith, 
Cunningham et al. 2005). Non-classic signalling through ERE-independent pathways 
have also been described in the kisspeptin rodent ARC (Gottsch, Navarro et al. 
2009). Studies in sheep have also demonstrated normalisation of increased KiSS1-
mRNA expression in ovariectomised ewes by add-back of estradiol (Smith, Clay et 
al. 2007). 
1.3.1.2 Testosterone feedback 
Early studies of testosterone feedback on gonadotropin secretion demonstrated that 
LH and FSH pulse frequency are enhanced in hypogonadal men and that exogenous 
testosterone decreases these parameters, suggesting that testosterone (and/or its 
metabolites have an inhibitory effect on hypothalamic GnRH secretion (Matsumoto 
and Bremner 1984). These findings are in keeping with similar observations made in 
rodents (Steiner, Bremner et al. 1982), sheep (D'Occhio, Schanbacher et al. 1982) 
and non-human primates (Plant 1982).  
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As testosterone is aromatised to estradiol, whether testosterone effected its inhibitory 
effect on LH secretion directly or through conversion to estradiol had to be 
established. Similarly as 5α-reductase converts testosterone to dihydrotestosterone, 
(DHT, a non-aromatisable androgen), differentiation of effects of testosterone and 
DHT are also important.  Santen’s elegant experiments involving the infusion of 
estradiol, testosterone and dihydrotestosterone to healthy men demonstrated that the 
effects of DHT were comparable to that of testosterone (Santen 1975). Moreover, 
GnRH sensitivity was preserved in men infused testosterone, whilst this was 
diminished in those infused estradiol (Santen 1975). Absence of inhibitory effects 
when DHT was administered to men with hypogonadotropic hypogonadism (IHH) 
treated with pulsatile LH therapy further suggests that DHT does not play a role, at 
least at the level of the pituitary (Bagatell, Dahl et al. 1994). Moreover, in healthy 
men pre-treated with ketoconazole (achieving biochemical castration through 
desmolase and aromatase inhibition), replacement therapy with physiological doses 
of testosterone decreased LH pulse frequency, suggesting a direct action of 
testosterone at the hypothalamus (Pitteloud, Dwyer et al. 2008). However, LH pulse 
frequency and amplitude have been demonstrated to remain unchanged in IHH men 
on GnRH therapy (with fixed doses and frequency) exposed to identical intervention, 
suggesting that the effects of testosterone on gonadotropes, would require 
aromatisation (Pitteloud, Dwyer et al. 2008).  
Steroid receptor cross-talk between AR and ER is another emerging paradigm that 
makes it harder to differentiate the functional roles of androgen and estrogen. 
Although these effects could be specific to the tissue and development stage of 
animal models studied, down-regulation of AR expression has been described in the 
prostate following neonatal estrogen exposure (Woodham, Birch et al. 2003) and co-
transfection of AR and ER to cell lines modulate AR transcription (Kumar, Leo et al. 
1994). Similarly, co-administration of DHT and estradiol decreased porcine 
endometrium ERα and ERβ mRNA in comparison to estradiol alone (Cárdenas and 
Pope 2004). 
Double-label immunohistochemistry studies in ovine hypothalami have demonstrated 
that few GnRH neurons (less than 0.5%) express AR (Herbison, Skinner et al. 1996). 
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GnRH neurons are thus considered to be reliant on intermediary neuronal 
populations for mediating testosterone feedback. Experimentation in male animal 
models suggests a key role for KNDy neurons in the ARC in effecting such feedback 
as these neurons express AR. Suppression of gonadotropin secretion using 
testosterone implants in male rhesus monkey is associated with a reduction of Kiss1 
mRNA in the medial basal hypothalamus (Shibata, Friedman et al. 2007), consistent 
with similar findings observed in rodents (Irwig, Fraley et al. 2004; Navarro, 
Castellano et al. 2004). Testosterone induced suppression of Kiss1 mRNA in the 
rodent ARC is identical to that observed with estradiol, but more than that observed 
with DHT administration, suggesting that aromatisation of testosterone is required to 
effect at least part of its effect on KNDy neurons (Smith, Dungan et al. 2005). 
Moreover, post-orchidectomy rise in LH in rodents can be blocked by kisspeptin 
antagonists in male rodents, further suggesting that kisspeptin-GPR54 system 
mediates hypothalamic androgen feedback (Roseweir, Kauffman et al. 2009). 
1.3.1.3 Progesterone feedback 
It has long been established that exogenous progesterone administration reduces LH 
pulse frequency, enhances LH pulse amplitude and decreases mean LH in women in 
the follicular phase (Soules, Steiner et al. 1984). LH secretory pattern in women 
exposed to exogenous progesterone was comparable to LH profiles observed in 
women in the mid-luteal phase, demonstrating that progesterone plays a central role 
in regulating the gonadotropin secretory pattern in the luteal phase of normal 
menstrual cycle (Soules, Steiner et al. 1984). These early findings were consistent 
with the then recent observations in sheep that estradiol had an inhibitory effect on 
LH pulse amplitude while LH pulse frequency was decreased by progesterone 
administration (Goodman and Karsch 1980). These inhibitory effects on 
gonadotropin secretion was subsequently shown to be mediated through the classic 
progesterone receptor (PR) although the inhibitory effect of progesterone on LH 
pulse frequency was rapid and detectable within one pulse (Skinner, Evans et al. 
1998). Moreover, the suppressive effect of progesterone on LH pulse frequency was 
diminished in the context of estrogen deficiency while co-administration of estradiol 
in this context restored it (Skinner, Evans et al. 1998), suggesting an interplay 
 
Literature Review 38 
between the two sex-steroids. However, the presence of PR expression on only a 
small subset of GnRH neurons (Fox, Harlan et al. 1990; King, Tai et al. 1995) has 
led to the notion that intermediary neurons and/or neurotransmitters are involved in 
the transduction of progesterone inhibitory signals to GnRH neurons. 
Immunohistochemical studies have lent further support to this notion with only one 
out of over seven hundred GnRH perikaya co-expressing GnRH and PR, while also 
demonstrating that PR immunoreactivity is observed in the preoptic area and the 
arcuate nucleus (Skinner, Caraty et al. 2001), - the latter being a key hypothalamic 
location involved in GnRH pulse frequency modulation. The importance of the ARC 
in the modulation of LH pulse frequency has been further characterised recently - the 
application of micro-implants containing progesterone receptor antagonist (RU486) 
to ovine hypothalami diminished the inhibitory effect of systemically administered 
progesterone on LH pulse frequency (Goodman, Holaskova et al. 2011). 
Progesterone feedback on GnRH neurons is also mediated by endogenous opioids 
through the κ opioid receptor (Goodman, Coolen et al. 2004). There is indirect 
evidence that KNDy neurons in the ARC hypothalamus play a role in mediating 
progesterone feedback on GnRH through dynorphin, a specific endogenous agonist 
at the κ receptor (Lehman, Coolen et al. 2010). Progesterone receptors have been 
demonstrated to be co-localised with dynorphin in the KNDy neuronal population in 
the ARC (Foradori, Coolen et al. 2002). Progesterone therapy has also been shown to 
be correlated with an increase in cerebrospinal fluid dynorphin concentration in 
ovariectomised ewes (Foradori, Goodman et al. 2005). The number of 
preprodynorphin mRNA expressing cells decreased in ovariectomised ewes and 
normalised with progesterone therapy to luteal levels (Foradori, Goodman et al. 
2005). Unpublished data from the same group also suggest that the application of 
progesterone antagonist implants to the ovine ARC disrupted the negative feedback 
effects of progesterone (Lehman, Coolen et al. 2010). 
1.3.2  Stress and Glucocorticoids 
Stress is widely considered to be a cause of amenorrhea in disease states like 
depression, malnutrition, eating disorders, excessive exercise and Cushing syndrome 
(Chrousos, Torpy et al. 1998; Kalantaridou, Makrigiannakis et al. 2004). 
Experimental evidence from animals models point towards cortisol-mediated 
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suppression of gonadotropin secretion as the final common pathway that effects 
gonadotropin suppression in response to various models of stress. There are also data 
to suggest that upstream factors in the hypothalamus-pituitary-adrenal axis such as 
Corticotropin Releasing Hormone (CRH) and Arginine Vasopressin (AVP) (Breen 
and Karsch 2006) play a mediatory role.  
1.3.2.1 Effects of glucocorticoids 
While it is clear that severe psychological and physical stress manifests as 
hypothalamic amenorrhea (a heterogeneous diagnosis of exclusion), determining 
relative contributions of hypothalamic-pituitary-adrenal axis activation and altered 
metabolic feedback remains to be elucidated in the human context. However, 24-
hour cortisol excretion in women with hypothalamic amenorrhea has been 
demonstrated to be elevated by 17% although cortisol pulsatility and diurnal 
rhythmicity were preserved (Berga, Mortola et al. 1989). Evening ACTH and cortisol 
concentrations are known to be higher in highly trained runners (Luger, Deuster et al. 
1987) and overtraining leads to elevated urinary free cortisol (Barron, Noakes et al. 
1985). Moreover, in women with anorexia nervosa, Corticotropin Releasing Factor 
(CRF) concentrations are elevated in the CSF (Kaye, Gwirtsman et al. 1987). 
Administration of modest doses of exogenous glucocorticoids for a fortnight to 
eugonadal regular cycling women was associated with a decrease in LH pulse 
frequency without alteration of LH pulse amplitude, suggesting that glucocorticoids 
have a negative influence on GnRH pulse frequency (Saketos, Sharma et al. 1993). 
However, it has to be noted that the corticosteroid regime involved the reversal of 
normal circadian rhythm with 10 mg hydrocortisone administered in the morning 
(0700-1000 hrs) and 10 mg between 1900 and 2200 (Saketos, Sharma et al. 1993). In 
sheep models, exogenous cortisol (25 and 100 µg/kg/hr cortisol) has been 
demonstrated to show suppression of LH amplitude in a dose dependant manner 
(Debus, Breen et al. 2002).  
Indirect inferences on the effects of cortisol on gonadotropin secretion can also be 
derived from observations in patients with Cushing’s syndrome – a clinical condition 
associated with excessive cortisol secretion. Exogenous GnRH in women with 
Cushing’s disease preferentially stimulates FSH, with LH remaining largely 
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unchanged (Boccuzzi, Angeli et al. 1975) with similar findings observed in men 
(Luton, Thieblot et al. 1977). Remission of Cushing’s disease in men has also been 
observed to be associated with resolution of hypogonadotropic hypogonadism in men 
(Luton, Thieblot et al. 1977). 
Studies in animal models have cast doubt on the assumption that glucocorticoid 
feedback on the reproductive endocrine axis is exerted at a supra-pituitary location. 
During studies carried out in juvenile rhesus monkey to assess gonadotropin activity 
at various reproductive stages, it was serendipitously observed that separation of 
juvenile animals from their mothers caused a sharp decline in gonadotropin secretion 
in the former (Pohl, deRidder et al. 1995). This suppression of gonadotropin function 
was associated with increased serum cortisol concentrations (Pohl, deRidder et al. 
1995).  Moreover, studies in sheep have shown a decrease in LH pulse altitude in 
response to exogenous cortisol (Breen and Karsch 2004; Breen, Stackpole et al. 
2004; Breen, Oakley et al. 2007), suggesting a pituitary locus for this feedback. This 
notion was lent further support by the observation that LH responses to pulsatile 
GnRH is diminished by cortisol (Breen, Oakley et al. 2007). However, direct 
measurement of GnRH in ovine portal blood following 27 hours of cortisol 
administration demonstrated a 40% decrease in GnRH pulse frequency (Oakley, 
Breen et al. 2009). Moreover, whilst cortisol alone had no impact on GnRH pulse 
frequency in ovariectomised ewes, co-administration of estradiol and progesterone 
led to a 70% decrease in GnRH pulse frequency, suggesting a modulatory role for 
ovarian steroids in cortisol induced suppression of the reproductive system (Oakley, 
Breen et al. 2009). Selective blockade of the type 1 and type 2 glucocorticoid 
receptors have also demonstrated that the suppressive effect of cortisol on LH 
secretion is mediated through the type 2 glucocorticoid receptor (Breen, Stackpole et 
al. 2004; Breen, Oakley et al. 2007). In summary, as with estrogen feedback on the 
hypothalamic-pituitary unit, it is likely that cortisol exerts a negative input both at the 
pituitary and at the hypothalamic levels. 
Decreased Kiss1 mRNA expression in the ARC has been reported in rats 
administered glucocorticoids or exposed to stress (hypoglycaemia, restraint and 
lipopolysacharide induced immunological stress) (Kinsey-Jones, Li et al. 2009). 
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Preliminary data also suggest that Kiss1 mRNA expression is reduced with models of 
stress (food deprivation and restraint) as well as exogenous glucocorticoid 
administration in male mice (Wang, Lanjuin et al. 2011). This study also reported the 
presence of glucocorticoid receptor on murine kisspeptin neurons. 
1.3.2.2 Hypoglycaemia as a model of stress 
Hypothalamic-Pituitary-Gonadal (HPG) axis activity, GnRH pulsatility in particular, 
is down regulated by stress. Using hypoglycaemia as a stressor, suppression of 
GnRH pulsatility has been demonstrated in rodents (Cagampang, Cates et al. 1997; 
Cates and O'Byrne 2000), sheep (Clarke, Horton et al. 1990; Adam and Findlay 
1998) and primates (Chen, O'Byrne et al. 1992; Chen, Ordog et al. 1996). Estrogen 
has been shown to exacerbate this stress-related suppression of GnRH secretion 
(Cagampang, Cates et al. 1997), and adrenomedullectomy prevents this inhibitory 
effect (Cagampang, Cates et al. 1997), suggesting sympathetic stimulation/cortisol 
activity as a causative mechanism.  
In human studies, LH and testosterone concentrations in serum have been shown to 
decrease in response to hypoglycaemic stress irrespective of the insulin dosage 
infused, suggesting hypoglycaemia rather than circulating insulin levels to be the 
aetiology of HPG axis suppression (Oltmanns, Fruehwald-Schultes et al. 2001). By 
inducing hypoglycaemic stress repetitively in the same human subject, it has also 
been shown that there is no short term adaptation or desensitisation of the HPG axis 
to stress (Oltmanns, Peters et al. 2005). 
1.3.3  Nutrition and metabolism 
A link between energy balance and reproductive function enables organisms to 
survive to reproductive maturity and to withstand the energy needs of parturition, 
lactation and other parental behaviour (Schneider 2004). This link optimises 
reproductive success under fluctuating metabolic conditions, ultimately ensuring the 
survival of the species (Schneider 2004).  
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1.3.3.1 Acute malnutrition 
Acute effects of decreased food intake on LH pulsatility have now been 
demonstrated in a number of species (Schneider 2004). Periods of fasting as short as 
1-2 days significantly decrease LH pulsatility and re-feeding rapidly restores normal 
LH secretion in rhesus monkeys (Schreihofer, Amico et al. 1993). In women, calorie 
restriction decreases LH pulse frequency and increases LH pulse amplitude (Loucks, 
Verdun et al. 1998). Graded calorie restriction (10, 20, 30 or 45 kcal/kg Lean Body 
Mass per day) in women with regular menstrual cycles have demonstrated a 
threshold for energy-deficit dependant LH suppression – only daily energy 
availability less than 30 kcal/kg decreased LH pulse frequency (and increased LH 
pulse amplitude) (Loucks and Thuma 2003). Moreover, calorie reduction was also 
associated with an amplification of nocturnal decrease in LH pulse frequency 
(Loucks and Thuma 2003). Leptin, a satiety hormone, whose levels drop rapidly in 
response to fasting in human subjects (Boden, Chen et al. 1996; Weigle, Duell et al. 
1997) may play a central role in facilitating this inter-regulation. Administration of 
recombinant leptin increased LH pulse frequency and mean LH in hypothalamic 
women (Welt, Chan et al. 2004). In healthy men, recombinant leptin prevents 
fasting-induced drop in testosterone and LH pulsatility (Chan, Heist et al. 2003).  
Nutritional deficiency has also been demonstrated to suppress gonadotropin secretion 
in males of a number of species (Bergendahl and Veldhuis 1995). Three and a half 
days of fasting by young men effected decreases in LH pulse frequency, pulse mass-
per-burst and mean LH, while these parameters were unchanged in older men 
(Bergendahl, Aloi et al. 1998). Orderliness of LH secretion (approximate entropy) 
increased with fasting in younger men, but sensitivity to 10 µg GnRH was not 
affected by fasting status or age (Bergendahl, Aloi et al. 1998). Fasting also led to 
significant increases in cortisol (Bergendahl, Aloi et al. 1998), making it difficult to 
attribute the changes in LH to fasting alone. However, augmentation of cortisol in 
response to stress is well-established and has been demonstrated to be due to 
increased secretion of cortisol, rather than impairment of its metabolic clearance 
(Bergendahl, Vance et al. 1996). Moreover, there is a shift in the diurnal pattern of 
cortisol secretion in models of stress, with peak concentrations observed in the early 
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afternoon (and not early in the morning as seen in normal subjects) (Bergendahl, 
Vance et al. 1996). 
Food deprivation is associated with a decrease in hypothalamic Kiss1 mRNA 
expression in rats, with concomitant increase in Kiss1R mRNA (Castellano, Navarro 
et al. 2005). Time-series studies have shown that decrease in hypothalamic GnRH 
mRNA expression in fasting is preceded by a decrease in Kiss1R mRNA expression 
(Luque, Kineman et al. 2007).  Moreover, exogenous kisspeptin restored vaginal 
opening, a marker of sexual maturation, in malnourished rodents (Castellano, 
Navarro et al. 2005). Animal models of type 1 diabetes, characterised by insulin 
deficiency and thus impaired cellular nutrition, demonstrate hypogonadotropic 
hypogonadism and decreased Kiss1 mRNA expression (Castellano, Navarro et al. 
2006). Repetitive administration of kisspeptin to these rodents with streptazocin-
induced diabetes increased prostate and testis weight (Castellano, Navarro et al. 
2006). Notably, LH response to kisspeptin in diabetic and control animals were 
comparable and exogenous kisspeptin normalised the diminished post-orchidectomy 
rise in LH observed in diabetic male rats (Castellano, Navarro et al. 2006). 
1.3.3.2 Chronic malnutrition 
Clinical observational studies of growing children carried out in the late 1960s 
demonstrated that the onset of puberty was triggered by the achievement of a critical 
body weight and not merely by chronological age – suggesting that pubertal 
development is triggered by metabolic signals (Frisch and Revelle 1970). Subsequent 
studies were in keeping with these observations, but additionally identified that ‘the 
degree of fatness’ rather than the total body weight alone was critical in the onset of 
menarche as well as the restoration of menstrual cycles in secondary amenorrhea 
(Frisch and McArthur 1974). Observations in children with cystic fibrosis (a disease 
state associated with net calorie deficit in the majority of patients), menarche was 
found to be correlated with the degree of illness and body fat content (Moshang and 
Holsclaw 1980). In keeping with these observations, pre-menarche athletic training 
has been found to be associated with later menarche, in comparison to control 
population (Frisch, Gotz-Welbergen et al. 1981). These studies led to the emergence 
of ‘critical fat’ hypothesis – i.e., that a hypothetical threshold exists for body fat 
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content exists below which reproductive function is compromised. Hypothalamic 
signalling pathways relaying nutritional status to the reproductive endocrine axis 
remained enigmatic until the discovery of leptin, a hormone secreted by adipocytes 
was shown to be a key metabolic signal modulating reproduction (Barash, Cheung et 
al. 1996). LH pulse frequency, pulse amplitude and mean serum LH concentrations 
increases with leptin administration in non-human primates (Finn, Cunningham et al. 
1998) and rodents (Nagatani, Guthikonda et al. 1998). However, it has to be noted 
that this stimulation of gonadotropin is only manifest when the HPG axis has been 
suppressed by fasting.  
However, in situ hybridization studies of hypothalami from multiple species have not 
demonstrated the presence of leptin receptors on GnRH neurons (Cunningham, 
Clifton et al. 1999), suggesting the need for an intermediary neuronal network to 
relay leptin signalling to the GnRH neuron (Quennell, Mulligan et al. 2009). 
Proopiomelanocortin, neuropeptide Y, and cocaine- and amphetamine-regulated 
transcript (CART) expressing neurons have been demonstrated to play at least a part 
in mediating this signalling (Quennell, Mulligan et al. 2009). A role for kisspeptin in 
this pathway was first suggested following the demonstration of decreased Kiss1 
expression in fasted rodents (Castellano, Navarro et al. 2005) and the normalisation 
of hypogonadotropic hypogonadism in energy deficient animal models with leptin 
administration (Castellano, Navarro et al. 2006). These findings have since been 
replicated in ovine models and kisspeptin neurons were subsequently demonstrated 
to express leptin receptors (Backholer, Smith et al. 2010). Moreover, kisspeptin 
neurons communicate with POMC and neuropeptide Y neurons and are able to 
modulate expression of relevant genes in these cells (Backholer, Smith et al. 2010) –
suggesting that kisspeptin’s role in the pathway that links reproductive function with 
metabolic input might be complementary, at least in part, to the roles played by other 
neuronal systems. Recent studies in leptin deficient rodent models have demonstrated 
that kisspeptin and GnRH neurons are not activated during induced LH surge 
(Quennell, Howell et al. 2011) – suggesting that afferent leptin input to the 
hypothalamic-pituitary gonadal axis is upstream of kisspeptin neurons. Furthermore, 
this study has also shown that in mice models prone to diet-induced infertility, high 
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fat diet administration and resultant obesity is associated with down regulation of 
kisspeptin expression (Quennell, Howell et al. 2011). 
Selective deletion of LepR from hypothalamic Kiss1 neurons in mice was not 
associated with adverse effects on puberty or fertility (Donato, Cravo et al. 2011). 
Although methodological issues such as incomplete knock out of hypothalamic 
KNDy and GnRH neurons, this finding suggests that direct leptin signalling in Kiss1 
neurons is not required for these processes. It has to be noted in this context that 
Estrogen induced Fos expression in GnRH neurons and produced a GnRH-dependent 
LH surge in GPR54 knock out rodents (Dungan, Gottsch et al. 2007). Taken 
together, these results suggest that there are pathways other than Kisspeptin-GPR54 
system that stimulate the GnRH neuronal population and Leptin’s effects are 
mediated by those alternate pathways. Studies in Ewes have demonstrated that 
reciprocal connections exist between kisspeptin cells and NPY and POMC cells 
(Backholer, Smith et al. 2010). Further work is required to elucidate the pathways 
that integrate leptin signalling with GnRh/LH secretion(Carol F 2012) .  
  
1.3.4  Neurokinin B 
A hypothalamic role for neurokinin B in the regulation of reproduction came to be 
established when genetic studies in patients from consanguineous families with 
normosmic idiopathic hypogonadotropic hypogonadism were found to have missense 
mutations in TAC3 (that encodes neurokinin B) and TACR3 (that encodes neurokinin 
B receptor) (Topaloglu, Reimann et al. 2009). In vitro characterisation of these 
receptors demonstrated diminished intracytosolic calcium response to neurokinin B 
(Topaloglu, Reimann et al. 2009). Men with these mutations had micropenis – 
suggesting inadequate intrauterine and post-natal testosterone input (Topaloglu, 
Reimann et al. 2009). A number of cases of NK3 and NK3R receptor mutations, both 
homozygous and heterozygous, associated with pubertal dysfunction have since been 
described (Guran, Tolhurst et al. 2009; Gianetti, Tusset et al. 2010; Young, 
Bouligand et al. 2010). Association of neurokinin B signalling defects with 
micropenis in males was demonstrated in these studies too, while the largest series 
amongst these also suggest that many such patients also demonstrate at least partial 
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reversal of hypogonadism in adult life (Gianetti, Tusset et al. 2010). The small 
sample size employed in these studies makes it difficult to make meaningful 
comparisons with other causes of IHH. However, the reported reversal rate in 
patients with neurokinin B signalling deficiencies, 80% (Gianetti, Tusset et al. 2010) 
and 15% (Topaloglu and Semple 2011) , are higher than that observed in other forms 
of IHH (Pitteloud, Acierno et al. 2005; Raivio, Falardeau et al. 2007). 
Neurokinins (A&B) are members of the tachykinin family of peptides that also 
include Substance P (SP) and stimulate three related GPCRs with Gq-coupled 
signalling (Topaloglu and Semple 2011). Although these receptors NK1R, NK2R, 
and NK3R (encoded by TACR1, TACR2 and TACR3) are not specific for individual 
tachykinins, NK3R is considered to show in vivo specificity for neurokinin 3 
(Sandoval-Guzmán and E. Rance 2004; Topaloglu and Semple 2011). 
The association of hypogonadotropic hypogonadism with neurokinin B signalling 
defect in humans is in contrast to observations made in neurokinin B receptor knock-
out rodent models (Kung, Crawley et al. 2004; Nordquist, Delenclos et al. 2008; 
Topaloglu, Reimann et al. 2009) not demonstrating a GnRH deficient phenotype. 
However, it has to be noted that Tac2 (the mouse orthologue of human TAC3) 
knock-out is yet to be studied (Topaloglu and Semple 2011).  
Interactions between kisspeptin and neurokinin B systems have also been studied 
recently in rodents – with divergent findings.  Central and peripheral administration 
of neurokinin B to intact wild-type rodents have shown no effect on circulating 
luteinising hormone (LH) in a recent study (Corander, Challis et al. 2010) while in 
earlier studies, the central administration of Senktide, a selective NK3 receptor 
agonist had demonstrated inhibition (rather than stimulation) of LH secretion in 
ovariectomised rats (Sahu and Kalra 1992; Sandoval-Guzmán and E. Rance 2004). 
Ex vivo co-stimulation of rat hypothalamic explants with kisspeptin and neurokinin B 
yielded lower LH stimulation than kisspeptin alone (Corander, Challis et al. 2010). 
Administration of Senktide evoked potent LH secretion in intact animals with over 
two-fold increase from baseline in both diestrus and proesterus (Navarro, Castellano 
et al. 2011). However, ovariectomised rats demonstrated a decrease in LH secretion, 
whilst the parallel arm of ovariectomised rats treated with a physiological dose of 
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estrogen showed an increase in LH (Navarro, Castellano et al. 2011). Interestingly, 
similar differences in responses based on sex steroid status have been demonstrated 
with other neurotransmitters. Examples include neuropeptide Y, opioids and 
glucocorticoids – as discussed in detail in section 1.3.5. 
A ten-fold increase in c-fos expression in Kiss1 neurons located in the ARC was also 
observed following Senktide administration, suggesting that neurokinin B signalling 
can activate KNDy neurons (Navarro, Castellano et al. 2011). Intracerebroventricular 
administration of kisspeptin and neurokinin B to rodents were also shown to effect 
larger increases in LH in comparison to kisspeptin alone (Corander, Challis et al. 
2010).  Furthermore, the stimulatory effect of senktide, (selective agonist of 
neurokinin B) was abolished in Gpr54 knock-out male (Garcia-Galiano, van Ingen 
Schenau et al. 2012), further suggesting that Neurokinin B exerts its action upstream 
of kisspeptin signalling. 
Studies in ruminants have demonstrated the modulatory effect of sex steroids on 
neurokinin B signalling at the hypothalamus (Billings, Connors et al. 2010). In 
ovariectomised goats, neurokinin B stimulated LH secretion only after pre-treatment 
with both estrogen and progesterone (Wakabayashi, Nakada et al. 2010). Arcuate 
electrical multi-unit activity corresponded to LH secretion, suggesting a 
hypothalamic site of neurokinin B signalling as well as a potential role for this 
neuropeptide in GnRH pulse generation (Wakabayashi, Nakada et al. 2010). Unlike 
studies involving administration of kisspeptin, not all episodes of electrical activity 
were associated with LH release (Wakabayashi, Nakada et al. 2010). Whilst 
neurokinin B increased LH pulse amplitude following central administration, no 
difference in pulse frequency was observed (Billings, Connors et al. 2010). Taken 
together, these observations suggest that KNDy neurons exert a stimulatory effect on 
GnRH pulse frequency through neurokinin B (Wakabayashi, Nakada et al. 2010). 
However, it has to be noted that the observations in rodents are 
divergent.  Intracerebroventricular administration of the selective neurokinin-3 
receptor agonist, senktide (100-600 pmol), caused a dose-dependent suppression of 
LH pulses and multiunit activity volleys in ovariectomized (OVX) and OVX 17β-
estradiol-replaced rats (Kinsey-Jones, Grachev et al. 2012). 
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Studies in primates have further strengthened knowledge of the role played by 
neurokinin B in the hypothalamic regulation of reproduction. Pre-treatment with 
GnRH antagonists abolished the stimulatory effect of neurokinin B, demonstrating its 
site of action to be at or above the GnRH receptor (Ramaswamy, Seminara et al. 
2010). Comparative studies of kisspeptin and neurokinin B in gonadectomised rhesus 
monkeys primed with pulsatile GnRH have demonstrated the amplitude of 
stimulatory LH response evoked by kisspeptin to be higher (Ramaswamy, Seminara 
et al. 2010). Pre-treatment with a specific neurokinin B antagonist abrogated 
neurokinin B’s stimulatory effect on LH secretion whilst having no impact on 
kisspeptinergic stimulation of LH secretion in these primate models (Ramaswamy, 
Seminara et al. 2010). This notion that kisspeptin exerts its stimulatory effect on LH 
independent of Neurokinin B stimulation is further supported by preservation of this 
effect in rhesus monkeys in whom LH stimulatory responses to Senktide were 
desensitised by repeated administration (Ramaswamy, Seminara et al. 2010; 
Ramaswamy, Seminara et al. 2011). Although it has been suggested that the order of 
magnitude of stimulation of LH by kisspeptin and neurokinin B are comparable 
(Topaloglu and Semple 2011), LH excursion was higher in primates administered 
boluses of kisspeptin (Ramaswamy, Seminara et al. 2010). Repeated administration 
of kisspeptin bolus as hourly pulses demonstrated persistence of LH response 
without tachyphylaxis, unlike neurokinin B (Ramaswamy, Seminara et al. 2010). The 
latter observation would suggest that desensitisation of LH responsiveness to 
repeated administration of Senktide occurs at a level above gonadotrope GnRH 
receptor. This notion is supported by recent studies where kisspeptin stimulation of 
LH release was preserved in rhesus monkeys desensitised to neurokinin B 
stimulation by continuous Senktide administration (Ramaswamy, Seminara et al. 
2010).  
In summary, the effects of NKB on GnRH/LH secretion appear to be dependent on 
the species studied and the prevailing gonadal steroid mileu. Studies in large 
mammals (ruminants and primates) suggest a stimulatory role for NKB, whilst the 
rodent data is not consistent. These emphasise the limitations of using animal models 
in studying human reproductive function. 
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1.3.5  Opiates and other neuropeptides 
A large number of neuropeptides and other substances have been shown to influence 
GnRH-gonadotrope function (Urban, Evans et al. 1988; Evans, Sollenberger et al. 
1992). Of these, the role played by the hypothalamic opioid peptide system has been 
investigated most in the human context. When a specific opioid receptor antagonist, 
naltrexone, was administered to healthy men whose LH pulse frequency had been 
iatrogenically reduced with DHT infusions, a restoration of LH pulse frequency was 
observed (Veldhuis, Rogol et al. 1984). Naltrexone also restored LH pulse frequency 
and LH pulse amplitude in estradiol treated men, suggesting that opiatergic input and 
sex-steroid milieu regulate GnRH function in a co-ordinated manner (Veldhuis, 
Rogol et al. 1984). These findings are consistent with earlier studies involving the 
administration of another opioid antagonist (naltrexone) to women during different 
phases of normal menstrual cycle – where stimulation of LH secretion was observed 
in the late follicular and mid-luteal phase, but not in the follicular phase (Quigley and 
Yen 1980). In women treated with oral medroxyprogesterone acetate (Provera), 
naloxone therapy has also been demonstrated to restore LH concentrations to pre-
Provera levels (Casper and Alapin-Rubillovitz 1985). These observations are also 
consistent with localisation of human β endorphins to the ARC nucleus in the human 
brain (Wilkes, Watkins et al. 1980). Perhaps predictably, attempts to control hot 
flushes in post-menopausal women using naloxone therapy were not successful 
(DeFazio, Verheugen et al. 1984). These observations are in keeping with studies in 
oophorectomised women, where no changes in LH concentrations were observed 
following naloxone administration unless co-administered with an estrogen or 
progestin (Shoupe, Montz et al. 1985). Preservation of naloxone-mediated increase in 
LH frequency in gonadectomised individuals with testicular feminisation syndrome 
also demonstrate that androgen action is not obligatory for opiatergic suppression of 
GnRH pulse frequency (Veldhuis, Rogol et al. 1985). Taken together, these studies 
have germinated the notion that endogenous opioids play a central role in the control 
of the menstrual cycle (Ferin and Vande Wiele 1984) and that opioid input has an 
inhibitory effect on GnRH –pituitary output. 
Interplay between opioid and sex-steroid input demonstrated in the human setting has 
been investigated in depth in animal models, especially in exploring differential 
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effects of opioid receptor subtypes (β, µ and δ) and their anatomical distribution. A 
subset of GnRH neurons in the ovine medial basal hypothalamus demonstrated 
increased Fos/Fos Related Antigen expression following non-specific opioid 
antagonist therapy, suggesting preferential suppression of these GnRH neurons by 
opioids (Boukhliq, Goodman et al. 1999). Administration of receptor specific opioid 
antagonists to ovariectomised sheep have further demonstrated that µ-receptors, (but 
not δ- or κ-receptors), play an inhibitory role in the regulation of GnRH surge (Walsh 
and Clarke 1996). However, κ (but not µ or δ) receptors play a part in the regulation 
of LH secretion during follicular and luteal phases in ewes, as evidenced in 
investigations involving the administration of κ – specific ligand, dynorphin 
(Goodman, Coolen et al. 2004). Furthermore, nearly 90% of all GnRH perikaya at 
the MBH are reported to be apposed to dynorphin (κ –ligand) containing varicosities 
in dual immunohistochemical analysis of ovine hypothalami, while electron 
microscopy has demonstrated dynorphinergic synapses with GnRH perikaya 
(Goodman, Coolen et al. 2004). 
In 2007, it was demonstrated that dynorphin and kisspeptin are co-localised along 
with Neurokinin B, another neuropeptide modulator of GnRH secretion in the same 
neuronal population within the ARC nucleus (Goodman, Lehman et al. 2007). Over 
three quarters of ARC dynorphin neurons co-expressed kisspeptin and vice versa, 
while most of the kisspeptin neurons also expressed Estrogen Receptor α and 
Progesterone Receptor (Goodman, Lehman et al. 2007), suggesting that this neuronal 
population (KNDy neurons - Kisspeptin, Neurokinin-B, Dynorphin neurons) 
mediates sex-steroid modulation of GnRH secretion (Goodman, Lehman et al. 2007). 
This population of neurons is also distinct from appetite regulating agouti-related 
peptide, Neuropeptide Y, melanocortin and β endorphin neurons and shows sexual 
dimorphism, with ewe hypothalami having more Neurokinin-B neurons in the ARC 
(Goodman, Lehman et al. 2007) .  
1.3.6  Prolactin 
The association between hyperprolactinemia and amenorrhea has long been 
established, accounting for around 14% of secondary amenorrhea in some series with 
clomiphene non-responsiveness and hypogonadotropism (Bohnet, Dahlen et al. 
1976). Hyperprolactinemia has also been reported in a third of women presenting 
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with infertility (Molitch 1985) and increased prolactin secretion plays a central role 
in lactational amenorrhea (Diaz, Seronn-Ferre et al. 1989). In men, 
hyperprolactinemia is evident in 16% of men with erectile dysfunction and 11% of 
men with oligospermia (De Rosa, Zarrilli et al. 2003). Decreased LH pulse frequency 
(and by inference GnRH pulse frequency) and increased pulse amplitude that 
characterises hyperprolactinemia responds to bromocriptine therapy, with increased 
pulse frequency observed in some patients within few days of therapy (Moult, Rees 
et al. 1982). Moreover, LH pulses are reported to be more irregular in 
hyperprolactinemic women and bromocriptine therapy increases regularity of LH 
pulses (Sauder, Frager et al. 1984). Pulsatile GnRH therapy has also been shown to 
restore ovulation and normal luteal function in bromocriptine resistant 
hyperprolactinemic women (Polson, Sagle et al. 1986; Lecomte, Lecomte et al. 
1997), suggesting that the central mechanism by which prolactin exerts its 
hypophysiotropic inhibition is through a reduction of GnRH pulse frequency. 
Neuroendocrine pathways by which prolactin inhibits GnRH pulse frequency remain 
to be fully elucidated. A direct action of prolactin on the GnRH neuronal network is 
possible as GT1 cells (an immortalised GnRH cell line), express prolactin receptors 
and GnRH biosynthesis in these cells is inhibited by prolactin (Milenković, D'Angelo 
et al. 1994). However, whether these findings can be applied to GnRH neurons in 
vivo remains unclear as adult GnRH neurons do not express prolactin receptor 
(Grattan, Jasoni et al. 2007). Prolactin has been demonstrated to influence other 
neuronal systems – including GABA (Kolbinger, Beyer et al. 1992), β endorphins 
(Sarkar and Yen 1985), neuropeptide Y (Li, Chen et al. 1999) and dopaminergic 
systems (Moore 1987). Whilst all these systems may have a role to play, 
dopaminergic inhibition has been shown to correlate with menstrual activity and is 
inhibited by acute sucking and lactation (Moore 1987). 
Studies in rodent models suggest that kisspeptin neurons in the ARC nucleus 
modulate dopamine release from dopaminergic neurons, thereby regulating prolactin 
secretion (Szawka, Ribeiro et al. 2010). In keeping with this, Kiss1 expression is 
decreased in lactation (a physiological state associated with hyperprolactinaemia) 
(Yamada, Uenoyama et al. 2007). Recent unpublished data suggest that KNDy 
 
Literature Review 52 
neurons in the ovine arcuate nucleus also express prolactin receptors (Li, Clarke et al. 
2011). 
1.3.7  Acute and chronic illness 
Chronic illness is associated with delayed puberty (Pozo and Argente 2002). Acute 
critical illness is also associated with hypogonadotropic hypogonadotropism, as 
demonstrated in patients admitted to intensive care facilities (Van den Berghe, 
Weekers et al. 2001). Although this population is likely to be a heterogeneous cohort 
with diverse pathology, critically ill patients admitted to intensive care units are in a 
catabolic state often associated with an acute inflammatory response. Repeated 
administration of GnRH to critically ill men failed to fully normalise testosterone, 
suggesting multi-level impairments in the  hypothalamic-pituitary gonadal axis (Van 
den Berghe, Weekers et al. 2001). Recent studies have shown a role for the 
kisspeptin-GPR54 system in mediating decreased GnRH secretion associated with 
systemic inflammation (Iwasa, Matsuzaki et al. 2008; Castellano, Bentsen et al. 
2010). Decreased Kiss1 expression has been described in the ARC nucleus of rats in 
whom gonadotrophic suppression was induced by administration of 
lipopolyscaharide (LPS), a glycolipid secreted by gram-negative bacteria that 
triggers inflammation through multiple pathways (Iwasa 2008). Administration of 
kisspeptin was shown to reverse iatrogenic hypogonadotropism in these animals 
(Iwasa 2008). It has also been demonstrated that inflammation-mediated suppression 
of Kiss1 expression in the ARC nucleus is independent of decreased calorie intake 
(Castellano, Bentsen et al. 2010). 
1.4 Clinical application of GnRH and analogues. 
Since the discovery and functional characterization of GnRH, the native peptide as 
well as analogues have been used extensively for diagnostic and therapeutic use, with 
annual sales of over two billion US dollars (Millar, Zhu et al. 2000). 
1.4.1.1 Diagnostic applications 
1.4.1.1.1 Precocious puberty 
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Provocative testing with GnRH has been widely used in the assessment of pubertal 
development (Lee 1994). Precocious puberty is defined as the appearance of 
secondary sexual characteristics in boys younger than nine years and girls younger 
than eight (Lee 1994; Carel, Eugster et al. 2009). Precocious puberty could arise due 
to increase in GnRH secretion when it is termed GnRH-dependant (or central 
precocious puberty) or due to extra-hypothalamic factors such as gonadotropin 
secreting tumours, adrenal hyperplasia or familial causes when it is termed non-
GnRH dependant (Lee 1994). As progressive central precocious puberty is associated 
with psychological and physical manifestations (Carel, Eugster et al. 2009), an early 
diagnosis is important. Although baseline and stimulated LH concentrations 
(following GnRH provocation) overlap prepubertal values, various testing regimes 
using native GnRH decapeptide or its analogues are used in the assessment with an 
assay-dependant prepubertal threshold for peak LH defined at 3.3 to 5.0 IU/L (Carel, 
Eugster et al. 2009). Moreover, provocative tests with GnRH administration have 
also been proposed as a tool to monitor therapeutic adequacy of gonadotropin 
suppressive therapy in central precocious puberty (Lee 1994). However, there is a 
lack of consensus on whether such monitoring adds value over and above clinical 
observations such as regular monitoring of growth, clinical assessment of pubertal 
development and radiometric assessment of bone age (Carel, Eugster et al. 2009). 
Whilst test regimes involving collection of multiple samples and calculations of 
LH:FSH ratio have been employed in the past, it has been demonstrated that a single 
LH value obtained 30 minutes after GnRH administration is sufficient to  distinguish 
central precocious puberty from other causes (Cavallo, Richards et al. 1995).  
1.4.1.1.2 Delayed puberty 
A lack of pubertal development by two standard deviations above the mean age of 
pubertal onset in the local population is considered as delayed puberty (Argente 
1999). Fourteen and thirteen years of age are widely regarded as the threshold to 
make the diagnosis in boys (testicular size <4 ml) and in girls (lack of thelarche) 
respectively (Argente 1999) . The diagnostic challenge in the management of these 
children is to differentiate pubertal delay that occurs due to inadequate hypothalamic-
pituitary activity (hypogonadotropic hypogonadism) and constitutional delay in 
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puberty (Segal, Mehta et al. 2009). Provocative test with GnRH analogues using 8 
IU/L as the cut-off for diagnosis was able to differentiate the two groups in one study 
(Kauschansky, Dickerman et al. 2002). It has subsequently been shown that 
combining Human Chorionic Gonadotropin (HCG) stimulation tests with GnRH 
provocative testing can improve this differentiation (Segal, Mehta et al. 2009). 
1.4.1.1.3 Other diagnostic applications 
Provocative testing with GnRH has been proposed as a tool to differentiate 
hypothalamic and pituitary causes of central hypogonadotropism (Swerdloff, 
Peterson et al. 1978). However, clinical studies have since shown that due to 
considerable variability in gonadotropin response in pathological settings with 
marked overlap with responses observed in healthy subjects, GnRH provocative 
testing may not be useful in the diagnosis of hypothalamic-pituitary-gonadal 
dysfunction (Mortimer, Besser et al. 1973; Westwood, Butler et al. 2000; Chammas, 
Chambers et al. 2008). With the development of sensitive and specific assays for 
gonadotropins, baseline LH and FSH are widely used in clinical practice, despite the 
theoretical concern that the timing of the sample relative to the underlying pulsatility 
will influence the observed results.  
1.4.1.2  Therapeutic applications 
1.4.1.2.1 Pubertal dysfunction 
GnRH analogue therapy in precocious puberty is aimed to suppress endogenous 
GnRH activity and exploits the desensitisation of the hypothalamic-pituitary unit to 
prolonged GnRH stimulation initially demonstrated in primate models (Belchetz, 
Plant et al. 1978). Children with peripheral and central precocious puberty were 
administered GnRH analogues as early as 1979, rapidly translating the findings in 
animal models (Pescovitz, Comite et al. 1986). Children with central puberty 
responded to the therapy, while those with peripheral causes did not (Pescovitz, 
Comite et al. 1986). Moreover, GnRH analogue therapy has been demonstrated to be 
safe, with pubertal development recommencing once the treatment was withdrawn 
(Pescovitz, Comite et al. 1986; Manasco, Pescovitz et al. 1988).  
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Pulsatile GnRH therapy has been demonstrated to initiate pubertal development in 
boys and girls presenting with delayed pubertal development (Hoffman and Crowley 
1982; Stanhope, Pringle et al. 1987). Whilst the requirement for hormonal 
replacement therapy in these individuals has been previously thought to be lifelong, 
there is emerging evidence that hypogonadotropic hypogonadism in some of these 
subjects could be reversed (Quinton, Cheow et al. 1999; Raivio, Falardeau et al. 
2007; Ribeiro, Vieira et al. 2007). Prospective studies have shown a 10% reversal 
rate (95% Confidence Interval 2 -18%) (Raivio, Falardeau et al. 2007) and in post-
reversal follow-up (range of duration of follow-up 0.6 to 23.7 years) thirteen of 
fifteen patients had adult serum testosterone throughout the follow-up period (Raivio, 
Falardeau et al. 2007). The mechanisms underpinning this apparent plasticity of 
GnRH neurons remain to be elucidated. However, as non-responders were identified 
as early as 7±4 weeks following discontinuation of therapy, brief withdrawal of 
therapy may be warranted in patients with delayed puberty who have achieved adult 
testosterone concentrations (Raivio, Falardeau et al. 2007). It has to be noted that 
non-pulsatile treatment with GnRH does not lead to progression of puberty, as 
observed in a study involving the administration of 500 µg of GnRH twice daily 
(Brook and Dombey 1979). 
1.4.1.2.2 Induction of ovulation 
Pulsatile administration of GnRH at physiologic doses and frequency has been 
demonstrated to induce ovulation in women with anovulatory infertility (Crowley 
and Mcarthur 1980; Leyendecker, Struve et al. 1980; Skarin, Nillius et al. 1983), 
providing conception and live birth rates comparable to normal women (Balen, Braat 
et al. 1994). In women with anovulation associated with polycystic ovary syndrome 
(PCOS), pulsatile GnRH administration immediately after GnRH-A suppression 
appears to be more effective (Filicori, Campaniello et al. 1988). While an ovulation 
rate of 76% and pregnancy rate of 28% per cycle were reported , subsequent studies 
have shown lower rate of success – at 47% ovulation rate and 10% pregnancy rate 
(Timmerman-van Kessel, Cikot et al. 2000). When pulsatile GnRH therapy following 
sex-steroid (combined oral contraceptive pill) suppression of gonadotropin secretion 
GnRH antagonist therapy was compared with identical pulsing regime preceded by 
 
Literature Review 56 
GnRH analogue therapy, the latter was found to be more effective (Gerhard, Matthes 
et al. 1993). However, the need for routine use of GnRH pumps in induction of 
ovulation has decreased with the widespread use of low-dose FSH protocol (Li, Van 
Esch et al. 2010). These protocols show cumulative live birth rates of up to 74.2%, 
with multiple live birth rate as low as 2.5% and are also less resource intensive (Li, 
Van Esch et al. 2010). 
In women with polycystic ovarian syndrome, higher serum LH concentrations were 
observed during the follicular phase in women administered pulsatile LH after GnRH 
analogue therapy when compared to women administered clomiphene citrate (a 
selective estrogen receptor modulator –SERM) (Timmerman-van Kessel, Cikot et al. 
2000). Higher LH concentrations in the follicular phase are considered to contribute 
to decreased conception rate and increased early loss of pregnancy (Homburg, Armar 
et al. 1988). Therapeutic approaches with a more nuanced stimulatory effect on LH 
may therefore be more beneficial in this context. In the treatment of women with 
clomiphene resistant anovulatory infertility associated with polycystic ovary 
syndrome, subcutaneous pulsatile GnRH (administered in a step-wise fashion as 
GnRH alone, combination of clomiphene citrate and GnRH, and combination of 
GnRH with gonadotropins) effected high cumulative conception rate with a low rate 
of multiple pregnancy and ovarian hyper stimulation syndrome (Tan, Farhi et al. 
1996). 
1.4.1.2.3 Gonadotropin suppression 
The ability of continuous GnRH stimulation to suppress gonadotropin release and 
thereby ovulation has been applied therapeutically in the treatment of endometriosis 
but requires sex steroid ‘add-back’ (replacement) to prevent deleterious effects on the 
skeleton, hot flushes and vaginal dryness (Guzick, Huang et al. 2011).  GnRH 
analogue therapy has also been demonstrated to be useful in reducing uterine fibroid 
dimensions before surgery (Lumsden, West et al. 1987). Moreover, androgen 
deprivation therapy using GnRH analogue therapy is the mainstay of the modern 
management of prostate cancer (Sharifi, Gulley et al. 2010). A number of other 
clinical applications of GnRH analogues have been reported – including in the 
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treatment of breast cancer (Mastro, Levaggi et al. 2011), premenstrual syndrome (Di 
Carlo, Palomba et al. 2001) and microprolactinoma (Rubio, Cabranes et al. 1989). 
1.5 Summary 
In summary, the hypothalamic GnRH neuronal network integrates developmental, 
environmental, endocrine and metabolic inputs, thereby modulating the reproductive 
endocrine axis (Please see figure 1.1). The discovery of GnRH has considerably 
deepened the understanding of reproductive neuroendocrine physiology, with 
resultant diagnostic and therapeutic applications. The discovery of kisspeptins and 
the KNDy neuronal network in the last decade has provided novel insights into the 
regulation of GnRH secretion and administration of exogenous kisspeptin appears to 
be a useful tool in probing GnRH neuronal function in vivo. Translational clinical 
studies, exploring kisspeptin responses in various physiological and pathological 
states are pivotal to exploring and elucidating potential clinical application for 
kisspeptins. 
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Figure 1.1 Schematic representation of neuroendocrine regulation of gonadotropin secretion.  
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1.6 Hypotheses  
The overarching hypotheses for the work described in this thesis are   
1) That exogenous kisspeptin-10, administered as acute boluses, would 
stimulate LH secretion in men and women. As the sex steroid feedback 
inhibition of the HPG axis appears to be exerted, at least in part, at the level 
of the kisspeptin neuron, it was hypothesised that this response to kisspeptin-
10 would be preserved in women with a range of prevailing steroid milieu. 
2) That continuous infusion of kisspeptin-10 would enhance LH pulse 
frequency. 
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2 Materials and Methods 
2.1 Ethical Standards and Research Governance 
2.1.1 Approvals by ethics committee 
All the clinical studies in this thesis are conducted in accordance with the principles 
of the International Conference on Harmonisation Tripartite Guideline for Good 
Clinical Practice (ICH GCP) and the Declaration of Helsinki. Studies were approved 
by a local research ethics committee (Lothian REC Ref 09/S1101/23 and 
09/S1101/67). 
2.1.2 Regulatory compliance in the first-in-human context 
Prior to the commencement of these studies, clarification was sought from the 
Medicines and Healthcare Products Regulatory Agency (MHRA) who confirmed that 
these studies are not clinical trials of investigational medicinal product (CTIMP). 
Regulatory approval has hence been sought as physiological studies of a naturally 
occurring peptide. The University of Edinburgh and NHS Lothian jointly sponsored 
the studies reported herein. 
2.1.3 Informed Consent 
Written informed consent was obtained from all volunteers. All potential participants 
were provided written and oral information and were provided the opportunity to 
clarify any points they do not understand and, if necessary, ask for more information.  
Where possible, information leaflets were provided by email or post ahead of the 
potential participant’s initial screening visit to ensure adequate time is available to 
consider the proposition. Information sheets also carried contact details for an 
independent endocrinologist. 
2.1.4 Confidentiality and data protection 
All laboratory specimens, evaluation forms, reports, and other study records were 
link-anonymised to maintain participant confidentiality.  Hard copies are held in an 
access-controlled area within the Royal Infirmary of Edinburgh while electronic data 
is held securely on University of Edinburgh servers. 
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2.2 Recruitment of volunteers 
2.2.1 Healthy volunteers 
Printed flyers and email invitations were sent to large employers in Edinburgh. 
Printed flyers were also placed in the New Royal Infirmary of Edinburgh and the 
Western General Hospital for the attention of visitors and carers. Once a potential 
recruit expressed an interest in taking part in a study was expressed, further 
information about the study was provided over telephone or as an email or printed 
flyer depending on individual preference. Once the prospective volunteer was 
satisfied with the information provided, they were invited to attend for a screening 
visit. 
2.2.2 Recruitment of volunteers with type 2 diabetes  
Participants with diabetes were identified from the diabetes clinics at the Royal 
Infirmary of Edinburgh and the Western General Hospital. The study was introduced 
to patients at routine clinic visits by clinical staff involved in their normal care. 
Subsequently contact was made with those interested and to make arrangements for a 
fuller discussion of the study and a screening visit.  
2.2.3 Recruitment of volunteers with Kallmann Syndrome 
Participants with Kallmann Syndrome were identified with the help of the Kallmann 
Society and Dr. Richard Quinton, Consultant Endocrinologist at Newcastle who 
kindly provided participants with information about the study. Volunteers were thus 
drawn across the UK and all studies were carried out in Edinburgh. 
2.2.4 Recruitment of patients with Neurokinin B signaling 
defects 
Four patients with TAC3 (NKB) or TACR3 (NK3R) biallelic mutations presenting 
with delayed puberty were identified by Dr. Jacques Young and enrolled in this 
study. Subjects were admitted to the Endocrinology and Reproductive Diseases 
Department (Bicêtre hospital, France) where blood sampling and administration of 
kisspeptin-10 was carried out. 
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2.2.5 Screening for eligibility 
All subjects who attend for a screening visit had their weight, height and baseline 
blood tests (including renal function, liver function, full blood count and 
testosterone/estradiol) obtained. Structured clinical history was obtained to identify 
pre-existing hypothalamic or pituitary disease.  
2.3 Drugs and devices used in the study 
2.3.1 Kisspeptin-10 
Kisspeptin-10 was custom-synthesised under GMP standards (Bachem GmBH, Weil 
am Rhein, Germany) and supplied in single use vials of 1 mg each. Purity was 
assessed by HPLC at 97% with a mass balance of 98.8%. For each participant, 
kisspeptin-10 was made up within the hour prior to injection by diluting 1 mg of 
lyophilised kisspeptin-10 in 5ml sterile normal saline. Stability of kisspeptin-10 in 
solution was assessed by in-vitro receptor binding studies comparing pre-incubated 
and freshly constituted 0.2mg/ml solution (kindly performed by Dr. Antonia 
Roseweir).  
2.3.2 GnRH 
Commercially available GnRH (Relefact, Sanofi Aventis, Frankfurt, Germany), 
supplied in 100 mg single-use ampoules were used for GnRH stimulation tests.  
2.3.3 Vehicle 
Sterile 0.9% saline was used as vehicle in these studies. Supplies were provided by 
NHS Lothian Clinical Research Facilities as sourced from various manufacturers. 
2.3.4 Intravenous infusion devices 
Dedicated infusion devices (Crono PCA, Cane, Rivoli, Italy), designed to deliver low 
infusion rates were used for kisspeptin-10 administration. To minimise adherence to 
plastic, syringes and tubing used to administer kisspeptin-10 were coated with the 
peptide prior to being loaded.  
2.3.5 Collection of samples 
All samples were drawn through an indwelling intravenous cannula inserted under 
aseptic precautions. After each sample was drawn, 5 ml of normal saline was injected 
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into the cannula to prevent coagulation of blood within the sampling system. Before 
each draw, 2 ml of blood was discarded to avoid contamination by residual saline in 
the cannula and attached tubing. Samples for hormone assays (LH, FSH, E and T) 
were collected in vacuum serum tubes (Monovette, Sarstedt UK Ltd, Leicestershire) 
and batch-processed in the Clinical Research Facility at regular intervals with 
centrifugation of whole blood 4 degrees C for 10 min at 3000rpm. Pre-labelled 
aliquot tubes were filled with serum and samples frozen at -20 degree celcius till 
analysis. 
2.3.6 Analysis of samples 
Hormone assays were carried out by assay lab technicians attached to the MRC 
Human Reproductive Sciences Unit using in-house assays. LH and FSH 
concentrations were determined by ELISA, and testosterone by RIA as previously 
described (Brady, Anderson et al. 2003). Inter-assay coefficient of variation for all 
hormonal assays was <5 % at the concentrations measured. Intra-assay coefficient of 
variation of LH was 2.9%. All samples from each of the study visits were analysed 
together in duplicate. 
2.3.7 Safety and screening bloods 
Full blood count, serum electrolytes, renal function tests and liver function tests were 
carried out at each of the study visits. These samples were sent to the hospital 
laboratories of NHS Lothian and processed on standard assay platforms.  
2.3.8 Statistical software 
Data are presented as mean±sem.  A two-sided P <0.05 was regarded as statistically 
significant for all analyses. All primary data are stored as Microsoft Excel files 
(Microsoft, Redmont, USA). The statistical software package Minitab 16 (Minitab 
Ltd, Coventry, UK) was used for analysis. Graphs and charts were produced using 
Graphpad Prism (Graphpad Software, CA, USA). Additional expert input was kindly 
provided by Ronnie Grant (Graphics Lab, MRC Centre for Reproductive Health) in 
preparing graphs and figure. 
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3 Kisspeptin-10 dose-dependently stimulates gonadotropin 
release in healthy male volunteers 
3.1 Introduction 
Since their discovery as obligatory elements to normal pubertal development, 
kisspeptins have been demonstrated to be modulators of GnRH function (section 
1.1).   
Administration of exogenous kisspeptin stimulates LH secretion in both men and 
women (Dhillo, Chaudhri et al. 2005; Dhillo, Chaudhri et al. 2007; Jayasena, Nijher 
et al. 2009). Human studies of kisspeptin have hitherto used the 54-amino acid 
peptide, kisspeptin-54 (Dhillo, Chaudhri et al. 2005; Dhillo, Chaudhri et al. 2007; 
Jayasena, Nijher et al. 2009; Jayasena, Nijher et al. 2010). Kisspeptin-54 is cleaved 
from the 145 amino acid precursor polypeptide encoded by KISS1 and is further 
processed to 14, 13 and 10 amino acid (kisspeptin-10) sequences, all sharing the 
same C-terminal decapeptide RF-amide sequence (Kotani, Detheux et al. 2001). 
Whilst kisspeptin-10 has intrinsic bioactivity similar to the longer kisspeptin 
fragments (Kotani, Detheux et al. 2001), it is also characterised by a shorter half-life 
and more rapid onset of action after iv administration in rodents (Mikkelsen, Bentsen 
et al. 2009). Kisspeptin-10 also has greater potential for pharmaceutical development 
as both agonists (Curtis, Cooke et al. 2009)  and antagonists (Roseweir, Kauffman et 
al. 2009; Millar, Roseweir et al. 2010) have been developed based on its decapeptide 
sequence. However, there have been no studies on the activity of kisspeptin-10 in 
humans. 
3.2 Objective 
The present study involved first-in-human studies of kisspeptin-10. The objective 
was to establish the dose dependency and time course of stimulation of LH and FSH 
secretion following intravenous bolus doses of kisspeptin-10. 
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3.3 Methods 
3.3.1 Participants 
Six healthy male volunteers took part in this acute kisspeptin stimulation study. All 
volunteers provided informed written consent and the study was approved by a local 
research ethics committee (Lothian REC Ref 09/S1101/23). The age of healthy male 
participants was 35.6±3.4 (mean±SEM) and body mass index was 26.1±0.8 kg/m2, 
all of whom had a minimum total testicular volume of 40 ml, normal physical 
examination and normal secondary sexual characteristics. Baseline full blood count, 
renal function, liver function and electrolytes were within normal limits.  
3.3.1 Kisspeptin-10 
Kisspeptin-10 was custom synthesised to GMP standards and prepared for 
administration as described in chapter 2.  
3.3.2 Protocol 
This study was designed to assess the magnitude and dose-dependency of 
gonadotropin secretion in response to six intravenous bolus doses (0.01, 0.03, 0.1, 
0.3, 1.0 and 3.0 µg/kg) of kisspeptin-10 or vehicle (normal saline). These doses were 
selected on the basis of a previous study of kisspeptin-54 in healthy male volunteers 
(Dhillo, Chaudhri et al. 2005). Additionally, based on studies in rodents 
demonstrating comparable efficacy, an assumption was made that kisspeptin-10 
would elicit gonadotropin responses observed with comparable doses of kisspeptin-
54. Moreover, as the study involved first-in-human administration of kisspeptin-10 
with concentrations reaching supraphysiological levels (albeit only for a short 
duration based on studies in animal models), the top dose was set at 3.0 µg/kg, ten 
times the equimolar equivalent of the maximally effective dose of kisspeptin-54 
(Dhillo, Chaudhri et al. 2005) in view of potential off-target effects. 
All volunteers attended the study in a fasting state and all visits commenced between 
0800 and 0900 to avoid diurnal bias. Blood samples were obtained through 
indwelling intravenous cannulae before (60, 45, 30, 20, 10 min and immediately) and 
after (10, 20, 30, 45, 60, 75 and 90 min) kisspeptin-10 or vehicle administration.  
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Doses were administered in increasing order for safety reasons and visits were at 
least 1 week apart.  All volunteers received at least 4 doses and 4 volunteers received 
all doses. Participants were blinded to the dose of kisspeptin-10.  
Blood pressure, pulse and peripheral oxygen saturations were measured every 3 min 
with standard automated techniques. Full blood count and serum electrolytes, liver 
function and renal function were checked at each visit. 
3.3.3 Hormone assays 
Blood samples were centrifuged immediately at 4oC for 10 min at 3000 rpm and 
serum frozen at -20oC until analysis. LH and FSH were determined by ELISA, and 
testosterone by RIA as previously described (22). Inter-assay coefficient of variation 
for all hormonal assays was <5 % at the concentrations measured. Intra-assay 
coefficient of variation of LH was 2.9%. All samples from each of the study visits 
were analysed together in duplicate. 
3.3.4 Statistical Analysis 
For the dose-finding study, 60-min mean LH and FSH concentrations and Area-
Under-Curve (AUC, by trapezoid integration) pre and post kisspeptin-10 bolus were 
calculated. Variance in mean LH and ΔAUC values in the dose-response study was 
analysed by ANOVA followed by Tukey’s simultaneous test. Student’s t test was 
used to analyse changes in mean LH, FSH and testosterone concentrations in the 
infusion studies. Data are presented as mean±sem.  A two-sided P <0.05 was 
regarded as statistically significant for all analyses. The statistical software package 
Minitab 16 (Minitab Ltd, Coventry, UK) was used. 
3.4 Results 
Acute kisspeptin administration elicited LH and FSH responses in a dose-dependent 
manner. 
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3.4.1.1 Effect of Kisspeptin-10 on LH secretion in healthy male 
volunteers – time course 
Intravenous injections of kisspeptin-10 elicited a rapid increase in LH in all 
volunteers, with peak concentrations seen by 45 min post injection for all doses 
studied. The maximum LH stimulation was seen following the 1µg/kg bolus, 
achieving peak LH concentration (12.4±1.7 IU/L) by 30 min (figures 3.1).  
 
Figure 3.1: Effect of Kisspeptin-10 on LH secretion in healthy male volunteers -time 
course of LH response following all doses of kisspeptin-10 administered as 
intravenous bolus doses. Kisspeptin-10 or vehicle administered intravenously to 
healthy volunteers at time 0.  
LH [IU/L] 
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3.4.1.2 Effect of Kisspeptin-10 on LH secretion in healthy 
male volunteers: LH dose responsiveness 
There was a clear dose-dependent increase in LH concentrations in response to 
kisspeptin-10 (P<0.0001).  Statistically significant increases were observed following 
the 0.03, 0.1, 0.3 and 1µg/kg bolus doses (P <0.01).  There was however no 
significant increase in LH concentration following the highest dose administered 
(3.0µg/kg) and mean LH following this dose was significantly less than following 
0.3 and 1µg/kg doses (both P <0.05). Figure 3.2 summarises baseline LH and peak 
LH observed following kisspeptin-10 administration for each of the doses studied. 
 
Figure 3.2: Effect of Kisspeptin-10 on LH secretion in healthy male volunteers- 
analysis of variation of dose-dependent stimulation of LH secretion. 
60 min -AUC following kisspeptin-10 administration also showed dose dependence, 
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Figure 3.3: Effect of Kisspeptin-10 on LH secretion in healthy male volunteers- 
analysis of variance of 60-min ΔAUC of LH following kisspeptin-10 administration. 
Asterisks denote doses significantly different from vehicle (P <0.05). ΔAUC of LH 
of each dose is compared in the figure to that observed following the administration 
of vehicle. 
3.4.1.3 Effect of Kisspeptin-10 on FSH secretion in healthy 
male volunteers:  
FSH secretion also increased dose-dependently following kisspeptin-10 
administration (P = 0.012).  The largest increase was observed with 1µg/kg where 
the mean 60-min FSH rose from 4.6±1.0 to 5.3±1.0 IU/L (Figure 3.4).  
Increases were seen in AUC of FSH following 0.3 and 1µg/kg kisspeptin-10, while 
3µg/kg again did not result in a significant increase in FSH concentration. The time 
course of FSH response to kisspeptin-10 stimulation is summarised is illustrated in 
Figure 3.5. 
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Figure 3.4: Effect of Kisspeptin-10 on FSH secretion in healthy male volunteers-
Analysis of variance of 60-min ΔAUC of FSH following administration. Asterisks 
denote doses significantly different from vehicle (P <0.05). 
 
Figure 3.5: Effect of Kisspeptin-10 on FSH secretion in healthy male volunteers-
time course of mean LH responses to doses studied. 
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3.4.1.4 Effect of Kisspeptin-10 on Testosterone secretion in healthy 
male volunteers 
Serum testosterone concentrations showed no statistically significant change with 
any of the doses studied using this protocol. Figure 3.6 summarises testosterone 
responses to kisspeptin-10.  
 
Figure 3.6: Effect of Kisspeptin-10 on LH secretion in healthy male volunteers: 
Testosterone responses to kisspeptin-10. No statistically significant changes were 
observed. 
3.4.1.5 Effect of Kisspeptin-10 on other pituitary hormones. 
Concentrations of Thyroid Stimulating Hormone, Prolactin and Cortisol (used as a 
surrogate for ACTH) were unchanged following 3 µg/kg kisspeptin-10 
administration. These hormones were analysed only following the largest dose 
studied as any such effects, based on observations in animal models were 
hypothesised to be GPR-54 mediated, not GnRH dependant effects. Insulin and 
glucose, measured in view of studies in animal models suggesting kisspeptinergic 
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potentiation of insulin secretion, were also unchanged (Bowe, King et al. 2009). 
Growth hormone showed a tendency to decrease but this was statistically non-
significant. A post-hoc analysis using paired t-test of baseline (0 min) excluding the 
subject with suppressed GH concentration at baseline yields statistical significance, 
but considering the high variability of GH, longer time-series studies in larger 
number of subjects are needed to clarify this. Table 3.1 and 3.2 details the 
concentration of these hormones in the subjects studied.  
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Table 3.1. Glucose and insulin response to an intravenous bolus of 3-µg/kg 
kisspeptin-10. 
Glucose Time points (minutes) 
Subject No -30 0 30 60 
1 5.4 5.2 5.4 5.4 
2 5.1 5.1 5.2 5 
3 5.7 5.6 5.5 5.6 
4 5.3 5.1 5.4 5.2 
5 5.4 5.2 5.1 5.2 
6 5.3 5.5 5.1 5.1 
Insulin Time points (minutes) 
Subject No -30 0 30 60 
1 5.4 5 3.8 4.7 
2 16.9 10.2 14.8 10.3 
3 7.2 6.5 6.1 6.6 
4 4.5 4.6 3.9 3.7 
5 10.3 11.4 9.2 11.6 
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Table 3.2. GH, TSH, Prolactin and Cortisol responses to 3 µg/kg intravenous 
bolus of kisspeptin-10 
GH Time points (minutes) 
S. No -30 0 30 60 
1 0.11 0.12 0.13 <0.10 
2 <0.10 <0.10 <0.10 <0.10 
3 0.18 0.15 0.11 0.2 
4 0.63 0.2 0.13 0.15 
5 0.37 0.4 0.1 <0.10 
6 0.85 0.35 0.13 <0.10 
 
TSH Time points (minutes) 
Subj No -30 0 30 60 
1 1.45 1.46 1.32 1.46 
2 0.83 0.76 0.70 0.65 
3 1.57 1.48 1.44 1.45 
4 1.00 0.94 0.85 0.91 
5 1.36 1.33 1.27 1.25 
6 2.47 2.27 2.27 2.26 
 
Prolactin Time points (minutes) 
Subj No -30 0 30 60 
1 151 139 142 123 
2 79 73 70 73 
3 187 195 200 191 
4 133 126 112 97 
5 88 72 64 60 
6 224 203 208 184 
 
Cortisol Time points (minutes) 
Subj No -30 0 30 60 
1 275 237 230 280 
2 279 219 185 219 
3 189 210 180 246 
4 164 127 111 105 
5 221 177 134 126 
6 313 264 198 194 
  
 
Effect of Sex Steroid Milieu 75 
3.4.1.6 Adverse effects 
Blood pressure, heart rate, peripheral oxygenation, liver function, renal function, 
haemoglobin, mean corpuscular volume and electrolytes remained stable in all 
subjects throughout the study period. No adverse events were reported. 
3.5 Discussion 
We have demonstrated that intravenous administration of kisspeptin-10 boluses 
result in potent and dose-dependent stimulation of LH secretion in healthy men. 
Doses of kisspeptin-10 as low as 0.03 µg/kg (23 pmol/kg) elicited a significant rise 
in LH when compared to vehicle, demonstrating the high potency of kisspeptin-10. 
This is in keeping with data from experimental animals where intracerebroventricular 
doses of kisspeptin as small as 1 fmol effected robust LH stimulation (Gottsch, 
Cunningham et al. 2004). Central rather than pituitary mediation of the effect of 
kisspeptin on LH secretion has been demonstrated by abolition of the effect of 
kisspeptin by pre-treatment with a GnRH antagonist (Gottsch, Cunningham et al. 
2004; Irwig, Fraley et al. 2004; Plant, Ramaswamy et al. 2006). 
The 2.5 fold increase in serum LH from baseline observed following kisspeptin bolus 
administration in our study is comparable to that observed in men administered 
equimolar doses of kisspeptin-54 as short infusions (Dhillo, Chaudhri et al. 2005). 
Moreover, as in human studies using kisspeptin-54 (Dhillo, Chaudhri et al. 2005), the 
stimulatory effect of kisspeptin-10 on LH secretion in our study was also markedly 
more pronounced than that on FSH secretion. Early animal studies suggested 
stimulatory effects on LH and testosterone secretion were seen only with the longer 
kisspeptin peptide, kisspeptin-54, and not shorter forms (Thompson, Murphy et al. 
2006). However, in vivo rodent data have subsequently shown equal potency of 
kisspeptin-10 and kisspeptin-54 (Gottsch, Cunningham et al. 2004; Tovar, Vazquez 
et al. 2006) and in in vitro binding assays, both peptides show equal affinity at the 
KISS1R receptor (Kotani, Detheux et al. 2001). Our results demonstrate that the 10 
amino acid form of kisspeptin is a potent LH secretagogue in vivo in humans.  
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While there was a clear dose-dependency of LH response to increasing doses of 
kisspeptin-10 up to 1 µg/kg, the 3 µg/kg (2.3 nmol/kg) bolus dose did not elicit a 
statistically significant increase when compared to vehicle, and mean and peak LH 
concentration following this dose was lower than corresponding values following 0.3 
and 1 µg/kg. This phenomenon has not been reported before following bolus 
administration of kisspeptin, but continuous infusion of kisspeptin-10 in primates 
(Seminara, DiPietro et al. 2006) and repeated subcutaneous administration of 
kisspeptin-54 in human subjects with hypothalamic amenorrhoea (Jayasena, Nijher et 
al. 2009) resulted in tachyphylaxis.  The kisspeptin receptor KISS1R is known to 
desensitise rapidly in vitro (Pampillo, Camuso et al. 2009), raising the possibility of 
rapid hypothalamic desensitisation. Whilst such desensitisation is a parsimonious 
explanation for the decreased response observed here, desensitisation has to be 
occurring rapidly after kisspeptin-10 administration before maximal stimulation of 
gonadotropes is achieved. As the fast half-life of LH in healthy men is 18 min 
(Veldhuis, Iranmanesh et al. 1993) lower peak LH following the 3 µg/kg would 
suggest that the gonadotrope stimulation was submaximal. An alternative 
explanation for this observation is that at high concentrations, kisspeptin-10 may 
stimulate another RF-amide receptor with an inhibitory effect on GnRH or LH 
secretion.  Kisspeptin-10, at nanomolar concentrations, has been shown to bind and 
activate the gonadotropin inhibitory hormone (GnIH) receptor (GPR 147, NPFFR1) 
(Oishi, Misu et al. 2010) which is expressed both in the hypothalamus and on 
gonadotropes (Ubuka, Morgan et al. 2009). Nanomolar plasma concentrations of 
kisspeptin were achieved after subcutaneous administration of doses of kisspeptin-54 
similar to the kisspeptin-10 used in our study (Dhillo, Chaudhri et al. 2007).  
However, whilst peak plasma kisspeptin-10 concentrations following the 3 µg/kg 
bolus may have been sufficient to activate GnIH receptors, there is little evidence for 
a functional role for GnIH in humans and in vivo studies in sheep (Clarke, Sari et al. 
2008) would suggest that its effects are relatively modest and it is not possible to 
exclude an effect of GnIH receptor involvement in the infusion studies. The reduced 
stimulatory efficacy of kisspeptin-10 at high concentrations demands careful dosing 
in any potential therapeutic applications. 
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The stimulatory effect of kisspeptin-10 appears to be limited to gonadotropins with 
no effect on prolactin, cortisol, insulin or TSH. Moreover, there were no adverse 
events or off-target effects observed at the doses studied here. 
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4 Effect of sex-steroid feedback and baseline gonadotropin 
concentration on gonadotropin responses to kisspeptin-
10 
4.1 Introduction 
Administration of kisspeptin-54 stimulates gonadotropin secretion in healthy women 
(Dhillo, Chaudhri et al. 2007) and women with hypothalamic amenorrhoea (Dhillo, 
Chaudhri et al. 2007; Jayasena, Nijher et al. 2010) making it a potential provocative 
test and therapeutic candidate in reproductive endocrine disorders. Studies of 
kisspeptin in women reported prior to this study being carried out, had used the 54-
amino acid peptide, kisspeptin-54 (Dhillo, Chaudhri et al. 2007; Jayasena, Nijher et 
al. 2009; Jayasena, Nijher et al. 2010). Although Kisspeptin-54 has been shown to be 
further processed to 14, 13 and 10 amino acid (kisspeptin-10) sequences (Kotani, 
Detheux et al. 2001) in vitro, there is no data to suggest that this occurs in vivo. 
Kisspeptin-10 has the full intrinsic bioactivity of the longer fragments (Kotani, 
Detheux et al. 2001; Roseweir and Millar 2009), but with a shorter half-life and 
quicker onset of action (Mikkelsen, Bentsen et al. 2009). 
Modulation of the human hypothalamic-pituitary-ovarian axis by sex steroid 
feedback is well established (Chetkowski, Meldrum et al. 1986; Gill, Sharpless et al. 
2002) and is the basis for sex steroid therapy for contraception. Sex steroids 
exquisitely regulate Kiss1 gene expression positively and negatively (section 1.3.1). 
During the menstrual cycle, rising estradiol in the follicular phase and the high 
estradiol and progesterone concentrations in the luteal phase slow pulsatile GnRH 
secretion and thus gonadotropin secretion. Inhibitory effects of the sex steroids and 
peptide inhibins at the pituitary gonadotrope also contribute to feedback regulation 
(Shaw, Histed et al. 2010). Conversely, the menopausal decline in circulating sex 
steroids and inhibins results in increased GnRH and gonadotropin secretion (Gill, 
Sharpless et al. 2002).  To fully characterise novel modulators of the GnRH axis, it is 
therefore important to study gonadotropin responses in models of sex steroid excess 
and deficiency as well as physiological states. Moreover, as there is a wealth of 
literature relating to the diagnostic and therapeutic use of GnRH (Schally 1999; 
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Engel and Schally 2007), translational applications of kisspeptin-10 can potentially 
be guided by comparing kisspeptin-10 mediated LH stimulation with that observed 
following administration of GnRH. 
4.2 Objectives 
The objectives of this study were 
1) To quantify and establish the time-course of the stimulatory effect of 
kisspeptin-10 on LH and FSH secretion in women with regular menstrual 
cycles, in post-menopausal women, and in women taking sex steroid 
contraceptive preparations.  
2) To compare kisspeptin-induced gonadotropin secretion with that following a 
maximally stimulatory dose of GnRH.  
4.3 Methods 
4.3.1 Participants 
Ten healthy women with regular menstrual cycles, 6 postmenopausal women, and 8 
women using progestogen implants or combined oral contraceptive pills for 
contraception were recruited to the study. All volunteers provided informed written 
consent and the study was approved by the local research ethics committee (Lothian 
REC Ref 09/S1101/67). Post-menopausal women had experienced a natural 
menopause (median months since menopause: 90, range 17-200) and had not taken 
hormone replacement therapy in the 6 months preceding their study visit. Women 
using progestogen implants (n=4) had subcutaneous implants containing 68 mg 
etonogestrel (Implanon, MSD, Hertfordshire, UK) in the arm, inserted between 3 and 
24 months previously.  Oral contraceptive pills contained 20-30 µg ethinylestradiol 
and a synthetic progestogen for 21 days of each menstrual cycle, and all women 
(n=4) had been established on this for a minimum of 6 months prior to study. Sample 
size calculations were made on the assumption that the effect sizes and variance of 
gonadotropin responses to kisspeptin-10 would be comparable to previous studies of 
kisspeptin-54 in women (Dhillo, Chaudhri et al. 2007). Baseline full blood count, 
renal function, liver function, electrolytes and glucose were within normal limits.  
 
Effect of Sex Steroid Milieu 80 
4.3.2 Experimental Protocol 
Volunteers attended Edinburgh Clinical Research Facilities in a fasting state and 
were provided a standardised breakfast. Blood samples were obtained through 
intravenous cannulae at 15-min intervals for 3 hours before and a further 3 hours 
after kisspeptin-10 (0.3 µg/kg) administration, as previous studies of kisspeptin-10 
have demonstrated that LH returns to baseline within this duration (Chan, Butler et 
al. 2011; George, Veldhuis et al. 2011). At the end of this 6-hour study period, a 100 
µg bolus of GnRH was administered intravenously and four further samples obtained 
at 15-min intervals - this dose of GnRH and sampling regime is used routinely for 
clinical assessment of GnRH responsiveness (Cavallo, Richards et al. 1995). 
Importantly, evidence from studies involving repeated pulsatile administration of 
GnRH indicate that there is no desensitisation of GnRH response when subsequent 
pulses are at least 90 minutes apart (Seminara, Beranova et al. 2000). Thus the GnRH 
response is unlikely to have desensitised to the kisspeptin-10 administered 3h earlier. 
LH was measured at all the time points and FSH at 30 min intervals. Premenopausal 
women not taking steroidal contraception were studied in the follicular phase of 
menstrual cycle (day 2-7 inclusive) and women taking the combined contraceptive 
pill were studied 2-7 days after restarting therapy following a routine scheduled 7-
day interruption. 
4.3.3 Study drugs 
Custom-synthesised GMP grade kisspeptin-10 was used for this study. Please see 
2.3.1 for details of the study drug 
4.3.4 Analysis of hormonal data 
Baseline LH and FSH were calculated as the mean of concentrations measured for 3 
hours before the administration of kisspeptin-10. Peak LH and FSH responses were 
identified as the highest concentration measured within 180 minutes of kisspeptin 
administration. Baseline and peak gonadotropins were compared within each of the 
study groups using paired Student’s t tests. ΔLH and ΔFSH post-kisspeptin was 
calculated as the arithmetic difference between peak and baseline concentrations. To 
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account for expected variability in baseline gonadotropin concentrations across study 
groups, percentage increases in ΔLH and ΔFSH over respective baseline values were 
calculated and one-way ANOVA followed by protected Fisher's test was used to 
compare groups.  
The ratio of ΔLH and ΔFSH following kisspeptin administration to corresponding 
values observed following GnRH stimulation in each individual was calculated, and 
groups compared using one way ANOVA followed by Tukey’s multiple comparison 
test.  
Additionally, 60-min mean Area-Under-Curve (AUC) pre and post kisspeptin-10 
bolus were calculated by trapezoid integration. To account for inter-individual 
variability mean serum gonadotropin concentration observed 60 minutes before the 
administration of kisspeptin-10 was deducted from observed gonadotropin 
concentrations. Data are presented as mean±SEM.   
Data not normally distributed were log-transformed prior to statistical analysis. A 
two-sided P <0.05 was regarded as statistically significant. The statistical software 
package Minitab 16 (Minitab Ltd, Coventry, UK) was used. 
4.4 Results 
Baseline age, weight, BMI, LH, FSH and estradiol of subjects are summarised in 
Table 4.1. Post-menopausal women had significantly lower estradiol and higher 
gonadotropin concentrations, and were older.  
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Table 4.1: Baseline Characteristics of women undergoing intravenous kisspeptin-10 
stimulation (0.3 µg/kg). Data shown as mean±SEM and analysed by one-way 
ANOVA followed by Fisher’s test. a, b Groups that do not share a letter show 
significant difference.  Post-menopausal women had significantly lower estradiol and 
higher gonadotropin concentrations, and were older.   
 Follicular  Postmenopausal Progesterone 
Implant 
COCP P value 
n 10 6 4 4  
Age (years) 33.4±2.8 58.2±1.8 a 26.3±1.1 26.3±1.8 <0.0001 
BMI (kg/m2) 25.3±1.2 a 25.1±1.1 a 23.4±1.4 a 27.1±2.4 a 0.545 
E (pmol/L) 133.7±18.7 a <50 b 98.0±16.0 a, b <50 b  0.008 
LH (IU/L) 8.0±1.4 29.3±4.7a 5.7±0.9 2.63±0.8 <0.0001 
FSH (IU/L) 6.3±0.8 65.7±8.8 a 5.1±0.3 6.2±2.6 <0.0001 
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4.4.1.1 Kisspeptin-10 stimulates LH secretion in women 
Acute intravenous administration of kisspeptin-10 resulted in a significant increase in 
LH in all groups of women.  In women in the follicular phase, LH rose from 6.3±1.2 
to 9.4±1.3 IU/L (P=0.006, Figure 4.1). Peak LH serum concentrations were achieved 
by 30 min, declining thereafter to reach pre-administration levels by 180 min. 
Postmenopausal women also responded to kisspeptin-10 administration, with an 
increase in serum LH from 35.3±2.8 to 44.7±3.4 IU/L (P=0.005). Women with 
etonogestrel implants and women taking ethinyl estradiol plus a progestogen in the 
combined contraceptive pill had the lowest pre-treatment LH concentrations but also 
showed a significant rise in LH in response to kisspeptin-10 (4.6±0.2 to 7.5±0.9 
IU/L, P=0.02; 2.3±0.9 to 3.7±1.4 IU/L P<0.001 respectively Figure 4.1). Analysis of 
60-min AUC of LH showed similar results, as summarised in figure 4.2. 
 
Figure 4.1: LH responses to kisspeptin-10 in women in follicular phase (red squares, 
n=10), progestogen implant (green triangles, n=4), women on combined oral 
contraceptives (closed purple circles, n=4) and postmenopausal women (blue open 
circles, n=6).   
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Figure 4.2. LH responses to intravenous kisspeptin-10 in women. A-D, AUC of LH 
60 minute before (basal) and after kisspeptin-10 stimulation in women. E, Δ AUC 
LH (60-min) following kisspeptin administration in the four groups of women 
studied. Groups that do not share a letter show significant statistical difference with 
each other (One- way ANOVA followed by Tukey’s test). Δ AUC LH in 
postmenopausal women were higher than that of women in follicular phase and 
women treated with combined oral contraceptive pills.  
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4.4.1.2 Comparison between kisspeptin and GnRH LH responses 
Following 100 µg GnRH bolus, serum LH increased significantly in women in the 
follicular phase (6.3±1.1 to 35.7±7.2 IU/L, P<0.001), postmenopausal women 
(35.3±2.8 to 94.0±10.3 IU/L, P<0.001) and in women with etonogestrel implants 
(4.6±0.2 to 26.5±5.2 IU/L, P=0.002). Women on the combined contraceptive pill 
showed a smaller response that did not reach statistical significance (2.3±0.9 to 
7.2±2.1 IU/L P=0.17 Figure 4.3). 
Peak LH observed following kisspeptin-10 was 30.3±4.3 % of the GnRH induced 
LH peak in women studied in the follicular phase, 49.3±4.8 % in postmenopausal 
women, 30.0±4.1 % in women with etonogestrel implants and 66.7±26.0 % in 
women on the combined contraceptive pill. 
 
 
Figure 4.3: Comparison of Peak LH response to kisspeptin-10 and GnRH. Serum 
LH at baseline (white column), peak LH following kisspeptin administration (black 
columns) and peak LH following GnRH (100 µg) administration (grey columns). 
Mean±sem,* P<0.05, **P<0.01, *** P<0.001 vs. baseline. 
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4.4.1.3 Kisspeptin-10 stimulates FSH secretion in women 
Serum FSH also increased following kisspeptin-10 administration, from 3.2±0.4 to 
3.4±0.3 IUL/L (P=0.04) in women in follicular phase, from 21.8±4.9 to 25.7±4.4 
IU/L (P=0.04) in postmenopausal women and from 2.4±0.1 to 2.6±0.1 IU/L (P=0.02) 
in women with etonogestrel implants. FSH however remained unchanged in women 
taking the combined contraceptive pill (4.1±1.8 to 4.7±2.0 IU/L P=0.17 Figure 4.4). 
Analysis of 60-min AUC showed significant increase in FSH only in the post-
menopausal group (Figure 4.5). 
In response to 100 µg GnRH, serum FSH increased in women in the follicular phase 
(3.2±0.4 to 4.4±0.5 IUL/L, P<0.001), in postmenopausal women (21.8±4.9 to 
32.6±4.6 IU/L P=0.008), and in women with etonogestrel implants (2.4±0.1 to 
3.6±0.2 IU/L P=0.001). As with LH, women on the combined contraceptive pill 
showed no significant change in FSH in response to GnRH (4.1±1.8 to 5.6±1.9 IU/L 
P=0.22) (Figure 4.4). Peak FSH observed following kisspeptin-10 was 73.9±2.6 % of 
the GnRH-induced LH peak in women studied in the follicular phase, 82.4±11 % in 
postmenopausal women, 72.4±3.4 % in women with etonogestrel implants and 
75.0±20.4 % in women on the combined pill.  
 
Figures 4.4: Comparison of Peak FSH response to kisspeptin-10 and GnRH. Serum 
FSH at baseline (white column), peak FSH following kisspeptin administration 
(black columns) and peak FSH following GnRH administration (grey columns). 
Mean±sem,* P<0.05, **P<0.01, *** P<0.001 vs. baseline. 
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Figure 4.5. FSH responses to intravenous kisspeptin-10 in women A-D, AUC of 
FSH 60 minute before (basal) and after kisspeptin-10 stimulation. E, Δ FSH (60-min) 
following kisspeptin in the four groups of women studied. * P<0.05. Groups that do 
not share a letter show significant statistical difference (One- way ANOVA followed 
by Tukey’s test). Postmenopausal women had higher LH than the other groups 
studied. 
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4.4.1.4 Incremental gonadotropin rise in postmenopausal women 
and women exposed to sex steroids. 
The incremental rise in LH and FSH in response to kisspeptin-10 was compared 
between the groups studied.  Both ΔLH and ΔFSH as a proportion of baseline 
LH/FSH were similar in the four study groups (P=0.07 and 0.095 respectively, 
Figure 4.6A and B). ΔLH and ΔFSH following GnRH administration were also 
similar in all groups (P=0.95 and 0.93).  
The ratio of gonadotropin response following kisspeptin-10 administration to that 
observed following GnRH administration also showed no statistically significant 
difference between study groups for both LH (P=0.28) and FSH (P=0.32).  
 
Figure 4.6: Gonadotropin responses to kisspeptin-10 and GnRH. A: ΔLH as 
percentage of baseline LH following 0.3 µg/kg kisspeptin-10 (white columns) and 
100 µg GnRH (black columns) administered intravenously to premenopausal women 
in follicular phase of menstrual cycle (‘Follicular’, n=10), women with progesterone 
implant (‘Progesterone Implant, n=4), women on combined oral contraceptives 
(‘COCP’, n=4) and postmenopausal women ( n=6). B: ΔFSH as percentage of 
baseline FSH following 0.3 µg/kg kisspeptin-10 (white columns) and 100 µg GnRH 
(black columns) administered intravenously. No significant variance was observed 
(P= 0.07 for LH and 0.095 for FSH on ANOVA). Note the difference in scale 
between the two column graphs. 
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4.5 Discussion 
These data demonstrate that kisspeptin-10 has a stimulatory effect on LH and FSH 
secretion in women.  These responses are preserved in postmenopausal women and 
in women exposed to steroidal contraceptives.  
Our results, in keeping with previous studies (Dhillo, Chaudhri et al. 2005; Dhillo, 
Chaudhri et al. 2007; George, Veldhuis et al. 2011), demonstrate that kisspeptin 
preferentially stimulates LH over FSH, an observation of significance to consider in 
potential therapeutic applications. An explanation is that the magnitude and/or 
duration of GnRH release in response to kisspeptin may not be sufficiently large 
enough to stimulate FSH secretion, which is known to have a constitutive component 
which is less dependent on GnRH pulsatility (Padmanabhan, McFadden et al. 1997). 
This observation is consistent with earlier studies using a lower dose (25 µg) of 
GnRH which elicited isolated LH secretion (Franchimont, Becker et al. 1974). 
Another plausible explanation for preferential secretion of LH is kisspeptin mediated 
increase in GnRH pulse frequency. The frequency of GnRH pulsatility has been 
demonstrated to selectively regulate gonadotropin subunit gene transcription. High 
pulse frequency preferentially increases α and LH-β gene expression whilst lower 
pulse frequency increases FSH-β gene transcription (Dalkin, Haisenlender et al. 
1989; Haisenleder, Dalkin et al. 1991; Kaiser, Jakubowiak et al. 1997). A decrease in 
GnRH pulse frequency has also been reported in animal models administered 
kisspeptin antagonists (Li, Kinsey-Jones et al. 2009).  
In the present study, we have also demonstrated that maximal kisspeptin-10 -induced 
LH secretion is less than that observed with a maximally stimulatory dose of GnRH, 
irrespective of the steroidal milieu. We compared the magnitude of secretion of LH 
following administration of a maximally stimulatory dose of kisspeptin-10 with that 
observed following administration of a maximally stimulatory dose of GnRH (100 
µg intravenous bolus). LH secretory response to GnRH was higher than the response 
to kisspeptin-10 in all groups. Kisspeptin independent GnRH secretion has been 
demonstrated in Kiss1 and GPR54 knock-out rodents models (Chan, Broder-Fingert 
et al. 2009) and kisspeptin antagonists, unlike GnRH antagonists, do not lower LH to 
sub-basal levels (Roseweir, Kauffman et al. 2009; Millar, Roseweir et al. 2010). Our 
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observations are consistent with these studies and the notion that while the principal 
mode of action of kisspeptin is GnRH mediated (Oakley, Clifton et al. 2009), there is 
a kisspeptin independent component of GnRH secretion. This suggests potential 
therapeutic application of kisspeptin and its agonist analogs will primarily be in areas 
where modest rises in serum concentration of gonadotropins are desirable, such as 
induction of mono-ovulation rather than super-ovulation prior to IVF. Similarly, 
kisspeptin antagonists would, in principle, be an attractive proposition in the 
treatment of hormone dependant diseases (e.g. endometriosis) where a partial 
lowering rather than complete suppression of sex steroids would be therapeutically 
advantageous. 
In studies of kisspeptin-10 effects in men, we have demonstrated a doubling of LH 
from baseline following the administration of a bolus dose of kisspeptin-10 (chapter 
3). LH responses in women studied here are smaller, with peak values being 50-60% 
higher than baseline. Nevertheless, the magnitude of LH stimulation observed in this 
study (3.1±0.7 IU/L) during the follicular phase was markedly higher than that 
observed following subcutaneous administration of kisspeptin-54 (0.12 ± 0.17 IU/L) 
to women in similar menstrual phase at comparable doses (0.23 nmol/kg of 
kisspeptin-10 vs. 0.4 nmol/kg kisspeptin-54) (Dhillo, Chaudhri et al. 2007). 
Moreover, kisspeptin-10 in our studies elicited peak LH responses within 30 minutes 
of intravenous administration, compared to peak values observed more than 2 hours 
following subcutaneous kisspeptin-54 administration. Whilst these observations 
might merely reflect the differences in pharmacokinetics following administration 
through intravenous and subcutaneous routes, they are also in keeping with rodent 
data showing a faster onset of action and shorter half-life for kisspeptin-10 
(Mikkelsen, Bentsen et al. 2009).  
There are further physiological inferences to be made from our studies. There is an 
increase in Kiss1 expression and corresponding increase in LH secretion in 
ovariectomised rodents, monkeys and sheep, which is reversed by treatment with sex 
steroids (Rometo, Krajewski et al. 2007; Smith, Clay et al. 2007; Navarro, Gottsch et 
al. 2009). Histological analysis of the human hypothalamus has demonstrated an 
increase in KiSS1 expression in the infundibular nucleus following menopause 
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(Rometo, Krajewski et al. 2007), consistent with findings in animal models (Rometo, 
Krajewski et al. 2007; Smith, Clay et al. 2007; Navarro, Gottsch et al. 2009). The 
robust response to kisspeptin-10 in postmenopausal women in this study suggests 
that although hypothalamic KISS1 gene expression is increased with hypertrophy of 
kisspeptin neurons (Rance and Uswandi 1996; Rance 2009), there is residual 
capability for GnRH neurons to respond to kisspeptin. This suggests that endogenous 
kisspeptin secretion in the postmenopausal state is lower than that required to elicit 
maximal GnRH response. This suggests that factors other than sex steroids might 
regulate KiSS1 expression. 
We have demonstrated stimulatory effects of kisspeptin-10 in women exposed to 
excess steroid, in steroid-deficient women and in steroid-sufficient women. As 
kisspeptin’s action are predominantly GnRH mediated (Oakley, Clifton et al. 2009), 
these observations support the notion that sex steroid feedback in women occurs both 
at the level of the pituitary and at the hypothalamus (Crowley and Mcarthur 1980; 
Hall, Taylor et al. 1994; Pitteloud, Dwyer et al. 2008).  The relatively smaller 
response in women taking combined estogen/progestogen contraceptive is also 
consistent with an inhibitory negative feedback effect of estrogen at the pituitary 
level (Shaw, Histed et al. 2010).  The lower ΔLH observed here following GnRH 
administration in postmenopausal women and in women taking combined the 
contraceptive pill (in comparison to women in the follicular phase) are also 
consistent with previous clinical studies of GnRH (Thomas, Cardon et al. 1973; 
Franchimont, Becker et al. 1974; Cohen and Katz 1979; Geller and Scholler 1980).  
While it is clear that GnRH secretion is inhibited by endogenous and exogenous 
estrogen (Herbison 1998; Couse and Korach 1999; Gill, Sharpless et al. 2002), the 
pathways involved remain unclear. The absence of expression of estrogen receptor 
alpha (ESR1) in GnRH neurons (Shivers, Harlan et al. 1983; Herbison and Theodosis 
1992) suggest another hypothalamic neuronal population is required to mediate this 
feedback effect. Kisspeptin neurons express ERα and are strong candidates for this 
role (Tena-Sempere 2005; Rance 2009) and the presence of detectable LH response 
to kisspeptin in women taking exogenous steroids lends indirect support to this 
notion that steroid input is not received directly at the level of the GnRH neuron.  
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Had this been the case, kisspeptin would not have been able to stimulate GnRH 
secretion.  
Our findings are at variance with the recently published report that kisspeptin-10 
does not stimulate LH or FSH secretion in women studied in the follicular phase 
when administered as intravenous boluses of 1, 3 and 10 nmol/kg (Jayasena, Nijher 
et al. 2011). These doses used by Jayasena et al were 5 to 50 times higher than the 
0.23 nmol/kg dose that we have used in the present study and similar to those we 
have previously shown to result in a reduced LH secretion in healthy men (chapter 
3). It has to be noted that Jayasena and colleagues only tested LH responses in 
women at the higher doses  (1,3 and 10 nmol/kg) whereas the men were administered 
an additional lower dose (0.3 nmol/kg) at which they had significant LH and 
testosterone responses (Jayasena, Nijher et al. 2011). Interestingly, an absence of 
significant testosterone response at 3 and 10 nmol/kg in men studied by Jayasena and 
colleagues, further suggesting that the apparent lack of effect observed in the study is 
a function of the dosage employed. There are a number of potential explanations for 
the diminished LH response with higher doses of kisspeptin-10, including rapid 
desensitization and stimulation of inhibitory RF-amide receptors, as outlined in 
Chapter 3. The present study also has a higher number of women studied in the 
follicular phase (n=10 in the present study vs. 5) providing greater statistical power 
to detect small but significant changes. Moreover, the present study employed a 180 
min baseline LH profile enabling comparisons of LH secretion before and after 
kisspeptin-10 administration in the same individual. This approach provides the 
opportunity to obtain a more accurate view of baseline secretion in gonadotropin 
concentrations both within and between individuals, thereby increasing the 
sensitivity to detect small changes. However, it has to be noted that the increases in 
LH observed in these studies are small and the physiological significance of such 
small increases in LH are yet unclear. Therefore, from the perspective of 
translational clinical applications, the present findings are consistent with the 
findings reported by Jayasena and colleagues (Jayasena, Nijher et al. 2011). The 
modest increase in LH observed in the present study and the lack of LH stimulation 
observed by Jaysena et al raises the possibility that kisspeptinergic stimulation of LH 
may not be applicable to clinical care. Whilst this is indeed the parsimonious 
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conclusion, it has to be noted that the stimulation of LH observed in men following 
continuous exposure to kisspeptin-10 (Chapter 5) is considerably higher than that 
observed following the administration of intravenous bolus doses (Chapter 3). The 
translational therapeutic/diagnostic value of kisspeptin-10 in women can only be 
fully understood with prolonged administration studies using a range of doses.  
Our study did not involve the measurement of kisspeptin immunoreactivity as the 
plasma half-life of kisspeptin-10 is very short and evaluation would require higher 
frequency of sampling. Moreover, in mass-spectroscopic assays of serum samples 
from our recent studies of kisspeptin-10 involving administration of higher doses in 
men, concentrations of kisspeptin-10 and its cleavage products (kisspeptin 9, 7 or 4) 
were below the detection limit (1 ng/ml) (Chapter 5). 
In conclusion, kisspeptin-10 stimulates LH release in women irrespective of 
prevailing steroid milieu. We have also demonstrated that kisspeptin induced LH 
secretion in women is only a proportion of that observed with a maximally 
stimulatory dose of GnRH. 
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5 Continuous intravenous infusion of kisspeptin-10 elicits 
sustained LH and testosterone secretion in men. 
5.1 Introduction 
Appropriate modulation of GnRH pulsatility is integral to the development and 
maintenance of adult reproductive function (see section 1.1.3). Alterations in GnRH 
pulsatility and thus LH secretion are a feature of a number of reproductive disorders. 
Individuals with some forms of male hypogonadism (Veldhuis, Keenan et al. 2009) 
and hypothalamic amenorrhea (Gordon 2010) show decreased pulse frequency while 
women with polycystic ovarian syndrome show an increase (Blank, McCartney et al. 
2006). However, neuroendocrine mechanisms underpinning GnRH pulse generation 
are yet to be fully delineated (Krsmanovic, Hu et al. 2009) as summarised in chapter 
1.1.3). Experimental animals exposed to kisspeptin antagonists demonstrate 
decreased LH pulsatile secretion suggesting that kisspeptin modulates GnRH pulse 
frequency (Li, Kinsey-Jones et al. 2009).  
Continuous exposure to kisspeptin has been demonstrated to lead to desensitisation 
of kisspeptin response. In juvenile male rhesus monkeys infused with kisspeptin-10 
(100 µg/hr, approximately 30 µg/kg/hr), an initial surge in LH response was 
observed in the first three hours but declined thereafter. Subsequent serum LH 
concentrations were indistinguishable from those observed in control animals infused 
vehicle (Seminara, DiPietro et al. 2006). Similar observations have been made in 
adult male rhesus monkeys (Ramaswamy, Seminara et al. 2007) and rodents (Roa, 
Vigo et al. 2008). In women with hypothalamic amenorrhea receiving subcutaneous 
Kp-54 (37 µg/kg; 6.4 nmol/kg) twice daily for two weeks, potent increases in serum 
LH and FSH seen on day one  were significantly diminished at the end of the study 
(Jayasena, Nijher et al. 2009).  
Experimental animals exposed to kisspeptin antagonists demonstrate decreased LH 
pulsatile secretion suggesting that kisspeptin modulates GnRH pulse frequency (Li, 
Kinsey-Jones et al. 2009) and infusion of kisspeptin-10 at 4 µg/kg/hr elicited 
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sustained increase in LH secretion with suggestion of an increase in LH pulse 
frequency. 
5.2 Objectives 
The objectives of the study were: 
• To investigate the effects of infusion of kisspeptin-10 on LH pulsatility. 
• To determine if continuous infusion of a maximally stimulatory dose of 
kisspeptin-10 induces tachyphylaxis/desensitisation of LH response. 
• To compare the magnitude of maximal kisspeptin-10 mediated LH secretion 
with that following a maximally stimulatory dose of GnRH. 
• To determine the effect of continuous exposure to kisspeptin-10 on LH pulse 
frequency. 
5.3 Materials and methods 
5.3.1 Volunteers 
Four healthy men took part in this study. All volunteers provided informed written 
consent and the study was approved by a local research ethics committee (Lothian 
REC Ref 09/S1101/23). The age of healthy male participants was 35.6±3.4 
(mean±SEM) and body mass index was 26.1±0.8 kg/m2, all of whom had a minimum 
bilateral testicular volume of 40 ml, normal physical examination and normal 
secondary sexual characteristics. Baseline full blood count, renal function, liver 
function and electrolytes were within normal limits.  
5.3.2 Protocol 
5.3.2.1 Effects of prolonged high-dose infusion of kp-10 on LH 
pulsatility in healthy men 
Following overnight fast, 4 volunteers attended our clinical research facility for a 34-
hour supervised stay. Blood samples were collected at 10 min intervals for two 12 
hour periods on consecutive days and hourly overnight. After 9 hours of baseline 
sampling, 3µg/kg of kisspeptin-10 (the highest dose previously investigated) was 
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administered as an iv bolus and a continuous iv infusion of kisspeptin-10 (Crono 
PCA, Cane, Rivoli, Italy) commenced 90 min later at 4µg/kg/hr. This infusion rate, 
maintained for 22.5 hrs, was selected to aim to give a comparable hourly dose to the 
maximally effective bolus doses, bearing in mind the expected short half-life of 
kisspeptin-10. A 100 µg/kg iv bolus of GnRH was administered 60 min before the 
end of the infusion. 
Serum LH during the 9 hour baseline frequent sampling period was compared with 
the corresponding 9 hour frequent sampling period on the second day of the study 
during the iv infusion of kisspeptin-10. In addition, we compared the mean LH 
values observed in the initial 90 min of kisspeptin-10 infusion with the mean LH 
values observed in the final 90 min of infusion before GnRH administration to 
identify any potential tachyphylaxis. 
Comparisons were made between mean LH over the 60 min before GnRH 
administration and the peak LH 30 min after. Serum testosterone was analyzed at 30-
min intervals during the two 9-hour frequent sampling periods before and during the 
infusion. 
All subjects were provided with standardised meals throughout the study and a 
period of overnight fast maintained between 2200 and 0900. Full blood count, 
electrolytes, liver function and renal function were checked at the beginning of the 
study, 24 hours later and at the end of the study.  
5.3.2.2 Effects of low dose infusion of kp-10 on LH pulsatility in 
healthy men 
Four healthy men attended our clinical research facility for two visits five days apart 
for 10-min blood sampling. At the first visit, baseline LH pulsatility was assessed 
over a 9-hour period. During the second visit, an intravenous infusion of kisspeptin-
10 was administered for 9 hours at 1.5µg/kg/hr after an hour of baseline sampling. 
Subjects were provided with standardised meals during the study visits. 
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5.3.3 Study Drugs 
GMP kisspeptin-10 was prepared as 0.2mg/ml solution as described in chapter 3.3.1 
and GnRH was sourced from Sanofi-Aventis (Relefact, Sanofi Aventis, Frankfurt, 
Germany). 
5.3.4 Statistical Analysis 
LH pulses were identified using a deconvolution algorithm using cluster analysis 
with 93% sensitivity and specificity on blinded data, and basal, pulsatile and total LH 
secretion calculated (Liu, Keenan et al. 2009). Paired Student’s t test was used to 
assess changes in pulse frequency and changes in mean LH, FSH and testosterone 
concentrations. Data are presented as mean±sem.  A two-sided P <0.05 was regarded 
as statistically significant for all analyses. The statistical software package Minitab 
16 (Minitab Ltd, Coventry, UK) was used. 
5.4 Results 
5.4.1.1 Effects of prolonged high-dose infusion of kp-10 on LH 
pulsatility in healthy men 
Infusion of 4-µg/kg/hr kisspeptin-10 resulted in sustained increases in LH 
concentration. LH profiles observed in the 4 individual study subjects are represented 
in Fig. 5.1. Bolus injection of 3µg/kg kisspeptin-10 resulted in an increase in LH to 
13.6 ±1.7 IU/L (P <0.05 vs. baseline) at 30 min. Continuous kisspeptin-10 infusion 
(4 µg/kg/hr) resulted in a further increase in LH secretion in all subjects which was 
sustained throughout the 22.5 hours of infusion. Mean LH during kisspeptin-10 
infusion was 20.9±4.9 vs. 5.5±0.8 IU/L over the 9 hours pre-treatment period (P 
<0.05, Fig 5.1).  
Mean LH concentrations in the final 90 min of infusion (23.9±6.8 IU/L) were 
comparable to that in the first 90 min of infusion (16.3±2.8 IU/L, P=0.34).  These 
data therefore do not indicate tachyphylaxis of the LH response to kisspeptin-10 
administration at this dose and duration of exposure.  
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Figure 5.1. Serum LH profiles of four individual subjects receiving 4 µg/kg/hr 
kisspeptin-10 infusion (black bar) after 9 hour baseline sampling and 3µg/kg iv bolus 
administered at 9 hours (black arrow). Serum samples were obtained at 10 min 
intervals except overnight when samples were obtained hourly. Note the difference 
in scale between individual subjects. 
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Intravenous administration of 100 µg bolus of GnRH 60 min before the end of the 
kisspeptin-10 infusion increased LH further with a peak of 89.3±6.1 IU/L. This 
stimulatory effect of GnRH was at least 2.5-fold greater in all subjects than the peak 
LH observed with the iv bolus of kisspeptin-10 (13.6±1.7 IU/L, P <0.001) and the 
peak LH achieved during kisspeptin-10 infusion (28.7±7.0 IU/L, P <0.01). 
Analysis of LH pulse frequency during the 9-hour baseline sampling and the 
corresponding 9-hour period on the second day of infusion was performed. 
Characteristic pulsatile LH secretion was observed in all 4 subjects at baseline, but 
was not well defined during kisspeptin-10 infusion. Nevertheless, deconvolution 
analysis showed an in increase in pulse frequency in three subjects (from 0.4 to 0.6, 
0.6 to 0.8 and 0.6 to 1.2 pulses/hr, Fig. 5.1A to 5.1C respectively) while one subject 
showed a slight decrease from 0.7 to 0.6 pulse/hr giving a mean pulse frequency of 
0.6±0.1 pulses/hr at baseline and 0.8±0.2 during kisspeptin-10 infusion (ns).  
Although FSH showed an increase in all subjects during infusion of 4 µg/kg/hr 
kisspeptin-10, this was not statistically significant (2.7±0.8 to 5±2.0 IU/L, P = 0.17, 
Fig. 5.2 B) whereas testosterone concentration significantly increased from 16.6±2.4 
to 24.0±2.5 nmol/L (P <0.001, Fig. 5.2 C).  
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Figure 5.2. Gonadotropin and testosterone response to infusions of 4 µg/kg of 
kisspeptin-10 in healthy men (n=4). A: Mean serum LH at baseline and during the 
final hour of kisspeptin-10 infusion. B: Mean serum FSH before and during 
kisspeptin-10 infusion. C: Mean serum testosterone before and during kisspeptin-10 
infusion. Error bars represent SEM. * P<0.05, *** P<0.001. 
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5.4.1.2 Effects of low dose infusion of kp-10 on LH pulsatility in 
healthy men 
Mean LH increased significantly from 5.2±0.8 IU/L at baseline to 14.1±1.7 IU/L 
during kisspeptin-10 infusion (P <0.01, n=4, Fig 5.3). LH showed a steady increase 
throughout the course of the infusion, increasing from 7.2±2.3 IU/L in the first 90 
min of infusion to 20.4±3.5 IU/L in the last 90 min (P <0.05, Fig. 5.3). 
 
Figure 5.3: Gonadotropin response to 9-hour intravenous infusion of 1.5 µg/kg 
kisspeptin-10 (n=4). A to D: LH profiles from individual subjects during baseline 
(closed circles) and kisspeptin-10 infusion (open triangles) visits. Note the difference 
in scale between individual subjects. 
Deconvolution analysis demonstrated an increase in LH pulse frequency in all 
subjects, with a mean increase from 0.7±0.1 to 1.0±0.2 pulses/hr (P = 0.01) during 
kisspeptin-10 infusion at 1.5 µg/kg/hr (Fig. 5.4). Secretory mass of LH per pulse also 
increased in all subjects during the infusion, from 3.9±0.4 to 12.8±2.6 IU/L (P <0.05, 
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Fig 5.4). Pulsatile LH secretion increased as a proportion of total LH secretion in all 
subjects from 41.3±5.7% to 69.5±5.9% during the infusion.  
 
Figure 5.4: Mean LH pulse frequency and secretory mass of LH per pulse during 
baseline and kisspeptin-10 infusion visits. Error bars represent SEM. * P<0.05. 
Serum FSH also increased progressively during the lower dose kisspeptin-10 
infusion. FSH observed during the final 90 minutes of the infusion (6.6±0.8 IU/L) 
showed a significant increase from the first 90 min (3.8±0.8 IU/L P < 0.05) of the 
infusion and baseline (3.9±0.7 IU/L P < 0.05).    
5.5 Discussion 
Continuous infusion of kisspeptin-10 elicited sustained LH secretion without any 
evidence of rapid desensitisation. Tachyphylaxis of the GnRH/LH system during 
continuous infusion of kisspeptin-10 has been demonstrated in primate models, with 
LH returning to baseline a few hours after an initial rise (Seminara, DiPietro et al. 
2006; Ramaswamy, Seminara et al. 2007).  Despite continually infusing kisspeptin-
10 for 22.5 hours, we found no such desensitisation and indeed LH secretion tended 
to increase progressively. This is possibly a function of the dose of kisspeptin-10 
used in our study being lower than that used in the primate studies –i.e. 4 µg/kg/hr in 
the present study vs. approximately 30-40 µg/kg/hr in primates (Seminara, DiPietro 
et al. 2006; Ramaswamy, Seminara et al. 2007). Tachyphylaxis of LH response has 
been seen during the twice-daily administration of kisspeptin-54 to women with 
hypothalamic amenorrhea, but this occurred over a much longer time period, i.e. two 
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weeks (Jayasena, Nijher et al. 2009). One possibility, albeit with only indirect 
evidence, is diminished pituitary sensitiveness to increased GnRH secretion triggered 
by kisspeptin-10. In ovine models infused kisspeptin-10, LH concentrations 
diminished after an initial surge, while GnRH concentrations (measured directly 
from portal circulation) did not show a similar decline – suggesting a pituitary locus 
for desensitisation (Messager, Chatzidaki et al. 2005). However, responsiveness to 
GnRH was preserved in the primates where kisspeptin infusions lead to 
desensitisation and in the present study, which is not consistent with this observation 
in sheep. Finally, it is possible that interspecies difference do exist between rhesus 
monkeys and humans – as illustrated by a lack of effect reported to 200 µg/hr (20 
µg/kg/hr) kisspeptin-10 in contrast to observations in the present study. 
Another key observation is the relative constancy of serum LH concentrations during 
kisspeptin-10 infusion although serum testosterone increased significantly.  
Androgens have been shown to down -regulate Kiss1 gene expression in the non-
human primate hypothalamus (Shibata, Friedman et al. 2007) and kisspeptin-
secreting neurones have been proposed to constitute part of the pathway mediating 
sex steroid negative feedback (Oakley, Clifton et al. 2009). Despite significant 
increases in serum testosterone, although within the normal range, there was no late 
decline in LH suggesting that within the physiological range, testosterone has limited 
ability to modulate the ability of the GnRH neuron to respond to kisspeptin-10 and 
the pituitary gonadotropes to respond to GnRH.   
It has to be noted that the responses to 3-µg/kg bolus of kisspeptin-10, administered 
at the start of the infusion was comparable to the responses observed in studies 
described in chapter 1. In chapter 1, comparison is made between vehicle and various 
doses of kisspeptin-10 studies analysing variance simultaneously across various 
groups. In the present experiment however, comparison is made between LH 
concentrations before and after the 3 µg/kg dose, giving rise to apparent 
inconsistency. However, as outlined in section 4.4.1.1, all doses of kisspeptin-10 
studied in experiments described in chapter 1 elicited a significant rise in LH from 
baseline. This indicates that kisspeptin responsiveness to a given dose is consistent. 
The translational applications of this are described in chapter 8. 
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While three subjects demonstrated an increase in LH pulse frequency in response to 
the higher-dose kisspeptin-10 infusion, one did not. Deconvolution analysis (Liu, 
Keenan et al. 2009), like other algorithms to detect LH pulses (see section 1.1.3.5) is 
less sensitive with high LH secretion rates as the distinct increase in LH 
concentration achieved by individual pulsatile discharges of LH can be obscured. 
The high mean LH concentrations during the higher dose kisspeptin-10 infusion are 
likely to have prevented reliable analysis of pulse frequency leading to 
underestimation. 
Stimulatory effects of kisspeptin-10 on LH, FSH and testosterone established in this 
study could inform future studies using kisspeptin as a diagnostic or therapeutic 
agent. Potent kisspeptin agonists (Curtis, Cooke et al. 2009) and antagonists (Millar, 
Roseweir et al. 2010) currently being tested in animal models are amino acid 
substitutions of the decapeptide sequence of kisspeptin-10. Moreover, we have also 
demonstrated that GnRH responsiveness is preserved in subjects receiving 
kisspeptin-10 infusion and that maximal LH responses seen with kisspeptin-10 are 
considerably lower than that achieved with GnRH. Therefore, kisspeptin-10 might 
provide a more physiological stimulation of the human reproductive axis with 
potential therapeutic advantages in stimulation of ovulation.  
Our study protocols did not incorporate measurement of kisspeptin immunoreactivity 
for two reasons. With the expected very short plasma half-life of kisspeptin-10 (12), 
the post-injection blood sampling schedule would need to include samples much 
earlier and more frequently than just at 10 minutes, for accurate analysis. Moreover, 
immunological assays can potentially give ‘false-positive’ results in the presence of 
cleavage products of the peptide as non-specific binding of kisspeptin antibodies is 
well established (42). Mass-spectroscopic assays of serum samples for kisspeptin 10 
at various time-points during the 4 µg/kg/hr kisspeptin-10 infusion were therefore 
attempted by collaborators (Pfizer, Sandwich, Kent, UK) but concentrations of 
kisspeptin-10 and its cleavage products (kisspeptin 9, 7 or 4) were below the 
detection limit (1 ng/ml) at almost all time points, most likely due to suboptimal 
sample processing.  
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This study demonstrates the novel phenomenon that continuous infusion of 
kisspeptin-10 increases LH pulse frequency.  Along with increased secretory mass in 
individual pulses, this increase in pulse frequency resulted in pulsatile secretion 
contributing to a higher proportion of total LH secreted. Data from other 
investigators has not shown that GnRH pulse frequency is increased by an acute 
bolus of kisspeptin-10 (Chan, Butler et al. 2011), indicating the need for continuing 
kisspeptin stimulation, to study it’s influence on GnRH pulse frequency.  The 
dependency of LH pulsatility on pulsatile GnRH secretion (Clarke and Cummins 
1985; Millar, Lu et al. 2004)  is well established, and kisspeptin has been shown to 
directly stimulate GnRH secretion (Messager, Chatzidaki et al. 2005) with 
electrophysiological studies showing intense and prolonged activation of rodent 
GnRH neurons by kisspeptin-10 (Han, Gottsch et al. 2005). There is a marked 
stochastic increase in LH when kisspeptin is applied to the hypothalamic arcuate 
nucleus in rodents which might reflect an acceleration of LH pulse frequency (Li, 
Kinsey-Jones et al. 2009) and a kisspeptin antagonist decreases LH pulse frequency 
in this model (Li, Kinsey-Jones et al. 2009).  Systemic administration of kisspeptin-
10 in our study prevents us from concluding whether this increase in LH (and by 
inference GnRH) pulse frequency is mediated by a direct effect on GnRH neurons 
(Krsmanovic, Hu et al. 2009) or through stimulation of the hypothalamic pulse 
generator (Ohkura, Takase et al. 2009). However, we have demonstrated that LH 
pulsatility is dependent on kisspeptin, increasing significantly during continuous 
administration. However, it is possible that endogenous release of kisspeptin is 
pulsatile, and pulsatile administration may have a different impact on GnRH 
pulsatility, modulated by co-transmitters such as neurokinin B and dynorphin 
(Wakabayashi, Nakada et al. 2010). There may also be species and sex differences in 
GnRH pulse regulation as unlike rodents, a GnRH surge is not obligatory for the 
preovulatory LH surge in women (Adams, Taylor et al. 1994).  
An increase in LH pulse size (secretory mass per pulse or burst size) was observed in 
our study, with pulse sizes computed by a well validated, automated analytical 
program. This increase in secretory mass in individual pulses observed during 
kisspeptin-10 infusion can be a function of two factors either in isolation or in 
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combination – one, an increase in the quantity of GnRH secreted and two, an 
increase in pituitary sensitivity to GnRH. As no known changes in the hormonal 
milieu with a potential to increase gonadotrope sensitivity arises from kisspeptin 
administration, it is logical to conclude that kisspeptin augments GnRH pulse size. 
However, one has to be cognisant that the deconvolution algorithm employed in the 
present study – as well as other algorithms to assess LH pulsatility as discussed in 
section 1.1.3.5 – is designed to assess physiological LH secretion, where adjacent 
pulses are sufficiently demarcated to allow a clear definition of baseline. When a 
subsequent pulse is generated before LH concentration return to nadir, the 
identification of ‘baseline’ needs mathematical modelling and may not be reflective 
of underlying physiology. Interestingly, pioneering investigators of LH pulsatility 
had identified this difficulty in differentiating ‘basal’ and ‘pulsatile’ secretion (Yen, 
Tsai et al. 1972). Three decades on, these challenges remain –and are likely to 
remain for the foreseeable future. With a short half-life (12-15 min) and good 
correlation with LH, free α subunit (FAS) could be used a surrogate of GnRH pulse 
frequency. Although there is desensitisation in free α subunit secretion at rapid 
GnRH frequencies, it has been shown to be a superior marker to LH at GnRH 
frequencies around 30 min but the sensitivity of FAS and LH are comparable at the 
pulse frequencies observed in the present study in the region of a pulse every hour 
(Hayes, McNicholl et al. 1999). 
In conclusion, continuous infusion of kisspeptin-10 increases mean serum LH, LH 
pulse frequency, LH secretory mass-per-burst and testosterone secretion without 
rapid desensitisation/tachyphylaxis of effect observed in other species.
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6 Gonadotropin responses to kisspeptin-10 in patients with 
pubertal delay 
6.1 Introduction 
Reactivation of the GnRH pulse generator that is active in infancy but quiescent in 
childhood with associated increase in LH pulse frequency is critical for pubertal 
development (Roth, Kelch et al. 1972; Conte, Grumbach et al. 1980; Waldhauser, 
Weissenbacher et al. 1981; Balasubramanian, Dwyer et al. 2010).  As discussed in 
section 1.4, precocious puberty is associated with premature activation of GnRH 
pulse frequency and pubertal delay associated with delayed activation of the same. 
Having established that kisspeptin-10 evokes robust LH responses (Chapter 3) and 
that kisspeptin-10 infusion enhances LH pulse frequency in healthy men (Chapter 5), 
we sought to establish the kisspeptin-10 response profile in patients with GnRH 
deficient phenotype. Towards this, kisspeptin-10 responses were assessed in patients 
with pubertal delay associated with neurokinin B (NKB) signalling deficiency (see 
chapter 1.3.4) 
6.2 Objectives and hypothesis 
• In patients with NKB signalling defects, we hypothesised that kisspeptin-10 
will evoke LH secretion, demonstrating that NKB signalling is not obligatory 
for kisspeptinergic stimulation of GnRH neurons. 
Studies reported herein are observational studies in small number of patients with 
a clear reproductive phenotype and provides preliminary data. Studies of larger 
cohorts of such patients are required to fully test the hypotheses. 
6.3 Studies in patients with neurokinin B signalling defects 
6.3.1 Participants 
Two patients each, with loss of function mutations in the NKB gene (TAC3) (13) and 
the gene encoding NK3R (TAC3R) were recruited from Bicêtre Hospital (Paris, 
France). Patients harbouring TAC3 mutations were both men (aged 21 and 31), while 
a 26 year-old woman and 28 year old man harbouring TAC3R mutations also took 
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part.  The Paris Sud University and Bicêtre Hospital ethics committees approved the 
study and all participants gave their informed consent (Dr. Jacques Young). 
Patients 1 and 2 harbour the c.209-1G_C homozygous mutation in the NKB gene 
(TAC3)(13). This mutation is located in the IVS3 acceptor splice-site and unmasks a 
cryptic splice-site in IVS3, leading to the insertion of 22 nucleotides between exons 3 
and 4 in the transcript. This insertion results in a frame-shift downstream of codon 67 
and the emergence of a premature stop codon at position 76, causing the termination 
of translation upstream of the NKB coding region. Patient 3 has a homozygous 
deletion (c.483_499del) in the gene encoding NK3R (TAC3R). This deletion leads to 
a frameshift downstream of codon 161 resulting in a premature stop codon at 
position 183 truncating the NK3R after the third transmembrane domain. 
Patient 4 harbours the homozygous c.738-1G_A mutation in the NK3R gene. This 
results in the loss of the natural splice acceptor site of intron 2 resulting in truncation 
of the receptor after the second extracellular loop, thus eliminating transmembrane 
domains 5–7 and the associated intracellular and extracellular loops (Young, 
Bouligand et al. 2010). 
Testosterone and estradiol replacement in the male and female patients were 
discontinued three months prior to study visits. 
6.3.1 Protocol 
This study was undertaken in collaboration with Dr. Jacques Young at the Bicêtre 
Hospital (Paris, France). Volunteers were admitted to the Bicêtre Hospital at 0800 
for 12 hours of blood sampling every 10 minutes for 2 consecutive days. On the first 
day, normal saline was infused as vehicle and on the second, kisspeptin-10 was 
administered at a rate of 1.5 µg/kg/hr for 11 hrs based on observations in healthy 
volunteers reported in chapter 5. LH, FSH, testosterone, estradiol and inhibin B 
levels were measured in Paris (Dr. Jacques Young) using methods previously 
reported (13). LH and FSH pulses were identified using the Thomas algorithm (an 
adaptation of the Santen –Bardin method of pulse detection)(Young, Bouligand et al. 
2010). Additionally, serial LH data was also analysed using the deconvolution 
analysis described in chapter 3 to determine the number of pulses, LH pulse size 
(burst mass) and the relative contribution of basal and pulsatile secretion of LH to 
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total LH secretory output (Dr. Johannes Veldhuis). These two analytical methods 
were chosen as there is no ‘gold standard’ method of pulse detection and different 
pulse detection algorithms have different sensitivity and specificity as summarised in 
section 1.1.3. 
6.3.2 Results 
6.3.2.1 Mean LH, FSH and Inhibin B 
Administration of kisspeptin-10 increased mean LH, FSH and Inhibin B 
concentrations as summarized in the table 6.1 below. Serial gonadotropin data during 
baseline LH pulsatility analysis and kisspeptin-10 infusion in the four subjects 
studied is summarized in figure 6.1. 
 LH  (IU/L) FSH  (IU/L) Inhibin B (pg/mL) 
 Saline Kisspeptin Saline Kisspeptin Saline Kisspeptin 
P1/M 0.2±0.1 0.4±0.2*** 15.9±3.2 27.4±4.6* 2.9±0.2 3.4±0.5*** 
P2/M 0.62±0.41 1.21±0.60*** 10.4±1.6 19.1±3.1* 4.4±0.6 7.1±1.1*** 
P3/F 0.22±0.06 1.25±0.56*** 8.15±2.9 26.2±4.7** 2.05±0.1 4.2±0.9*** 
P4/M 0.42±0.10 1.12±0.43*** 66±7.4 112±13.7** 3.0±0.2 5.4±0.7*** 
Table 6.1: LH, FSH and Inhibin B Responses to kisspeptin-10 and normal saline in 
patients with mutations in TAC3 (patients 1 and 2) or TACR3 (patients 3 and 4). *p< 
0.05 ; **p<0.01; ***p<0.0001 (paired t test) ; M : male, F :female. At both visits, 12 
random measurements of inhibin B were performed. 
  
 




Figure 6.1 Serum LH and FSH concentrations in patients with neurokinin B 
signalling defect. Blue lines denote basal LH and FSH profiles and black lines are 
used to represent values observed during kisspeptin-10 infusion. Asterisks represent 
LH and FSH pulses detected using the Thomas algorithm (an adaptation of the 
Santen –Bardin method of pulse detection).  
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6.3.2.2 Mean Testosterone and Estradiol 
Increases in gonadotropin concentrations were associated with significant increases 
in sex steroids in all the four subjects studied (Figure 6.2). 
 Testosterone (ng/mL) Estradiol (pg/mL) 
 Saline Kisspeptin Saline Kisspeptin 
P1/M 0.13±0.1 0.4±0.2* - - 
P2/M 0.12±0.08 0.6±0.14* - - 
P3/F - - 6.4±1.9 18.2±3.1** 
P4/M 0.42±0.10 1.12±0.43* - - 
Table 6.2: Gonadal steroid responses to kisspeptin-10 and vehicle in patients with 
TAC3 (patients 1 and 2) or TACR3 (patients 3 and 4) mutations. *p< 0.05; **p<0.01; 
***p<0.0001 (paired t test); M : male, F :female. -  : Not determined.   
6.3.2.3 LH pulse frequency 
LH and FSH pulse frequency increased significantly during kisspeptin-10 infusion 
compared to vehicle (Figure 6.2) when data was analysed using Thomas algorithm. 
 
Figure 6.2 Changes in LH and FSH pulse frequency in patients with neurokinin B 
signalling defect. * P<0.05 (paired t test). 
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Deconvolution analysis demonstrated an increase in LH pulse frequency in the two 
patients with TAC3 mutations from seven to ten, and from five to eight pulses 
respectively in 12 hours. However, in patients with TACR3 mutations, LH pulse 
frequencies during saline and kisspeptin-10 infusions were unchanged (6 and 7 
pulses every 12 hours). 
 
Series Number of 
pulses 
Basal LH Pulse LH Total LH MPP 
P1 Basal 7.0 2.3 1.6 4.0 0.2 
P1 Kp 10.0 4.5 4.4 8.9 0.4 
P2 basal 5.0 7.3 9.6 16.9 1.9 
P2 Kp 8.0 4.8 23.1 27.9 2.9 
P3 basal 6.0 5.4 5.2 10.6 0.9 
P3 Kp 6.0 15.8 9.8 25.5 1.6 
P4 basal 7.0 3.4 2.8 6.1 0.4 
P4 Kp 7.0 10.5 4.9 15.4 0.7 
 
Table 6.3: Deconvolution analysis of LH pulse frequency. Subjects 1 and 2, with 
neurokinin B secretory defects showed an increase in LH pulse frequency while 
subjects 3 and 4 (with TACR3 mutations) show similar pulse frequency at baseline 
and during kisspeptin-10 infusion 
6.4 Discussion 
The present exploratory study, although carried out in a small number of subjects, 
provides some insights into the neuroendocrine regulation of human reproduction. 
As discussed in section 1.2.3, evidence from animal models and in vitro studies 
suggest that kisspeptin stimulation of gonadotropin secretion is mediated through the 
GnRH neuron. The observation that kisspeptin-10 has no effect on LH secretion in 
men with Kallmann Syndrome (with functional impairment of GnRH neurons) is 
consistent with this notion. However, it has to be noted that these men were on 
exogenous testosterone therapy and their pituitary gonadotropes were not primed 
with prior exposure to GnRH.  
Kisspeptin-10 infusions effected a small but significant increase in both LH and FSH 
secretion in patients with neurokinin B signalling defects caused by TAC/TACR3 
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mutations. These observations suggest that neurokinin B signalling not obligatory for 
kisspeptinergic stimulation of gonadotropin secretion and are consistent with studies 
in animal models. In primates, neurokinin B antagonist abrogated neurokinin B 
dependant stimulation LH secretion whilst having no impact on kisspeptinergic 
stimulation of LH (Ramaswamy, Seminara et al. 2010).  
Discordance of results between LH pulse frequency using the Thomas algorithm and 
a deconvolution algorithm highlights the challenges posed by the lack of a 
universally valid ‘gold-standard’ method to perform gonadotropin pulsatility analysis 
(described in section 1.1.3.5). However, it has to be noted that the two patients with 
TAC3 signalling showed an increase in LH pulse frequency on deconvolution 
analysis whilst patients with TACR3 receptor did not. Further studies in larger 
number of participants are required to explore whether these observations can be 
reproduced in larger cohorts of patients.  
Whilst LH and FSH secretion were stimulated during kisspeptin-10 infusion the 
resultant mean concentrations and pulse frequency were lower than that observed in 
healthy volunteers (chapter 5). There are two potential explanations. One, that the 
pituitary gonadotropes in these patients were not been primed by normal GnRH 
pulsatility. Secondly, it is possible that neurokinin B has an additive positive impact 
on GnRH output that is, at least in part, independent of kisspeptin signalling. 
Development of specific kisspeptin antagonists that are effective on peripheral 
administration in humans will be an important step in exploring hierarchical 
regulation of reproductive function in the human hypothalamus. 
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7 Translational application of kisspeptin-10 physiology: 
Normalisation of testosterone secretion in hypogonadal 
men with type 2 diabetes. 
7.1 Introduction 
Low serum testosterone concentration is observed in one-quarter to one-half of men 
with type 2 diabetes (Dhindsa, Prabhakar et al. 2004; Kapoor, Aldred et al. 2007; 
Grossmann, Thomas et al. 2008; Dandona and Dhindsa 2011). Men with type 2 
diabetes have lower free testosterone concentrations when compared to age- and 
BMI-matched men (Dhindsa, Miller et al. 2010) and the prevalence of hypogonadism 
in this population increases with age and BMI (Ding, Song et al. 2006; Grossmann, 
Thomas et al. 2008). Low endogenous testosterone is associated with significant 
long-term health implications and is associated with increased risk of all-cause 
mortality and cardiovascular death in men (Araujo, Dixon et al. 2011).  Decreased 
serum testosterone in the vast majority of men with type 2 diabetes is not 
accompanied by a compensatory increase in pituitary secretion of luteinising 
hormone (LH) (Dhindsa, Prabhakar et al. 2004; Dandona and Dhindsa 2011), 
suggesting that hypothalamic-pituitary dysfunction is part of the pathophysiology of 
hypogonadism associated with type 2 diabetes (Hill, Elmquist et al. 2008; George, 
Millar et al. 2010). However, the neuroendocrine mechanisms underlying this 
relative deficit in LH secretion remain to be elucidated (Hill, Elmquist et al. 2008). 
The central role for GnRH neurons as the final integrator of metabolic and endocrine 
modulators of the hypothalamic-pituitary-gonadal axis is well established (Millar, Lu 
et al. 2004). Pituitary secretion of LH, and thereby testicular testosterone production, 
is regulated by changes in the amplitude and frequency of pulsatile hypothalamic 
GnRH secretion (Millar, Lu et al. 2004; Balasubramanian, Dwyer et al. 2010). Novel 
neuropeptide regulators of GnRH have recently been identified, with kisspeptins 
being crucial for pulsatile GnRH secretion, as demonstrated in both human and 
animal studies (de Roux, Genin et al. 2003; Seminara, Messager et al. 2003; 
Roseweir and Millar 2009). Studies in experimental animals have shown changes in 
Kiss1 gene expression in response to factors known to lower GnRH secretion, 
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including hyperglycaemia (Castellano, Navarro et al. 2006), inflammation (Iwasa 
2008), and estrogen feedback (Oakley, Clifton et al. 2009), suggesting that decreased 
endogenous kisspeptin secretion may account for decreased hypothalamic-pituitary-
gonadal function in men with type 2 diabetes (George, Millar et al. 2010). 
Low testosterone in men with type 2 diabetes is associated with an adverse cardio-
metabolic phenotype – decreased high density lipoproteins, increased triglycerides, 
increased body mass index and insulin resistance (Grossmann, Thomas et al. 2008). 
Moreover, in men with type 2 diabetes, decreased testosterone concentrations are 
associated with a three-fold increase in cardiovascular mortality (Ponikowska, 
Jankowska et al. 2010). While there is a paucity of long-term clinical outcomes in 
relation to testosterone replacement therapy in these men (Bhasin, Cunningham et al. 
2010), recent short-term studies suggest improvements in cardiovascular-risk profile 
following testosterone replacement in hypogonadal men with type 2 diabetes (Jones, 
Arver et al. 2011). However, in individuals at high-risk for cardiovascular disease, 
testosterone therapy (where serum testosterone concentrations often exceed the 
physiological range) has been associated with serious adverse events (Basaria, 
Coviello et al. 2010). Stimulation of endogenous testosterone secretion by enhancing 
GnRH secretion and increasing testosterone within the physiological range (chapter 
3), may therefore be therapeutically advantageous in this context.    
7.2 Objectives and hypothesis 
Clinical studies were designed to test the hypothesis that kisspeptin mediates 
hypogonadotropic hypogonadism in men with type 2 diabetes and that administration 
of exogenous kisspeptin will stimulate LH and testosterone secretion (George, Millar 
et al. 2010). Acute responses in serum LH to maximally stimulatory intravenous 
doses of kisspeptin-10 and GnRH in hypogonadal men with type 2 diabetes were 
compared with those in healthy volunteers. Kisspeptin-10 was subsequently 
administered intravenously for 11 hours to assess the effects of sustained  stimulation 
on LH and testosterone secretion. 
 
Kisspeptin in type 2 diabetes  116 
7.3 Research Design and Methods 
7.3.1 Participants 
Acute LH responses to kisspeptin-10 and GnRH were assessed in five men with type 
2 diabetes and newly diagnosed hypogonadotropic hypogonadism (age 33.6±3 years, 
BMI 40.6±6.3 kg/m2, testosterone 7.4±0.7 nmol/L, LH 4.7±0.7 IU/L, FSH 3.4±0.6 
IU/L, HbA1c <8 %, duration of diabetes <5 years) and seven age matched healthy 
men (age 31.2±1.8 years, BMI 25±1.6 kg/m2, LH 5.5±0.8 IU/L, FSH 4±0.6 IU/L, 
testosterone 19.6±1.5 nmol/L, normal glucose tolerance). Four men with type 2 
diabetes also participated in the kisspeptin-10 intravenous infusion study. 
Studies were approved by the Lothian Research Ethics Committee (Ref 
09/S1101/23) and all participants provided written informed consent. All volunteers 
had normal secondary sexual characteristics with minimum total testicular volume of 
40 ml and normal physical examination. Baseline full blood count, renal function, 
liver function and electrolytes were within normal limits. Healthy volunteers 
underwent a 75-g glucose tolerance test to demonstrate normoglycaemia. 
7.3.2 Study design 
7.3.2.1 Acute kisspeptin-10 and GnRH stimulation study. 
This study was designed to compare acute LH responses to kisspeptin-10 in 
hypogonadal men with type 2 diabetes with age-matched healthy volunteers and 
involved two 6-hr visits to the Edinburgh Clinical Research Facilities, at least a week 
apart. All visits commenced between 0800 and 0900 following overnight fast to 
avoid diurnal and nutritional bias. Blood samples were obtained at 15-min intervals 
for three hours following which an intravenous bolus of 100 µg of GnRH was 
administered at the first visit and 0.3 µg/kg (0.23 nmol/kg) kisspeptin-10 at the 
subsequent visit. Samples were collected at 15-min intervals for a further three hours. 
Standardised meals were provided. Blood pressure, heart rate and peripheral 
oxygenation were monitored regularly throughout the study. Full blood count, serum 
electrolytes, liver function, renal function and serum glucose were measured at the 
start and the end of all visits as safety measures as kisspeptins had not previously 
been administered to men with diabetes. 
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7.3.2.2 Kisspeptin-10 infusion study 
This study was designed to assess whether the persistent and robust increase in mean 
serum LH concentration, LH pulse frequency, LH secretory-burst per pulse and 
serum testosterone concentration during continous infusion of kisspeptin-10 
previously demonstrated in healthy volunteers (Chapter 3) was reproducible in 
hypogonadal men with type 2 diabetes.  
Volunteers attended for two 12-hr visits, five days apart. Both visits involved 
collection of 2 mls of blood at 10-min interval for 12 hours. At the second visit, 
baseline sampling was performed for one hour following which kisspeptin-10 was 
infused intravenously (Crono PCA, Cane, Rivoli, Italy) at 4 µg/kg/hr. Standardised 
meals were provided and safety checks carried out as in the acute kisspeptin-10 
stimulation study.  
7.3.3 Study Drugs 
Kisspeptin-10 was custom-synthesised to GMP standards (Bachem GmBH, Weil am 
Rhein, Germany) with 97% purity on HPLC with a mass balance of 98.8% and 
prepared by reconstituting 1 mg kisspeptin-10 in 5 ml normal saline (Chapter 2). 
Maximally stimulatory dose of kisspeptin-10 (0.3 µg/kg) was identified from our 
dose-escalation study in healthy male volunteers (Chapter 3). The infusion rate of 4 
µg/kg/hr was chosen to achieve maximal stimulation of LH secretion with a view to 
having maximal stimulation of endogenous testosterone secretion. Although a lower 
dose (1.5 µg/kg/hr) was shown to enhance LH pulse frequency in healthy men 
(Chapter 5), sustained and robust increase in LH secretion was observed without any 
evidence of desensitisation with the larger 4 µg/kg/hr dose. Commercially supplied 
GnRH (Relefact, Sanofi Aventis, Frankfurt, Germany) was used for GnRH 
stimulation.  
7.3.4 Hormone assays 
Blood-samples were batch-processed by centrifugation at 4oC for 10 min at 3000 
rpm and serum was frozen at -20oC until analysis. LH was assayed in all samples by 
ELISA and testosterone in hourly samples by extraction RIA as previously described 
(Chapter 2). Samples from individual study visits were analysed together. Inter-assay 
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coefficients of variation for all hormonal assays were <5 % at the concentrations 
measured. Intra-assay coefficient of variation of LH was 2.9%. 
7.3.5 Statistical Analysis 
Data are presented as mean±sem.  The statistical software package Minitab 16 
(Minitab Ltd, Coventry, UK) was used. Data not normally distributed were log-
transformed prior to analysis. A two-sided P <0.05 was regarded as statistically 
significant.  Sample size calculations were made on the assumption that effect sizes 
and variance of gonadotropin responses to kisspeptin-10 in hypogonadal men with 
type 2 diabetes would be comparable to those observed in healthy volunteers 
(chapter 3). 
7.3.5.1 Acute kisspeptin and GnRH stimulation study 
As LH secretion is pulsatile, baseline LH for each study visit was calculated as the 
mean of LH concentrations in the 18 samples during the 3-hr sampling period prior 
to kisspeptin-10 or GnRH administration. Δ LH was calculated by subtracting this 
baseline LH value from the peak LH concentration observed following kisspeptin-10 
or GnRH stimulation. ΔLH responses to kisspeptin-10 and GnRH in hypogonadal 
men were compared with healthy controls using two sample Student’s t tests.  
7.3.5.2 Kisspeptin infusion study 
LH, FSH and testosterone responses to kisspeptin-10 were calculated by comparing 
the baseline visit with corresponding data points during kisspeptin-10 infusion using 
Student’s paired t test. 
A deconvolution algorithm with 93% sensitivity and specificity (Liu, Keenan et al. 
2009) was used to calculate  basal, pulsatile and total LH secretion on blinded data. 
This algorithm also provided read-outs of basal (non-pulsatile) and pulsatile 
components of total LH secretion. Student’s paired t test was used to compare pulse 
size and frequency at baseline and during kisspeptin-10 infusion. 
Leydig cell sensitivity, i.e. the ratio of serum testosterone to LH concentrations, was 
calculated during baseline and kisspeptin-10 infusion visits and compared using 
paired t tests. 
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Additionally, LH pulsatility and Leydig cell sensitivity to LH observed in the study 
subjects during the baseline visit and kisspeptin-10 infusion were compared to data 
from contemporaneous study of healthy age-matched volunteers without diabetes 
using two-sample t tests (chapter 3). 
7.4 Results 
7.4.1 Acute kisspeptin-10 and GnRH responses are preserved in 
men with type 2 diabetes 
LH increased significantly following kisspeptin-10 administration in both 
hypogonadal men with type 2 diabetes (4.7±0.7 to 10.7±1.2 IU/L P=0.02) and 
healthy men (5.5±0.8 to 14.5±1.8 IU/L, P =0.002), with peak serum LH observed 30 
minutes after kisspeptin in both groups.  ΔLH was comparable (6.0±1.3 in men with 
diabetes vs. 8.9±1.1 IU/L P=0.18, Figure 7.1), with peak LH showing respectively 




Figure 7.1 Serum LH responses to intravenous bolus of 0.3 µg/kg of kisspeptin-10 in 
healthy volunteers (squares) and hypogonadal men with type 2 DM (circles).  
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Following GnRH administration, LH increased from 4.3±0.4 to 37.7±9.9 IU/L in 
men with hypogonadism and diabetes, and from 5.6±0.6 to 42.0±4.1 in healthy 
controls. ΔLH response to GnRH was similar in the two groups (ΔLH 36.4±3.9 vs. 




Figure 7.2 Serum LH responses to intravenous bolus of 100 µg GnRH in healthy 
volunteers (squares) and hypogonadal men with type 2 DM (circles).  
 
7.4.2 Kisspeptin-10 infusion stimulates LH and testosterone 
secretion in hypogonadal men with type 2 diabetes 
LH pulse frequency at baseline was significantly lower in hypogonadal men with 
diabetes than healthy controls (0.6±0.1 vs. 0.8±0.1 pulses/hr, P=0.03). LH increased 
significantly during kisspeptin-10 administration in all hypogonadal men with type 2 
diabetes. Mean LH increased from 3.9±0.1 at baseline to 20.7±1.1 IU/L during 
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kisspeptin-10 infusion (P=0.03, Figure 7.3 A-D).  LH showed a progressive increase 
during the first six hours of infusion, tending to plateau thereafter.  
 
Figure 7.3. Serum LH profile at baseline (squares) and during kisspeptin-10 infusion 
(triangles) in hypogonadal men with type 2 diabetes. Each of the panels represents a 
study subject. 
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The pulsatile component of LH secretion, calculated using deconvolution of LH data 
obtained at 10-min intervals, showed a significant increase from 32.1±8.0 IU/L at 
baseline to 140.2±23.0 during kisspeptin-10 infusion (P=0.007). Mean pulse 
frequency increased from 0.6±0.1 pulses/hr at baseline to 0.9±0 pulses/hr during 
kisspeptin-10 infusion, (P=0.05 Figure 7.4A) and LH secretory mass per pulse 
increased from 5.1±0.6 to 15.2±2.6 IU/L (P=0.017 Figure 7.4B). Pulse frequency 
during kisspeptin-10 infusion was also comparable to data from age-matched healthy 
male volunteers (0.9±0 vs. 1.0±0.1 pulses/hr in healthy controls P=0.4). 
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Figure 7.4 LH responses to kisspeptin-10 infusion in hypogonadal men with type 2 
diabetes. A, LH pulse frequency increased from 0.6±0.1 to 0.9±0 pulses/hr during 
kisspeptin-10 infusion (P=0.05).  B, LH secretory-burst (mass per pulse) increased 
from 5.1±0.6 to 15.2±2.6 IU/L (P=0.017). Mean testosterone increased from 8.5±1.0 
at baseline to 11.4±0.9 nmol/L at the end of kisspeptin-10 infusion, P=0.002, (Figure 
7.5). Leydig cell responsiveness in hypogonadal men with T2DM, as estimated as the 
ratio of serum testosterone to LH, were also comparable with healthy volunteers at 
both the baseline visit (4.6±1.1 in T2DM vs. 2.7±0.9, P=0.23) and during the 
kisspeptin-10 infusion visit (1.7±0.4 in T2DM vs. 0.9±0.3, P=0.76).  
Serum FSH concentration did not show a significant change during kisspeptin-10 
infusion (3.9±1.1 IU/L at baseline vs. 5.5±1.1 IU/L, also consistent with observations 
in healthy male volunteers (Chapter 3). 
No adverse events were identified.  
 
Figure 7.5 Testosterone response to kisspeptin-10 infusion in hypogonadal men with 
type 2 diabetes. Mean testosterone increased from 8.5±1.0 at baseline to 11.4±0.9 
nmol/L at the end of kisspeptin-10 infusion (P=0.002). 
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7.5 Discussion 
Our acute studies in hypogonadal men with diabetes demonstrate normal 
responsiveness of the hypothalamic GnRH neuronal population to kisspeptin-10, and 
of pituitary gonadotropes to GnRH. Testosterone concentrations also normalised 
during kisspeptin-10 infusion in response to increased LH, suggesting that the cause 
of the hypogonadism is predominantly central in origin, in keeping with the 
demonstration here that basal LH pulse frequency is low, and observations in rodent 
models of experimental diabetes (Castellano, Navarro et al. 2006).  Normalisation of 
testosterone during continuous kisspeptin-10 infusion with testosterone to LH ratios 
comparable to healthy male volunteers suggests that Leydig cell responsiveness to 
LH is also preserved in hypogonadal men with type 2 diabetes.  
Kisspeptin signalling through its cognate receptor GPR54 (Kiss1R) has been 
proposed as one of the mechanisms whereby metabolic signals modulate the 
hypothalamic-pituitary-gonadal axis (Castellano, Bentsen et al. 2010; George, Millar 
et al. 2010). Studies in animal models have shown that factors associated with 
hypogonadism in diabetes such as hyperglycaemia (Castellano, Navarro et al. 2006), 
inflammation, decreased leptin input (Smith, Acohido et al. 2006) and increased 
estrogen feedback (Oakley, Clifton et al. 2009) down-regulate Kiss1 gene  
expression. Our observations are consistent with the notion that the hypothalamic-
pituitary-gonadal axis per se is functionally intact in hypogonadal men with type 2 
diabetes and that the reduced activity of the hypothalamic-pituitary-gonadal axis 
occurs in response to perturbed afferent inputs, which include metabolic and 
endocrine pathways.  
A direct pathological effect of diabetes on Leydig cell function has been proposed as 
some men with type 2 diabetes show submaximal testosterone response to hCG 
stimulation (Ermetici, Donadio et al. 2009). Insulin resistance has also been 
demonstrated to be associated with decreased serum testosterone in men (Pitteloud, 
Hardin et al. 2005). However, our results show robust Leydig cell response to 
kisspeptin-stimulated endogenous LH comparable to observations in healthy male 
volunteers suggesting that Leydig cell sensitivity to LH may be preserved in 
hypogonadal men with type 2 diabetes. The subjects in this exploratory study were 
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relatively young in age, and with a brief duration of diabetes. It is possible that 
longer-term hypogonadotropism may lead to gonadal dystrophy not yet manifest in 
these men.   It is also possible that the modest testicular stimulation induced by 
kisspeptin may not reveal deficiencies in maximal testosterone secretory potential 
elicited by hCG. Yet, it has to be noted that the levels of LH stimulation induced by 
kisspeptin-10 in type 2 diabetic males are in the physiological range. Moreover, our 
observation of preserved Leydig cell response in hypogonadal men with T2DM in 
the present study is in keeping with observations of normal hCG response in obese 
non-diabetic men (Vermeulen, Kaufman et al. 1993). 
Decreased circulating serum LH concentrations observed in hypogonadal men with 
type 2 diabetes can arise from decreased LH pulse frequency (due to reduced GnRH 
pulse frequency), decreased pulse size (a function of GnRH secretory mass and 
pituitary gonadotrope sensitivity) or both. Baseline LH pulse frequency in our study 
subjects was lower than the pulse frequency reported in healthy men without diabetes 
while the secretory mass per LH pulse was comparable to that seen in healthy 
volunteers (chapter 3). This novel observation supports the notion that the 
inappropriately low concentrations of serum LH observed in men with type 2 
diabetes (Dhindsa, Prabhakar et al. 2004; Dandona and Dhindsa 2011) may arise 
from a decrease in hypothalamic GnRH (and therefore LH) pulse frequency – as the 
link between decreased LH frequency and lower mean LH is well established (Spratt, 
Finkelstein et al. 1987). LH pulse frequency in obese men has previously been 
reported to be comparable to healthy volunteers, suggesting that the pathogenesis of 
hypogonadism in type 2 diabetes might be different from hypogonadism associated 
with obesity alone (Vermeulen, Kaufman et al. 1993).  Because LH secretory burst-
mass increased three-fold during the kisspeptin-10 infusion in men with diabetes, 
reduced GnRH secretion may also characterise diabetes. Whilst our results do not 
provide direct mechanistic explanations of this pathophysiological process, the 
observed normalisation of LH secretory parameters after exogenous administration 
of kisspeptin-10, taken together with the demonstration that kisspeptin antagonists in 
animal models decrease LH pulse frequency (Li, Kinsey-Jones et al. 2009; Roseweir, 
Kauffman et al. 2009; Millar, Roseweir et al. 2010) lends indirect support to the 
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hypothesis that hypogonadism in diabetes is mediated, at least in part, by reduced 
hypothalamic kisspeptin secretion (George, Millar et al. 2010).  
Testosterone rapidly normalised during kisspeptin-10 infusion in our study with 
comparable Leydig cell responses to those seen in healthy male volunteers. However, 
longer term administration of kisspeptin-10 or its analogues is required to assess 
whether this increase can be sustained within the physiological range as 
tachyphylaxis of kisspeptin response has been reported in rodents (Roa, Vigo et al. 
2008) and primates (Seminara, DiPietro et al. 2006; Ramaswamy, Seminara et al. 
2007). A gradual decline in LH responsiveness to kisspeptin-54 has been reported in 
women when it was administered twice daily (Jayasena, Nijher et al. 2010). Twice-
weekly kisspeptin-54 administration resulted in only partial desensitization, in 
contrast to the complete desensitisation observed with twice-daily administration 
(Jayasena, Nijher et al. 2010). However, desensitisation was not observed in the 
present study during 11 hours of infusion or in our previous studies involving 
intravenous infusion of kisspeptin-10 at 4 µg/kg/hr for 22.5 hours in healthy men 
(George, Veldhuis et al. 2011). Nevertheless, considering the phenotypic 
heterogeneity in men presenting with type 2 diabetes and hypogonadism (Dandona 
and Dhindsa 2011), longer studies with a larger number of participants are required 
to explore the pharmacological potential of kisspeptin analogues in hypogonadal men 
with diabetes.  
As a potential therapeutic approach, there are theoretical advantages to the use of 
kisspeptin-mediated stimulation of endogenous testosterone over conventional 
testosterone replacement. Fertility is likely to be preserved as FSH secretion is 
maintained, unlike therapy with exogenous testosterone (Anderson and Baird 2002). 
Moreover, testosterone concentrations would be restored to the physiological range 
rather than raised to supraphysiological concentrations, as often observed with 
exogenous testosterone therapy which results in lowering of gonadotropin levels 
proportionately with serum testosterone (Swerdloff, Wang et al. 2000). The latter is 
particularly pertinent since there are safety concerns regarding the use of exogenous 
testosterone in individuals at high cardiovascular risk although there are small studies 
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reporting metabolic advantages to exogenous testosterone therapy in men with 
diabetes (Basaria, Coviello et al. 2010; Grossmann 2011).  
Observations in the present study also have pharmacological implications for other 
types of male hypogonadism. Currently, central stimulation of the hypothalamic-
pituitary axis is achieved with GnRH, delivered in a pulsatile manner to avoid 
pituitary desensitisation (Pitteloud, Hayes et al. 2002). This study provides the first 
demonstration that continuous rather than pulsatile kisspeptin-10 administration can 
achieve sustained LH stimulation in male hypogonadism, at least over the time 
period we have studied.  
In conclusion, kisspeptin-10 evokes rapid and robust normalisation of LH pulse 
frequency and LH secretion in hypogonadal men with type 2 diabetes with resultant 
normalisation of circulating testosterone. These results suggest that the 
hypogonadism observed in men with type 2 diabetes is predominantly hypothalamo-
hypophyseal in origin. These observations also suggest a potential therapeutic role 
for kisspeptin analogues in normalising endogenous testosterone secretion in 
hypogonadal men with type 2 diabetes. 
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8 Conclusions 
In addition to the primary results discussed in chapters 3 to 8, there are also some 
additional observations – some of which potentially hypothesis generating- that can 
be made when the findings from two or more of the studies reported in this thesis are 
considered together.  
8.1 Comparative stimulatory effect of GnRH vs. GnRH and 
Kisspeptin-10 
In acute studies discussed in chapter 5, seven healthy male volunteers attended for 
two visits, at one of which, they were administered 100 µg of GnRH. From a 
baseline of 5.6±0.6 IU/L, LH increased by 36.4±3.9 IU/L to a peak of 42±4.1 IU/L. 
In comparison, when four healthy men with similar baseline LH (5.0±0.3 IU/L) were 
administered GnRH following a 22 hr infusion of kisspeptin-10, the peak LH 
observed was 66.2±2.1 IU/L. A two-sample t test demonstrates this increased 
responsiveness to GnRH co-administration to be statistically significant (P=0.001). 
In a volunteer who took part in both these studies, the peak LH observed following 
GnRH alone was 30.52 IU/L in comparison to 72.2 IU/L observed with co-
administration of kisspeptin-10 and GnRH.  
There are a few potential explanations for these observations, based on current 
knowledge – some more plausible than others. Firstly, the total amount of GnRH 
stimulating pituitary gonadotropes would be higher in the context of co-
administration of GnRH - i.e., a sum of enhanced endogenous GnRH secreted and 
the 100 µg of exogenous GnRH would be available to stimulate LH secretion. Whilst 
this is the parsimonious explanation, it has to be noted that in dose-response studies 
of GnRH in men, near maximal stimulation of GnRH was observed with a 50 µg/kg 
dose, with doses as high as 250 µg and 500 µg not eliciting further stimulation 
(Snyder, Reitano et al. 1975). A 100 µg bolus dose is widely used as stimulatory test 
to assess maximal LH secretion in response to GnRH (Zevenhuijzen, Kelnar et al. 
2004). It is therefore unlikely that endogenous GnRH secretion, although amplified 
with kisspeptinergic stimulation is likely to elicit an additive gonadotrophic response, 
unless there is an associated change in pituitary sensitivity. That GnRH has a self-
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priming effect on pituitary gonadotropes is well established (Aiyer, Chiappa et al. 
1974). An increase in pituitary sensitivity to pulsatile GnRH has also been 
demonstrated in patients with hypogonadotropic hypogonadism manifesting as 
delayed puberty (Smals, Hermus et al. 1994). However, increased GnRH 
responsiveness following pulsatile GnRH administration has not yet been 
demonstrated in eugonadal subjects. Nevertheless, these observations are consistent 
with the notion that there are two pools of LH in the human pituitary – one 
responding acutely to GnRH and the other responding to more prolonged stimulation 
by GnRH (Bremner and Paulsen 1974). Observations from men administered GnRH 
infusions demonstrating biphasic response in LH secretion – i.e. an early peak 
followed by late peaks support this notion (Bremner and Paulsen 1974). 
8.2 Repetitive Kisspeptin-10 stimulation 
Observations made in men with Kallmann Syndrome that kisspeptin-10 does not 
elicit LH stimulation raises the possibility that kisspeptin-10 could be used as a 
provocative diagnostic test to identify individuals with functional impairment of 
GnRH neuronal activity. However, for such a test to be of clinical use, the responses 
elicited in ‘healthy’ controls should be reproducible. As two volunteers had taken 
part in more than one clinical study involving kisspeptin-10 administration, we were 
able to compare the LH responses within the same individual when kisspeptin-10 
was administered on different occasions. In three subjects administered 0.3 µg/kg 
kisspeptin-10 boluses twice, the peak LH observed was 2.7 times the baseline value 
(2.7±0.15 in studies described in the dose escalation studies described in chapter 3 
and 2.7±0.4 in translational studies described in chapter 7) with a paired t test 
demonstrating statistical similarity (P = 0.99).   
Another advantage of performing a kisspeptin stimulation test would be the 
remarkable similarity of proportionate stimulation from baseline values observed in 
individuals with diverse sex-steroid milieu, as described in chapter 4. Whilst these 
findings need to be reproduced in a larger cohort of individuals, these observations, 
when taken together with the fact that the current ‘gold standard’ provocative test, 
100 µg GnRH test, elicits a wide range of responses in healthy volunteers - three to 
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ten-fold increase from baseline- (Apter, Cacciatore et al. 1989; Brito, Batista et al. 
1999) suggests the diagnostic potential for a kisspeptin-10 provocative test. 
8.3 Summary of findings 
In conclusion, observations from the series of exploratory clinical studies reported in 
this thesis, would suggest that 
• Kissppeptin-10 stimulates LH and FSH secretion in both men and women. 
• Kisspeptin-10 stimulates LH secretion more than FSH secretion. 
• Kisspeptinergic stimulation of LH secretion is only a fraction of maximal 
GnRH stimulated LH secretion. 
• Kisspeptin-10 can stimulate LH secretion in women (including 
postmenopausal women). 
• Kisspeptin-10 increases LH pulse frequency and LH pulse mass size – and 
thus GnRH pulse frequency by inference. 
• GnRH signaling, but not Neurokinin B signaling, is obligatory for 
kisspeptinergic stimulation of gonadotropic secretion. 
• Kisspeptin-10 can enhance testosterone secretion in men with 
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therefore hypothesise that decreased endogenous kiss-
peptin secretion is the common central pathway that links 
metabolic and endocrine factors in the pathology of testos-
terone deficiency seen in men with obesity and T2DM. We 
propose that the kisspeptin system plays a central role in in-
tegrating a range of metabolic inputs, thus constituting the 
link between energy status with the hypothalamic-pituitary-
gonadal axis, and put forward potential clinical studies to 
test the hypothesis.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Over the past few decades, obesity has become a glob-
al health challenge. Between 1980 and 2004 the preva-
lence of obesity increased from 15 to 33% in the United 
States – a pattern mirrored across the world  [1] . Inter-
linked with this, the number of people with type 2 diabe-
tes (T2DM) has also risen, and is predicted to rise further 
 [2] . There is also an emerging consensus that T2DM and 
obesity are part of the same disease spectrum such that 
the term ‘metabolic syndrome’ is used to describe these 
overlapping pathophysiological processes  [3] .
 Whilst the cardiovascular effects of T2DM and obe-
sity have been extensively studied, the impact on fertility 
and hypogonadism remains relatively under-explored. 
 Key Words 
 Kisspeptin  ! Obesity  ! Metabolism  !  KISS1  !  KISS1R  ! 
GPR-54  ! Diabetes  ! Metabolic syndrome  ! Hypogonadism  ! 
Testosterone 
 Abstract 
 Hypogonadism occurs commonly in men with type 2 diabe-
tes (T2DM) and severe obesity. Current evidence points to a 
decreased secretion of gonadotropin-releasing hormone 
(GnRH) from the hypothalamus and thereby decreased se-
cretion of gonadotropins from the pituitary gland as a cen-
tral feature of the pathophysiology in these men. Hypergly-
caemia, inflammation, leptin and oestrogen-related feed-
back have been proposed to make aetiological contributions 
to the hypogonadotropic hypogonadism of T2DM. However, 
the neuroendocrine signals that link these factors with mod-
ulation of GnRH neurons have yet to be identified. Kiss-
peptins play a central role in the modulation of GnRH secre-
tion and, thus, downstream regulation of gonadotropins and 
testosterone secretion in men. Inactivating mutations of the 
kisspeptin receptor have been shown to cause hypogonado-
tropic hypogonadism in man, whilst an activating mutation 
is associated with precocious puberty. Data from studies in 
experimental animals link kisspeptin expression with indi-
vidual factors known to regulate GnRH secretion, including 
hyperglycaemia, inflammation, leptin and oestrogen. We 
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Low testosterone concentrations in men have been shown 
to be associated with obesity and T2DM  [4] . Plasma-free 
testosterone, total testosterone and sex hormone-binding 
globulin are low in obesity and recover in proportion to 
the degree of weight loss  [5] . In men with established 
T2DM, decreased plasma-free testosterone is found in a 
third to half of all patients  [6] .
 The relationship between hypogonadism and meta-
bolic status, consistently seen across race and ethnic 
groups  [7] , also seems to be bidirectional. In obese men, 
biochemical hypogonadism (low testosterone) increases 
the risk of future development of diabetes  [8] . In hypogo-
nadal individuals with T2DM, treatment with testoster-
one improves the glucose and lipid profile  [9] , and en-
hances quality of life and cardiac performance  [10] .
 The pathophysiology of low plasma testosterone in 
men with T2DM as well as the broader neuroendocrine 
signalling processes by which the metabolic milieu in-
fluences reproduction remains poorly understood  [11] . 
However, the recent discovery of kisspeptin and its cog-
nate receptor GPR-54  (KISS1R) as modulators of GnRH 
and, thus, downstream secretion of gonadotropins and 
testosterone  [12] may help solve at least a part of this com-
plex jigsaw.
 Here we review human and animal experimental data 
on the potential role for kisspeptin in mediating meta-
bolic inputs that modulate the hypothalamic-pituitary-
gonadal (HPG) axis and put forward propositions for 
clinical studies to test this central role for kisspeptin as 
an integrator of metabolic cues with reproductive func-
tion in men with metabolic syndrome.
 Hypothesis 
 We hypothesise that decreased endogenous kisspeptin 
secretion plays a central role in mediating hypogonado-
tropic hypogonadism in men with obesity and T2DM.
 Hypogonadism in Obesity and Diabetes 
 A number of possible pathologies have been proposed 
as causative factors for hypogonadism in individuals with 
obesity and/or T2DM. Metabolic factors (hyperglycae-
mia, inflammation, oxidative stress) and testicular fac-
tors (decreased Leydig cell function) have all been pro-
posed as factors contributing to the hypogonadal state in 
these individuals  [4] . However, current evidence points to 
a decreased secretion of gonadotropin-releasing hor-
mone (GnRH) from the hypothalamus as the key factor 
 [4] , as evidenced by the low or relatively low luteinising 
hormone (LH) and follicle-stimulating hormone (FSH) 
concentrations in the large majority of these men with 
low plasma testosterone. LH pulse amplitude and secre-
tory masses are significantly lower in obese men than in 
lean controls  [13] . Moreover, there is a highly significant 
negative correlation between plasma-free testosterone 
and body mass  [13] . A normal LH and FSH response to 
GnRH has also been demonstrated in obese individuals, 
suggesting a hypothalamic rather than a pituitary defect. 
 [14] .
 The Role of Kisspeptin in GnRH Secretion 
 Kisspeptins are peptide products of the  KISS1 gene 
 [15] . Various forms of kisspeptin have been identified, all 
of which have the same decapeptide amino acid sequence 
at the C-terminus  [12] . Kisspeptins regulate the repro-
ductive axis by stimulation of their cognate receptor 
 KISS1R (also called GPR-54) on GnRH neurons, thereby 
regulating LH and FSH secretion  [12] . Administration of 
kisspeptin has been shown to increase plasma LH, FSH 
and testosterone in a dose-dependent manner in a num-
ber of species including man  [16] , and a central role of 
kisspeptin in the metabolic regulation of reproductive 
function is well-recognised  [17] . Patients with mutations 
of  KISS1R exhibit hypogonadotropic hypogonadism but 
normal responses to GnRH and no reported metabolic 
derangement  [18–20] . It is also important to note that 
metabolic abnormalities have not been reported in knock-
out models lacking kisspeptin or its receptor  [21] , sug-
gesting that perturbation in the kisspeptin system is more 
likely to be the effect rather than the cause of a metabolic 
phenotype.
 In rodents, two distinct populations of kisspeptin neu-
rons exist in the arcuate (ARC) and anterior periventric-
ular (AVPV) nuclei, with differential functional respons-
es  [22] . Kisspeptin neurons in the ARC have been shown 
to respond to negative feedback by gonadal steroids, while 
AVPV kisspeptin neurons in the female rodent respond 
to positive feedback by oestrogen  [22] . However, AVPV is 
not an anatomical area present in the human hypothala-
mus and no kisspeptin neurons have been demonstrated 
in the corresponding rostral periventricular region of the 
third ventricle in humans  [22] . The infundibular nucleus 
is the human homologue of the ARC where the presence 
of kisspeptin neurons has been documented  [23] . In the 
rodent data reviewed here, we will focus on the kisspeptin 
population in the ARC nucleus as the oestrogen-mediat-
ed positive feedback seen in the female is not of particular 
relevance in the context of male hypogonadism. Howev-
er, it has to be borne in mind that in mRNA analyses of 
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gene expression, whole hypothalami are often used rath-
er than specific nuclei, such as the ARC or AVPV, thus 
potentially lowering the sensitivity and specificity of any 
changes detected in Kiss1 mRNA expression.
 Support for the Hypothesis 
 Oestrogen-Mediated Negative Feedback and 
Kisspeptin 
 Peripheral conversion of androgens to oestrogens in 
obese men leads to increased circulating oestrogens, 
which in turn suppress the hypothalamic-pituitary axis 
and thus the production of testosterone  [24] . Serum oes-
trone and 17- ! -estradiol are elevated twofold in morbid-
ly obese men, with the urinary excretion rates of these 
hormones elevated in proportion to the degree of obesity 
 [24] . Treatment with an aromatase inhibitor (preventing 
conversion of testosterone to estradiol) produces a sus-
tained normalisation of serum total testosterone in obese 
men with hypogonadism  [25] .
 However, adult GnRH neurons lack oestrogen recep-
tor- " (ER- " ) and rely on signaling from other oestrogen 
responsive hypothalamic neurons to facilitate oestrogen-
mediated regulation  [26] . The phenotypic identity of cells 
that receive input from gonadal steroids and relay this 
information to GnRH neurons remains unknown; how-
ever, kisspeptin neurons appear likely to play this role 
 [27] . The hypothalamic content of  Kiss1  (mRNA) increas-
es significantly after gonadectomy and decreases with sex 
steroid replacement  [28] . Kisspeptin neurons in sheep ex-
press ER- " receptors  [29] and in mouse models that lack 
functional ER- " receptors,  Kiss1  mRNA expression does 
not change in response to estradiol treatment  [30] . A mi-
nority of kisspeptin neurons express the oestrogen recep-
tor isoform ER- ! in addition to ER- "  [30] . In the absence 
of ER- ! (in knockout mouse models), the inhibitory ef-
fect of E2 on transcription of  Kiss1 is enhanced  [30] , in-
dicating functional roles of both ER types in the regula-
tion of kisspeptin neurons.
 Leptin and Kisspeptin 
 Leptin secreted from adipocytes conveys information 
about the body’s energy stores to the brain and thus regu-
lates a number of physiological processes, including in-
flammation, immune function and reproduction  [31] . 
Humans and mice lacking leptin (ob/ob mice) or leptin 
receptor (db/db mice) develop obesity, insulin-resistant 
diabetes and hypogonadism  [31] . In obese men, circulat-
ing androgen is inversely correlated with circulating 
leptin  [32] and a functional resistance to leptin in human 
obesity has been described  [33] .
 GnRH neurons, however, show little or no expression 
of Ob-R mRNA  [34] and, therefore, must rely on interme-
diary neurons for transmission of information on leptin 
concentrations  [34] . Kisspeptin neurons may fulfill this 
role, as they express leptin receptors  [35] . Reversal of fast-
ing-induced inhibition of gonadotropins by exogenous 
kisspeptin  [36] and the ability of intracerebroventricular 
kisspeptin administration to correct the decrease in LH 
secretion seen in pubertal animals after central immu-
noneutralisation of endogenous leptin with antileptin an-
tibody  [37] provide further evidence for a role of kiss-
peptin in affecting the influence of leptin on the HPG axis.
 Hypothalamic  Kiss1  mRNA expression is significant-
ly reduced in ob/ob compared to wild-type mice and are 
increased in ob/ob mice treated with leptin  [35, 38] . More-
over, administration of leptin increases hypothalamic 
 Kiss1  mRNA as well as LH and testosterone concentra-
tions in hypogonadotropic diabetic male rats  [38] .
 Hyperglycaemia and Kisspeptin 
 Plasma testosterone is inversely related to glycaemic 
control in men with T2DM. However, when compared 
with age- and BMI-matched men  [4] as well as men with 
type 1 diabetes of a comparable age, men with T2DM 
have a higher prevalence of hypogonadism  [39] . This sug-
gests insulin resistance as well as hyperglycaemia could 
also play a role in the pathogenesis of hypogonadism in 
this setting  [4] . Mice with neuron-specific deletion of in-
sulin receptors (NIRKO mice) have increased body mass 
and hypogonadotropic hypogonadism, confirming that 
insulin sensing in the brain is required for normal activ-
ity of the HPG axis  [40] .
 Hypothalamic  Kiss1  mRNA  is decreased in strepto-
zotocin-induced diabetic rats (a model of type 1 diabetes), 
and the post-orchidectomy rise in  Kiss1  mRNA  in these 
hyperglycaemic animals is severely blunted  [38] . Kiss-
peptin administration has been shown to evoke robust 
LH and testosterone secretion and enhance post-gonad-
ectomy LH concentrations in hypogonadotropic strepto-
zotocin-induced diabetic male rats  [38] . Repeated admin-
istration of kisspeptin to diabetic rats also partially res-
cued prostate and testis weights  [41] . However, no studies 
have yet been carried out on  Kiss1  mRNA expression in 
animal models of T2DM.
 Inflammation and Kisspeptin 
 Obesity and T2DM are now well recognised to be as-
sociated with inflammation and increased oxidative 
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stress  [42] . Circulating C-reactive protein, an inflamma-
tory marker associated with cardiovascular risk, has been 
shown to be significantly higher in hypogonadal men 
with T2DM in comparison to men with normal plasma 
testosterone  [4] .
 There are emerging data linking kisspeptin and in-
flammation. Administration of a pro-inflammatory 
agent (lipopolysaccharide) decreased hypothalamic  Kiss1 
 mRNA  expression as well as plasma LH in ovariec-
tomised rats  [43] . Indomethacin, an anti-inflammatory 
drug, completely blocked both these suppressive effects 
 [43] . Whilst inflammation has long been recognised to 
suppress the reproductive axis (e.g. in severe or chronic 
illness), these early findings suggest a link between kiss-
peptin and inflammation.
 Figure 1 summarises the normal physiology and the 
proposed pathophysiology underpinning our hypothesis.
 Testing the Hypothesis 
 To test the hypothesis directly, comparison between 
endogenous kisspeptin secretion in obese and lean sub-
jects would have to be made. However, the concentration 
of kisspeptin entering the peripheral circulation from the 
hypothalamus is likely to be undetectable. Accessing por-
tal circulation via petrosal sinus sampling for sampling is 
technically and ethically challenging. Highly specific and 
sensitive assay methods to measure kisspeptins are not 
yet widely available  [44, 45] . Moreover, even if the techni-
cal barriers are overcome, circulatory concentrations of 
kisspeptin may not correlate with the intracranial milieu.
 Recent advances in kisspeptin biology offer indirect al-
ternatives to test our hypothesis. Kisspeptin neuronal hy-
pertrophy and increased kisspeptin gene expression has 
been demonstrated in the hypothalamic infundibular nu-
 Fig. 1. Normal physiology and the patho-
physiological processes underpinning our 
hypothesis. 
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cleus in postmenopausal women  [23] . Similar post-mor-
tem histological analysis of hypothalami from obese men 
may show hypotrophy of kisspeptin neurons and/or de-
creased  KISS1 expression. A comparable situation of hy-
pogonadotropic hypogonadism is seen in women with hy-
pothalamic amenorrhoea who show a significantly higher 
LH response to acute administration of kisspeptin-54 in 
comparison to healthy women in the follicular phase of 
menstrual cycle  [46] . As hypogonadal men with metabol-
ic syndrome have a similar gonadotropin profile to wom-
en with hypothalamic amenorrhoea, stimulatory re-
sponses in LH to exogenous kisspeptin in these men may 
also be increased, which if confirmed in exploratory stud-
ies, raises the possibility of using a provocative kisspeptin 
stimulation test as a marker of metabolic status. In recent 
animal studies, kisspeptin antagonists have been shown 
to inhibit kisspeptin-induced LH release and also block 
the post-gonadectomy rise in LH  [47] . Moreover, in male 
rats with streptozocin-induced diabetes, the LH response 
to kisspeptin was significantly higher than control ani-
mals  [48] . By analogy, increased sensitivity to kisspeptin 
analogues in men with hypogonadism associated with 
T2DM would indirectly lend support to our hypothesis. 
Such studies could be performed by acute stimulation 
with a single dose of kisspeptin, akin to the GnRH pro-
vocative test used in numerous clinical settings.
 Implications of the Hypothesis 
 There are physiological and clinical implications if our 
postulates are correct.
 The pathophysiology of hypogonadism in obese men 
remains poorly understood. Current evidence linking in-
sulin, leptin, oestrogen and inflammation with hypogo-
nadism fails to explain how these factors have effects on 
GnRH neurons which lack corresponding receptors. If 
our hypothesis is correct, kisspeptin will constitute the 
neuroendocrine link conveying information about whole 
body energy balance to the GnRH neuronal system.
 From a translational perspective, there is potential for 
pharmacological therapies to be developed to address hy-
pogonadism. A number of kisspeptin analogues are be-
ing developed with agonistic and antagonistic activities. 
If our hypothesis is correct, kisspeptin agonists consti-
tute putative therapeutic targets for low circulating tes-
tosterone seen in obesity and diabetes. Current treatment 
of hypogonadism with testosterone tends to decrease 
sperm production through negative feedback on FSH se-
cretion with resultant sub-fertility in at least some pa-
tients. Pharmacological modulation with kisspeptin ago-
nists will potentially not have this adverse effect.
 In  summary,  we   postulate   low   kisspeptin   secretion 
is part of the pathophysiology of hypogonadotropic hy-
pogonadism seen in men with obesity and T2DM. The 
kisspeptin/KISS1R system is likely to be a central link be-
tween energy status and the HPG axis in man as has been 
demonstrated in experimental animals.
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Kisspeptin-10 Is a Potent Stimulator of LH and
Increases Pulse Frequency in Men
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Context: Kisspeptins stimulate GnRH and thus gonadotropin secretion. Kisspeptin-10 is the min-
imal kisspeptin sequence with full intrinsic bioactivity, but it has not been studied in man.
Objective: We investigated our hypothesis that kisspeptin-10 increases GnRH and thus LH pulse
frequency.
Design and Participants: The dose response of kisspeptin-10 was investigated by administering iv
bolus doses (0.01–3.0 !g/kg) and vehicle to healthy men. Effects on LH pulse frequency and size
were determined by deconvolution analysis during infusion of kisspeptin-10 for up to 22.5 h.
Results: Intravenous bolus kisspeptin-10 resulted in a rapid and dose-dependent rise in serum LH
concentration, with maximal stimulation at 1 !g/kg (4.1 ! 0.4 to 12.4 ! 1.7 IU/liter at 30 min, P "
0.001, n # 6). Administration of 3 !g/kg elicited a reduced response vs. 1 !g/kg (P " 0.05). Infusion
of kisspeptin-10 at 4 !g/kg ! h for 22.5 h elicited an increase in LH from a mean of 5.4 ! 0.7 to 20.8 !
4.9 IU/liter (n # 4; P " 0.05) and serum testosterone increased from 16.6 ! 2.4 to 24.0 ! 2.5 nmol/liter
(P " 0.001). LH pulses were obscured at this high rate of secretion, but a lower dose infusion of
kisspeptin-10 (1.5 !g/kg ! h) increased mean LH from 5.2 ! 0.8 to 14.1 ! 1.7 IU/liter (n # 4; P " 0.01)
and increased LH pulse frequency from 0.7 ! 0.1 to 1.0 ! 0.2 pulses/h (P " 0.05) and secretory burst
mass from 3.9 ! 0.4 to 12.8 ! 2.6 IU/liter (P " 0.05).
Conclusions: Kisspeptin-10 boluses potently evoke LH secretion in men, and continuous infusion
increases testosterone, LH pulse frequency, and pulse size. Kisspeptin analogues have therapeutic
potential as regulators of LH and thus testosterone secretion. (J Clin Endocrinol Metab 96:
E1228–E1236, 2011)
The central role of GnRH (LHRH) in regulating repro-duction by stimulating the secretion of pituitary go-
nadotropins (LH and FSH) is well established (1). Kiss-
peptin, a hypothalamic neuropeptide encoded by the
KISS1 gene, has recently emerged as a key central regula-
tor of GnRH secretion. Kisspeptin signaling is obligatory
for normal pubertal maturation, as evidenced by absent or
advanced pubertal development in individuals with mu-
tations in genes encoding kisspeptin (2) and its receptor
[KISS1R; also known as G protein-coupled receptor
(GPR) 54] (3–6). Administration of exogenous kisspeptin
stimulates LH secretion in both men and women (7–9).
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Human studies of kisspeptin have hitherto used the 54-
amino acid peptide, kisspeptin-54 (7–10). Kisspeptin-54 is
cleaved from the 145-amino acid precursor polypeptide
encoded by KISS1 and is further processed to 14, 13, and
10 amino acid (kisspeptin-10) sequences, all sharing the
same C-terminal decapeptide RFAmide (arginine-ami-
dated phenylalanine) sequence (11). Although kisspep-
tin-10 has intrinsic bioactivity similar to the longer kiss-
peptin fragments (11), it is also characterized by a shorter
half-life and more rapid onset of action after iv adminis-
tration in rodents (12). Kisspeptin-10 also has greater po-
tential for pharmaceutical development because both ago-
nists (13) and antagonists (14, 15) have been developed
based on its decapeptide sequence. However, there have
been no studies on the activity of kisspeptin-10 in humans.
Alterations in GnRH pulsatility and thus LH secretion
are a feature of a number of reproductive disorders. Indi-
viduals with some forms of male hypogonadism (16) and
hypothalamic amenorrhea (17) show decreased pulse fre-
quency, whereas women with polycystic ovarian syn-
drome show an increase (18). However, neuroendocrine
mechanisms underpinning GnRH pulse generation are yet
to be fully delineated (19). Experimental animals exposed
to kisspeptin antagonists demonstrate decreased LH pul-
satile secretion, suggesting that kisspeptin modulates
GnRH pulse frequency (20). Although administration of
kisspeptin-54 acutely stimulates LH secretion in men and
women (7, 8), it is unclear whether this is mediated by a
change in LH pulse frequency, which would indicate an
underlying stimulatory effect on GnRH pulse frequency.
In these first-in-human studies of kisspeptin-10, we
aimed to establish the dose dependency and time course of
stimulation of LH secretion after iv bolus doses of kiss-
peptin-10 and to compare the magnitude of this stimu-
lated LH secretion with that after a maximally stimulatory
dose of GnRH. Having established that kisspeptin-10 is an
effective LH secretagogue, we further investigated the ef-
fects of infusion of kisspeptin-10 on LH pulsatility. We
also examined whether high-dose continuous infusion of
kisspeptin-10 induces tachyphylaxis of LH response, as
previously suggested in a male primate model (21).
Participants and Methods
Participants
Six healthy male volunteers took part in acute kisspeptin stim-
ulation studies and four healthy males in each of the infusion
studies. All volunteers provided informed written consent, and
the study was approved by a local research ethics committee
(Lothian Research Ethics Committee References 09/S1101/23
and 09/S1101/67). The age of healthy male participants was
35.6 ! 3.4 (mean ! SEM) and body mass index was 26.1 ! 0.8
kg/m2, all of whom had a minimum bilateral testicular volume of
40 ml, normal physical examination, and normal secondary sex-
ual characteristics. Baseline full blood count, renal function, liver
function, and electrolytes were within normal limits.
Study drugs
Kisspeptin-10 was custom synthesized under GMP standards
(Bachem GmBH, Weil am Rhein, Germany). Purity was assessed
by HPLC at 97% with a mass balance of 98.8%. For each par-
ticipant, kisspeptin-10 was made up within the hour before in-
jection by diluting 1 mg of lyophilized kisspeptin-10 in 5 ml
sterile normal saline. Stability of kisspeptin-10 in solution was
assessed by in vitro receptor binding studies comparing prein-
cubated and freshly constituted 0.2 mg/ml solution (data not
shown). A bolus of 0.5 ml sterile normal (0.9%) saline was in-
jected as vehicle. Commercially available GnRH (Relefact;
Sanofi Aventis, Frankfurt, Germany) was used for GnRH
stimulation.
Protocols
Kisspeptin-10 dose response study
This study was designed to assess the magnitude and dose
dependency of gonadotropin secretion in response to six iv bolus
doses (0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 !g/kg) of kisspeptin-10
or vehicle (normal saline).
All volunteers attended the study in a fasting state, and all
visits commenced between 0800 and 0900 h to avoid diurnal
bias. Blood samples were obtained through an indwelling iv can-
nulae before (60, 45, 30, 20, and 10 min and immediately) and
after (10, 20, 30, 45, 60, 75, and 90 min) kisspeptin-10 or vehicle
administration. Doses were administered in increasing order for
safety reasons and visits were at least 1 wk apart. All volunteers
received at least four doses and four volunteers received all doses.
Participants were blinded to the dose of kisspeptin-10.
Blood pressure, pulse, and peripheral oxygen saturations
were measured every 3 min with standard automated techniques.
Full blood count, serum electrolytes, liver function, and renal
function were checked at each visit.
High-dose kisspeptin-10 iv infusion
This study was designed to assess LH secretion and potential
desensitization of kisspeptin-KISS1R with a continuous high-
dose infusion of kisspeptin-10.
After an overnight fast, four volunteers attended our clinical
research facility for a 34-h supervised stay. Blood samples were
collected at 10-min intervals for two 12-h periods on consecutive
days and hourly overnight. After 9 h of baseline sampling, 3
!g/kg of kisspeptin-10 (the highest dose previously investigated)
was administered as an iv bolus and a continuous iv infusion of
kisspeptin-10 (Crono PCA; Cane, Rivoli, Italy) commenced 90
min later at 4 !g/kg ! h. This infusion rate, maintained for 22.5 h,
was selected to aim to give a comparable hourly dose to the
maximally effective bolus doses, bearing in mind the expected
short half-life of kisspeptin-10. A 100-!g/kg iv bolus of GnRH
was administered 60 min before the end of the infusion.
Serum LH during the 9-h baseline frequent sampling period
was compared with the corresponding 9-h frequent sampling
period on the second day of the study during the iv infusion of
kisspeptin-10. In addition, we compared the mean LH values
observed in the initial 90 min of kisspeptin-10 infusion with the
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mean LH values observed in the final 90 min of infusion before
GnRH administration to identify any potential tachyphylaxis.
Comparisons were also made between mean LH over the 60
min before GnRH administration and the peak LH 30 min af-
terward. Serum testosterone was analyzed at 30-min intervals
during the two 9-h frequent sampling periods before and dur-
ing the infusion.
All subjects were provided with standardized meals through-
out the study and a period of overnight fast maintained between
2200 and 0900 h. Full blood count, electrolytes, liver function,
and renal function were checked at the beginning of the study,
24 h later, and at the end of the study.
Pulse frequency study
As there was an apparent increase in LH pulse frequency
during the high-dose kisspeptin-10 infusion, we examined this
further using a lower dose of kisspeptin-10.
Four healthy men attended our clinical research facility for
two visits 5 d apart for 10-min blood sampling. At the first visit,
baselineLHpulsatilitywasassessedovera9-hperiod.During the
second visit, an iv infusion of kisspeptin-10 was administered for
9 h at 1.5 !g/kg ! h after an hour of baseline sampling. Subjects
were provided with standardized meals during the study visits.
Hormone assays
Blood samples were centrifuged immediately at 4 C for 10 min
at 3000 rpm and serum frozen at !20 C until analysis. LH and
FSH were determined by ELISA and testosterone by RIA as pre-
viously described (22). Interassay coefficient of variation for all
hormonal assays was less than 5% at the concentrations mea-
sured. Intraassay coefficient of variation of LH was 2.9%. All
samples from each of the study visits were analyzed together in
duplicate.
Statistical analysis
For the dose-finding study, 60-min mean LH and FSH con-
centrations and area under the curve (AUC; by trapezoid inte-
gration) before and after the kisspeptin-10 bolus were calculated.
Variance in mean LH and "AUC values in the dose-response
study was analyzed by ANOVA followed by Tukey’s simulta-
neous test. Student’s t test was used to analyze changes in mean
LH,FSH,and testosterone concentrations in the infusion studies.
LH pulses were identified using a deconvolution algorithm
using cluster analysis with 93% sensitivity and specificity on
blinded data and basal, pulsatile, and total LH secretion calcu-
lated (23). Paired Student’s t test was used to assess changes in
pulse frequency.
Data are presented as mean # SEM. A two-sided P $ 0.05 was
regarded as statistically significant for all analyses. The statistical




Intravenous injections of kisspeptin-10 elicited a rapid
increase in LH in all volunteers, with peak concentrations
seen by 45 min after injection for all doses studied. The
maximum LH stimulation was seen after the 1-!g/kg bo-
lus, achieving peak (12.4 # 1.7 IU/liter) concentration at
30 min (Fig. 1A).
There was a clear dose-dependent increase in LH con-
centrations in response to kisspeptin-10 (P $ 0.0001).
Statistically significant increases were observed after
the 0.03-, 0.1-, 0.3-, and 1-!g/kg bolus doses (P $
FIG. 1. Gonadotropin response to acute administration of kisspeptin-
10 to normal men (n % 6). A, Serum LH concentration in response to 1
!g/kg kisspeptin-10 (filled circles), 3 !g/kg kisspeptin-10 (filled
triangles), or vehicle (open circles) administered to healthy volunteers
at time 0. B, " AUC (60 min) of LH after kisspeptin-10 and vehicle
administration. C, " AUC (60 min) of FSH after kisspeptin-10 and
vehicle administration. Mean # SEM. *, P $ 0.05 vs. vehicle.
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0.01). There was, however, no significant increase in
LH concentration after the highest dose administered
(3.0 !g/kg), and the mean LH after this dose was sig-
nificantly less than after the 0.3- and 1-!g/kg doses
(both P ! 0.05). Calculation of the AUC over 60 min
following the kisspeptin-10 administration showed a
similar pattern, with the 0.1-, 0.3-, and 1-!g/kg doses
achieving statistically significant changes compared
with vehicle (Fig. 1B).
FSH secretion also increased dose dependently after
kisspeptin-10 administration (P " 0.012). The largest in-
crease was observed with 1 !g/kg in which the mean 60-
min FSH rose from 4.6 # 1.0 to 5.3 # 1.0 IU/liter. In-
creases were seen in the AUC of FSH after 0.3 and 1 !g/kg
kisspeptin-10, with 3 !g/kg again not resulting in a sig-
nificant increase in FSH concentration
(Fig. 1C). Serum testosterone concen-
trations showed no statistically signif-
icant change with any of the doses
studied (data not shown).
Blood pressure, heart rate, periph-
eral oxygenation, liver function, renal
function, hemoglobin, mean corpuscu-
lar volume, and electrolytes remained
stable in all subjects throughout the




Infusion of 4 !g/kg ! h kisspeptin-10
resulted in sustained increases in LH
concentration. The LH profiles ob-
served in the four individual study sub-
jects are represented in Fig. 2. A bolus
injection of 3 !g/kg kisspeptin-10 re-
sulted in an increase in LH to 13.6 # 1.7
IU/liter (P ! 0.05 vs. baseline) at 30
min. Continuous kisspeptin-10 infu-
sion (4 !g/kg ! h) resulted in a further
increase in LH secretion in all subjects,
which was sustained throughout the
22.5 h of the infusion. Mean LH during
kisspeptin-10 infusion was 20.9 # 4.9
vs. 5.5 # 0.8 IU/liter over the 9-h pre-
treatment period (P ! 0.05, Fig. 3A).
Mean LH concentrations in the final
90 min of infusion (23.9 # 6.8 IU/liter)
was comparable with that in the first
90 min of infusion (16.3 # 2.8 IU/
liter, P " 0.34). These data therefore
do not indicate tachyphylaxis of the
LH response to kisspeptin-10 admin-
istration at this dose and duration of exposure.
Intravenous administration of 100 !g bolus of GnRH
60 min before the end of the kisspeptin-10 infusion in-
creased LH further with a peak of 89.3 # 6.1 IU/liter. This
stimulatory effect of GnRH was at least 2.5-fold greater in
all subjects than the peak LH observed with the iv bolus of
kisspeptin-10 (13.6 # 1.7 IU/liter, P ! 0.001) and the peak
LH achieved during kisspeptin-10 infusion (28.7 # 7.0
IU/liter, P ! 0.01).
Analysis of LH pulse frequency during the 9-h baseline
sampling and the corresponding 9-h period on the second
day of infusion was performed. Characteristic pulsatile
LH secretion was observed in all four subjects at baseline
but was not well defined during kisspeptin-10 infusion.
FIG. 2. Serum LH profiles of four individual subjects receiving 4 !g/kg ! h kisspeptin-10
infusion (black bar) after 9 h baseline sampling and 3 !g/kg iv bolus administered at 9 h
(black arrow). Serum samples were obtained at 10 min intervals except overnight when
samples were obtained hourly. Note the difference in scale between individual subjects.
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Nevertheless, deconvolution analysis showed an in in-
crease in pulse frequency in three subjects (from 0.4 to 0.6,
0.6 to 0.8, and 0.6 to 1.2 pulses/h, Fig. 2, A–C, respec-
tively), whereas one subject showed a slight decrease from
0.7 to 0.6 pulse/h (Fig. 2D), giving a mean pulse frequency
of 0.6 ! 0.1 pulses/h at baseline and 0.8 ! 0.2 during
kisspeptin-10 infusion (P " ns).
Although FSH showed an increase in all subjects during
infusion of 4 !g/kg ! h kisspeptin-10, this was not statis-
tically significant (2.7 ! 0.8 to 5 ! 2.0 IU/liter, P " 0.17,
Fig. 3B), whereas testosterone concentration significantly
increased from 16.6 ! 2.4 to 24.0 ! 2.5 nmol/liter (P #
0.001, Fig. 3C).
To investigate further whether continuous kisspep-
tin-10 exposure increases LH pulse frequency, we infused
a lower dose of 1.5 !g/kg ! h for 9 h. Mean LH increased
significantly from 5.2 ! 0.8 IU/liter at baseline to 14.1 !
1.7 IU/liter during kisspeptin-10 infusion (P # 0.01, n "
4, Fig. 4). LH showed a steady increase throughout the
course of the infusion, increasing from 7.2 ! 2.3 IU/liter
in the first 90 min of infusion to 20.4 ! 3.5 IU/liter in the
last 90 min (P # 0.05, Fig. 4).
Deconvolution analysis demonstrated an increase in
LH pulse frequency in all subjects, with a mean increase
from 0.7 ! 0.1 to 1.0 ! 0.2 pulses/h (P " 0.01) during
kisspeptin-10 infusion at 1.5 !g/kg ! h (Fig. 4E). Secretory
mass of LH per pulse also increased in all subjects during
the infusion, from 3.9 ! 0.4 to 12.8 ! 2.6 IU/liter (P #
0.05, Fig 4F). Pulsatile LH secretion increased as a pro-
portion of total LH secretion in all subjects from 41.3 !
5.7 to 69.5 ! 5.9% during the infusion.
Serum FSH also increased progressively during the low-
er-dose kisspeptin-10 infusion. FSH observed during the
final 90 min of the infusion (6.6 ! 0.8 IU/liter) showed a
significant increase from the first 90 min (3.8 ! 0.8 IU/
liter, P # 0.05) of the infusion and baseline (3.9 ! 0.7
IU/liter, P # 0.05).
Discussion
We have demonstrated that iv administration of kisspep-
tin-10 boluses result in potent and dose-dependent stim-
ulation of LH secretion in healthy men. Doses of kisspep-
tin-10 as low as 0.03 !g/kg (23 pmol/kg) elicited a
significant rise in LH when compared with vehicle, dem-
onstrating the high potency of kisspeptin-10. This is in
keeping with data from experimental animals where in-
tracerebroventricular doses of kisspeptin as small as 1
fmol effected robust LH stimulation (24). Central rather
than pituitary mediation of the effect of kisspeptin on LH
secretion has been demonstrated by abolition of the effect
of kisspeptin by pretreatment with a GnRH antagonist
(24–26).
The 2.5-fold increase in serum LH from baseline ob-
served after kisspeptin bolus administration in our study
is comparable with that observed in men administered
equimolar doses of kisspeptin-54 as short infusions (7).
Moreover, as in human studies using kisspeptin-54 (7), the
stimulatory effect of kisspeptin-10 on LH secretion in our
study was also markedly more pronounced than that on
FSH secretion. Early animal studies suggested stimulatory
effects on LH and testosterone secretion were seen only
with the longer kisspeptin peptide, kisspeptin-54, and not
shorter forms (27). However, in vivo rodent data have
subsequently shown equal potency of kisspeptin-10 and
kisspeptin-54 (24, 28), and in in vitro binding assays, both
peptides show equal affinity at the KISS1R (11). Our re-
FIG. 3. Gonadotropin and testosterone response to infusions of 4 !g/kg
of kisspeptin-10 (n " 4). A, Mean serum LH before and during kisspeptin-
10 infusion. B, Mean serum FSH before and during kisspeptin-10 infusion.
C, Mean serum testosterone before and during kisspeptin-10 infusion.
Error bars represent SEM. *, P # 0.05; ***, P # 0.001.
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sults demonstrate that the 10 amino acid form of kisspep-
tin is a potent LH secretagogue in vivo in humans.
Although there was a clear dose dependency of LH
response to increasing doses of kisspeptin-10 up to 1 !g/
kg, the 3-!g/kg (2.3 nmol/kg) bolus dose did not elicit a
statistically significant increase when compared with ve-
hicle, and mean and peak LH concentration after this dose
was lower than corresponding values after 0.3 and 1 !g/
kg. This phenomenon has not been reported before after
bolus administration of kisspeptin, but continuous infu-
sion of kisspeptin-10 in primates (21) and repeated sc ad-
ministration of kisspeptin-54 in human subjects with hy-
pothalamic amenorrhea (9) resulted in tachyphylaxis. The
kisspeptin receptor KISS1R is known to desensitize rap-
idly in vitro (29), raising the possibility of rapid hypotha-
lamic desensitization. Although such desensitization is a
parsimonious explanation for the decreased response ob-
served here, desensitization has to be occurring rapidly
after kisspeptin-10 administration before maximal stim-
ulation of gonadotrophs is achieved. Because the fast half-
life of LH in healthy men is 18 min (30), lower peak LH
after the3 !g/kgwould suggest that thegonadotrophstim-
ulation was submaximal.
An alternative explanation for this
observation is that at high concentra-
tions, kisspeptin-10 may stimulate an-
other RF-amide receptor with an inhib-
itory effect on GnRH or LH secretion.
Kisspeptin-10, at nanomolar concentra-
tions, has been shown to bind and acti-
vate the gonadotropin inhibitory hor-
mone (GnIH) receptor [GPR147,
NPFFR1 (neuropeptide FF receptor 1)]
(31), which is expressed both in the hy-
pothalamus and on gonadotropes (32).
Nanomolar plasma concentrations of
kisspeptin were achieved after sc admin-
istration of doses of kisspeptin-54 similar
to the kisspeptin-10 used in our study
(8). However, although peak plasma
kisspeptin-10 concentrations after the
3-!g/kg bolus may have been sufficient
to activate GnIH receptors, there is little
evidence for a functional role for GnIH
in humans, and in vivo studies in sheep
(33) would suggest that its effects are rel-
atively modest, and it is not possible to
exclude an effect of GnIH receptor in-
volvement in the infusion studies. The
reduced stimulatory efficacy of kiss-
peptin-10 at high concentrations de-
mands careful dosing in any potential
therapeutic applications.
Importantly, our studies demonstrate the novel phe-
nomenon that continuous infusion of kisspeptin-10 in-
creases LH pulse frequency. Along with increased secre-
tory mass in individual pulses, this increase in pulse
frequency resulted in pulsatile secretion contributing to a
higher proportion of total LH secreted. Data from other
investigators have not shown that GnRH pulse frequency
is increased by an acute bolus of kisspeptin (34), indicating
the need for continuing kisspeptin stimulation to study its
influence on GnRH pulse frequency. The dependency of
LH pulsatility on pulsatile GnRH secretion (1, 35) is well
established, and kisspeptin has been shown to directly
stimulate GnRH secretion (36) with electrophysiological
studies showing intense and prolonged activation of ro-
dent GnRH neurons by kisspeptin-10 (37). There is a
marked stochastic increase in LH when kisspeptin is ap-
plied to the hypothalamic arcuate nucleus in rodents,
which might reflect an acceleration of LH pulse frequency
(20), and a kisspeptin antagonist decreases LH pulse fre-
quency in this model (20). Systemic administration of kiss-
peptin-10 in our study prevents us from concluding
whether this increase in LH (and by inference GnRH)
FIG. 4. Gonadotrophin response to 9-h iv infusion of 1.5 !g/kg kisspeptin-10 (n ! 4). A–D,
LH profiles from individual subjects during baseline (closed circles) and kisspeptin-10 infusion
(open triangles) visits. Note the difference in scale between individual subjects. E, Mean LH
pulse frequency during baseline and kisspeptin-10 infusion visits. F, Secretory mass of LH per
pulse during baseline and kisspeptin infusion visits. Error bars represent SEM. *, P " 0.05.
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